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Abstract. 
Background: Systemic sclerosis (SSc) is a disease characterised by a triad of 
immunological abnormalities, endothelial cell dysfunction and fibrosis. Neutrophils are the 
most abundant circulating leukocyte. They contain several mediators which when released 
can lead to modulation of the inflammatory response, cause endothelial cell activation and 
injury and eventually lead to fibrosis. The peri-endothelial cell environment in SSc has the 
potential to lead to neutrophil activation and indeed this has been previously described in the 
literature in terms of reactive oxygen species (ROS) generation. In this thesis I aim to 
explore the hypothesis that: “Neutrophils are activated in SSc and contribute to endothelial 
cell activation and damage”.  
Methods: The functional phenotype of SSc neutrophils was explored in vitro. Functions 
investigated included; ROS generation, chemotaxis, integrin expression, apoptosis and 
CD16 expression. The protein expression of ex vivo SSc neutrophils was compared to 
healthy control neutrophils. The DIGE technology was used to explore the pan-proteome 
and iTRAQ was used to focus in on the plasma membrane proteome. The role of neutrophil 
elastase was explored in SSc by examining the serum neutrophil elastase concentration and 
activity and correlating these to clinical manifestations of disease. The role of neutrophil: 
endothelial cell interactions was modelled in vitro using live cell imaging by confocal 
microscopy looking for evidence of endothelial cell activation (E-selectin expression) and 
apoptosis. Experiments examined the role of neutrophil derived mediators in these 
interactions. 
Results: Functional studies revealed that SSc neutrophils are hypofunctional in terms of 
spontaneous ROS generation and chemotaxis in vitro. This may reflect in vivo activation. 
SSc neutrophils are similar in terms of integrin expression and baseline apoptosis to control 
neutrophils. Pan-proteomic studies reveal neutrophil activation in SSc since changes in 
protein expression mirror those seen in response to neutrophil activators TNFα and LPS. 
Proteomic studies also point to neutrophil priming in vivo. Serum neutrophil elastase 
concentrations and activity were not elevated in SSc, however, discrepancies between 
concentration and activity suggest a functional deficiency in elastase inhibitors in SSc serum. 
Serum elastase activity and concentrations were found to be lower in RNP 
(ribonucleoprotein) positive patients indicating that different mechanisms maybe involved in 
different SSc subtypes. In vitro models demonstrate that SSc serum causes endothelial cell 
activation and apoptosis and that neutrophils are essential for this effect. Serine proteases 
seem to play an important role in inducing apoptosis and IL-6 trans signalling is involved in 
endothelial cell activation and apoptosis. Neutrophils do not express IL-6 but are dominant 
sources of the soluble IL-6R which is essential for trans signalling. 
Conclusions: There is evidence that neutrophils are activated in SSc though; no specific 
activating signature is identified. In co-cultures, neutrophils are essential for endothelial cell 
activation and apoptosis in response to SSc serum. Neutrophil mediators including serine 
proteases and IL6R are likely to play important roles in this effect. Therefore neutrophils may 
play an important part in the propagation of inflammation and endothelial cell activation 
which eventually leads to the fibrotic phenotype which is characteristic of this disease. 
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Chapter 1: Introduction. 
 
1.1 Background  
SSc is a multisystem, connective tissue disease. It has an estimated prevalence of 0.1% and 
is more common in women than men with a male to female ratio of 1:4.  
Scleroderma, the cardinal symptom of SSc, is a fibrotic thickening of the skin and can be 
found alone or in association with systemic involvement (Fig.1). 
 
 
 
The clinical features of SSc fall into 3 main categories: vascular dysfunction including 
Raynaud’s phenomenon (RP), microvascular and macrovascular damage resulting in 
ischaemia and pulmonary hypertension, fibrosis involving the skin and internal organs, and 
immune abnormalities including typical autoantibodies and evidence of immune cell 
activation (Fig.2). 
Fig. 1. Classification of scleroderma. Thickening of the skin may be localised or there may 
be systemic involvement. In systemic disease, skin thickening may be distal only (limited), 
involve proximal skin (diffuse) or may be absent (sine scleroderma). 
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Diffuse cutaneous SSc (dcSSc) involves skin thickening both proximal and distal to the 
elbows, knees and neck. It is associated with anti-topoisomerase I antibodies, lung fibrosis 
and renal crisis. Limited cutaneous SSc (lcSSc) involves skin thickening distal to the elbow, 
knee and neck, it is associated with anti-centromere antibodies, late pulmonary artery 
hypertension, calcinosis, telangiectasia and prominent microvascular disease (Table 1).
 
More recently the definition of SSc has been broadened to try to diagnose patients early in 
the disease, before fibrosis has become established. These criteria for diagnosis are 
outlined in Table 2. 
Fig.2. The central pathological 
components of systemic 
sclerosis 
Table 1. Clinical features of limited and diffuse systemic sclerosis. 
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Gastrointestinal symptoms are common, occurring in both disease subtypes and can include 
oesophageal dysmotility with reflux, small bowel bacterial overgrowth due to dysmotility 
resulting in diarrhoea and malabsorption, constipation due to large bowel dysmotility and 
faecal incontinence. 
The pathogenesis of SSc remains unknown, but there is now a relatively consistent 
hypothesis regarding at least parts of the mechanism. 
1.2 The role of the endothelial cell in SSc pathogenesis. 
Historically, the first important clues to the pathogenesis of SSc came from histological 
studies of lesional skin from affected patients. Biopsies show typical changes in the 
microvasculature including: a fall in total blood vessel area, perivascular oedema, a 
mononuclear perivascular infiltrate. There are endothelial cell abnormalities culminating in 
denudation of the endothelial cell layer, basement membrane thickening and reduplication. 
There is also an increase in dermal collagen and extracellular matrix deposition 5. 
The University of California at Davis (UCD) 200 chickens develop almost all of the features 
of scleroderma and have been used as an animal model for the disease. Serial tissue 
Table 2. Criteria for the classification of early systemic sclerosis 2. 
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biopsies from these animals have shown that endothelial cell apoptosis is the earliest 
change seen in the pathogenesis of the disease preceding the inflammatory cell infiltrate and 
the development of fibrosis 6 7. This implies that induction of endothelial cell apoptosis is 
likely to be the initiating lesion in SSc. 
Endothelial cell apoptosis has also been reported in SSc lesional skin 8, though the 
mechanism is again unclear, and in vitro models have shown that the sera of a proportion of 
SSc patients contain anti-endothelial cell antibodies which have been implicated in the 
induction of apoptosis 9 10. However, for the rest of the patients the situation remains unclear. 
Reactive oxygen species (ROS) and proteases have been implicated in vitro but there is no 
convincing evidence for their in vivo involvement 11 12. Some authors contend that there is no 
direct evidence for endothelial cell apoptosis in vivo 13. 
In addition, there is evidence of endothelial cell activation. Endothelial cells produce more 
nitric oxide ex vivo, and also display an increase in the expression of adhesion molecules. 
Serum levels of soluble adhesion molecules (sICAM, sVCAM and sE-selectin) as well as 
other markers of endothelial cell activation (vWF and endothelin) are elevated in patients 
with SSc and have been reported to correlate with disease activity 14-20. 
As well as evidence of endothelial cell activation there is evidence for endothelial cell 
dysfunction in patients with SSc. Endothelial dependent vasodilatation, measured following 
iontophoresis of acetylcholine on to the digital vessels by laser Doppler, is decreased in 
patients with SSc 21-23. 
The implications of endothelial cell activation are that the usually anti-inflammatory, anti-
coagulant properties of the endothelial cell lining become pro-inflammatory and pro-
coagulant 15. Activated endothelial cells express leukocyte adhesion molecules increasing 
leukocyte adhesion and promoting infiltration. In addition, activated endothelial cells secrete 
chemokines including interleukin-8 (IL-8) and monocyte chemotactic peptide (MCP-1) that 
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also increase the leukocyte infiltration. They also secrete a number of pathogenically 
relevant cytokines and growth factors including endothelin which is pro-fibrotic and 
vasospastic as well as interleukin-6 which is profibrotic and promotes chronic inflammation 
(Fig. 3). 
The role of endothelial apoptosis is less clear, but apoptotic cells are likely to be 
phagocytosed by tissue macrophages and dendritic cells leading to the potential 
presentation of self antigen to T cells, which could promote autoimmunity. In addition, 
apoptotic endothelial cells are adhesive to platelets and leukocytes and can therefore 
activate the alternative complement and coagulation cascades. This may result in 
microthrombosis and consequent tissue ischaemia that may perpetuate the process. 
Laplante et al have shown that apoptotic endothelial cell conditioned media can inhibit 
fibroblast apoptosis, induce myofibroblast differentiation and increase production of type 1 
collagen. This mimics the pro-fibrotic fibroblast phenotype seen in SSc 24. 
Fig. 3. Endothelial cell activation. Endothelial cell activation leads to an increase in 
leukocyte adhesion molecules, and release of leukocyte chemotactins and a pro-
thrombotic phenotype. In addition, there is release of cytokines: ET-1=endothelin-1; IL-
6=interleukin-6; IL-8=interleukin-8; MCP-1= monocyte chemoattractant peptide. 
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1.3 The role of the fibroblast in SSc pathogenesis 
Fibroblasts have a central role in the pathogenesis of SSc. Fibroblasts isolated from SSc 
lesional skin have a unique phenotype that mimics fibroblast activation by TGFβ 25-28.  
Of particular interest is the fact that fibroblasts appear to be constitutively activated in ex vivo 
culture for several passages. They express increased collagen mRNA and protein 26 29-31, 
and constitutively express profibrotic and proinflammatory cytokines (e.g. IL-6, IL-1α), growth 
factors (e.g. CTGF) and chemokines (e.g. IL-8 and MCP-1) 30 32-36. 
Fibroblasts are heterogeneous depending on their tissue of origin and the surrounding 
environment 37. Activated fibroblasts differentiate to a myofibroblast phenotype which is 
identified by the expression of αSMA. Although there is no increase in the absolute number 
of skin fibroblasts in SSc there is an increase in the number of myofibroblasts 38. It is not 
clear whether the abundance of activated fibroblasts found in SSc lesional skin is a response 
to activating pro-inflammatory cytokines, or whether it represents the clonal expansion of a 
subpopulation of highly activated cells, although there is supporting evidence for both 27.  
Aberrant apoptotic responses can potentially be responsible for clonal expansion. During the 
normal response to injury or inflammation, there is fibroblast activation and an increase in 
extracellular matrix deposition. This is usually followed by a period of remodeling which 
involves matrix metalloproteinases (MMPs) and their regulators, tissue inhibitors of matrix 
metalloproteinases (TIMPs). Finally, this is followed by a period of resolution that is 
accompanied by apoptosis of activated fibroblasts. In SSc there is increased expression of 
TIMPs, therefore inhibiting the breakdown of the extracellular matrix 39-42. In addition, there is 
a paucity of fibroblast apoptosis and SSc fibroblasts in vitro are resistant to Fas-mediated 
apoptosis 43 44. SSc fibroblasts constitutively express increased concentrations of TIMP-1 
and are also more sensitive to the mitogenic effects of TIMP-1, supporting the clonal 
expansion theory 45.  
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Several candidate cytokines for paracrine fibroblast activation exist. IL-1β, IL-6 and MCP-1 
are elevated in the serum of patients with SSc and can give rise to fibroblast activation. 
Endothelial cell conditioned media increases DNA and protein synthesis in cultured SSc 
fibroblasts more than in normal fibroblasts 46. Antibodies against fibroblast growth factor 
(FGF) and IL-1β abrogate the effect of the conditioned media on DNA and protein 
expression, respectively 46.  
Several autoregulatory loops have been identified that might account for the autonomous 
phenotype seen in vitro. These include the MCP-1 signalling axis, IL-6 and TIMP-1 33 39 45 47. 
Constitutive expression of IL-1α by SSc fibroblasts increases the expression of IL-6 and 
PDGF that are capable of further fibroblast activation 35. 
Activated T-cells interact with fibroblasts via CD40 expressed on fibroblast cell membranes. 
SSc fibroblasts have an increased expression of CD40 and ligation of this increases the 
production of IL-6, IL-8 and MCP-1 48. Ligation also increases the expression of a co-
stimulatory molecule (CD80) on SSc fibroblasts. None of these changes were induced by 
ligation of CD40 on control fibroblasts 48. These data imply that direct cell contact may also 
have a role in fibroblast activation in SSc.  
Autoantibodies directed against fibroblasts have been detected in a proportion of patients 
with SSc and have been implicated in fibroblast stimulation 49. 
1.4 Cytokines and growth factors in SSc 
1.4.1 Transforming growth factor-β 
TGFβ is believed to play a major role in SSc as the typical fibroblast phenotype outlined 
above closely mimics the effects of TGFβ stimulation. Genome wide studies of lesional skin 
have demonstrated significant differences in TGFβ-related genes in the skin of diffuse SSc 
patients compared to controls 50.  
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There are contradictory studies of the tissue expression of TGFβ, some show an increase in 
TGFβ staining by histocytochemistry of lesional skin whereas others do not 36. This may be 
explained by a study that demonstrated that TGFβ expression was increased at the “leading 
edge” of the lesional skin and therefore may be implicated in the initiation and propagation of 
the fibrosis 51. Therefore, the discrepancy in biopsy based histocytochemistry may depend 
on the site of the biopsy. If it is taken from an established lesion, in may be devoid of TGFβ, 
whereas a biopsy from skin adjacent to established fibrosis may be within the “leading 
edge”. 
SSc fibroblasts do not produce excessive amounts of TGFβ and they are not more sensitive 
to TGFβ than normal fibroblasts. In fact, SSc fibroblasts appear to be less sensitive ex vivo 
to TGFβ than normal fibroblasts 27. It has been suggested that this may reflect insensitivity 
following excessive in vivo exposure. Consistent with this hypothesis, there is an increase in 
TGF receptor expression on the surface of SSc fibroblasts 27. In vitro studies reveal that 
over-expression of TGFβ receptor 1 is sufficient to reproduce the activated phenotype of 
SSc fibroblasts and is dependent on autocrine TGFβ secretion, but not on receptor kinase 
activity. Reversing the over expression using siRNA normalized the fibroblast phenotype 52.   
The canonical TGFβ signalling pathway involves Smad proteins, including Smad 2 and 3 
which lead to characterised responses to TGF, and Smad 7 which is an inhibitor of TGFβ 
signalling. Immunohistochemical analysis demonstrated increased Smad 2 and 3 expression 
in SSc non-lesional skin with increased translocation of the protein to the nucleus 53.  Skin 
involvement estimated by the Rodnan skin score correlates with levels of phosphorylated 
Smad 3 in protein extracts from SSc fibroblasts 54. Some investigators have reported a 
decrease in the expression of Smad 7 in SSc whilst others report no difference 54. 
TGFβ also signals through non-canonical pathways, in particular the c-Abl non-receptor 
tyrosine kinase that can be inhibited by Imatinib, and the early growth response-1 protein 
that can mediate increased transcription of collagen in response to TGFβ 55.  
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The production of TGFβ and its activation involves highly complex regulatory mechanisms. It 
is secreted in a latent form (latent TGFβ), containing a latency associated peptide which is 
cleaved to form the active TGFβ. Latent TGFβ is also associated with a binding protein 
(LTGF binding protein (LTBP)) which serves to bind LTGF to the extracellular matrix. This 
provides a large pool of latent TGFβ, stored in the ECM ready for rapid release on 
stimulation. Proteolytic cleavage of the active form can be performed by matrix 
metalloproteinases, serine proteases and integrins 56. TGFβ can also be dissociated from 
the latency-associated peptide by thrombospondin 57. This complicated system affords 
multiple levels of control over the activity of TGFβ. 
Animal models support a prominent role for TGFβ in SSc and anti-TGFβ strategies can 
prevent fibrosis in these animal models. However, many of the animal models incompletely 
represent the SSc phenotype and therefore the applicability of these strategies to humans is 
debatable 54. 
To date, strategies to block TGFβ in humans have been less successful than in the animal 
models. The human monoclonal antibody metelimumab was given in a randomized 
controlled trial to 45 patients with SSc, but no improvement was seen in skin scores or other 
disease manifestations. There was an increase in adverse events in the treatment arm but 
concerns about increased autoimmune events were not realised 58. Potential reasons for the 
failure include the restricted isotype and low binding affinity of the antibody used, the low 
number of patients studied and the short duration of the trial.  
Other strategies to block TGFβ are in the early stages of development and the results in 
clinical trials are eagerly awaited. The protein tyrosine kinase inhibitor Imatinib has been 
shown to block non-canonical TGFβ signalling, in addition to its other actions and could 
contribute to its beneficial effects  in animal models of SSc. Imatinib will be discussed in 
greater detail later. 
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1.4.2 Vascular endothelial growth factor 
Vascular endothelial cell growth factor (VEGF) is another important mediator in SSc. 
Endothelial cell expression of VEGF is transcriptionally induced by hypoxia via the 
transcription factor HIF1α. It is a potent angiogenic growth factor, increasing the recruitment 
of endothelial cell progenitor cells from the bone marrow and acting as an endothelial cell 
mitogen. It also has additional effects on inflammation including the induction of cytokines 
(IL-6) and chemokines (IL-8, GROα) 59.  
Despite the fact that there is ischaemia and a measurable hypoxia in the lesional skin of 
patients with SSc, there is no concomitant increase in angiogenesis. Instead, there is a 
disorganized architecture of the microvessels and an overall decrease in the number of 
vessels. 
Despite the lack of angiogenesis however, there is an increase in the tissue expression of 
VEGF in lesional and non-lesional skin. There is also an increase in the tissue expression of 
the VEGFRs 1 and 2. The increased expression does not correlate with the levels of HIF1α 
and is likely, therefore, to be as a result of HIF1-independent mechanisms 60. Cytokines such 
as TGFβ, IL-6, IL-1β and PDGF are all raised in patients with SSc and are capable of 
increasing the expression of VEGF. They may have an, as yet, unconfirmed role in VEGF 
over-expression in SSc. 
It appears that the kinetics of VEGF expression may be important in determining the 
response to VEGF. In a mouse model where VEGF expression is inducible by the 
administration of tetracyclines, experiments were conducted to explore the effects of VEGF 
kinetics. It seems that prolonged expression of VEGF, as seen in patients with SSc, can 
cause a disorganized and ineffective angiogenesis that very much resembles the picture 
seen in SSc 61. An alternative explanation for the lack of angiogenesis seen in response to 
elevated VEGF in SSc is there that is also an increase in the expression of opposing, 
Page 27 of 236 
 
angiostatic factors. The data regarding this is contradictory, and so far there is no convincing 
positive evidence for an increase in such a factor 62. 
There is some in vitro evidence to suggest that endothelial cells isolated from patients with 
SSc have a defective response to VEGF in a Matrigel tube formation assay 63. Investigators 
using circulating endothelial precursor cells (CEPs) isolated from SSc patients as a model 
for SSc endothelial cells have shown that SSc CEPs have a decreased up-regulation of 
VEGFR1 in response to hypoxia 64. This may help explain the apparent resistance to the 
pro-angiogenic effects of VEGF seen in SSc, however there is some evidence to suggest 
that VEGFR1 has an inhibitory role in VEGF signalling. In addition, it has not been 
completely established that CEPs are a good model for mature endothelial cell function. 
CEPs from patients with SSc are less able to differentiate in vitro than CEPs from healthy 
controls 65. Therefore, data derived from CEPs should only be taken as circumstantial 
evidence at the present time. 
1.4.3 Platelet derived growth factor 
Platelet derived growth factor (PDGF) is a potent mesenchymal mitogen. It has effects on 
fibroblasts including replication, survival, myofibroblast differentiation and migration and is 
produced by a number of cell types including fibroblasts, endothelial cells and mononuclear 
leukocytes. Release can be stimulated by injury, hypoxia and inflammatory cytokines, such 
as IL1-β.  
Four isoforms of PDGF exist, A, B, C and D. PDGF C and D are secreted in a latent form 
requiring proteolytic cleavage for activation. These form homodimers, while the A and B 
isoforms can form heterodimers. These dimers signal through two receptors PDGFRα and 
PDGFRβ. PDGF-AA signals exclusively through PDGFRα, PDGF-BB signals through 
PDGFRα, αβ, and β, PDGF-AB and C signal through PDGFRα and αβ, and PDGF-D signals 
preferentially through PDGFRβ (Fig.4).  
Page 28 of 236 
 
 
 
 
Expression of PDGF and its receptors are increased in SSc. Immunohistochemistry 
demonstrates that there is increased PDGF and PDGFR expression in the lesional skin of 
patients with SSc 66 67, localised to the endothelial cells and mononuclear leukocyte infiltrate, 
hair follicles and stromal cells. PDGF is almost undetectable in healthy control skin. PDGF A 
and B are also elevated in the bronchoalveolar lavage fluid of patients with SSc 68.  
Fibroblasts isolated from patients with SSc, when treated with TGFβ demonstrate increased 
expression of PDGFRα which is a unique feature of SSc fibroblasts and is not found in 
healthy control fibroblasts 69. This translated into an increase in the mitogenic response to 
PDGF-AA. Other investigators have shown that low dose TGFβ stimulates a mitogenic 
Fig.4. Platelet derived growth factor (PDGF) signalling. PDGFs stimulate dimerisation of 
α and β receptors and consequent autophosphorylation leads to activation of intracellular 
signalling cascades. 
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fibroblast response by inducing the autocrine production of PDGF-AA. However, at higher 
doses PDGFRα expression was down-regulated in a negative feedback mechanism 70. SSc 
fibroblasts mount a mitogenic response to TGFβ over a wide range of concentrations. In 
turn, PDGF-AA and AB up-regulate the expression of TGFβR2 on dermal fibroblasts 71. In 
summary, PDGF and TGFβ appear to work in concert to increase the mitogenic and 
profibrotic fibroblast phenotype.  
IL-1α is constitutively expressed by SSc fibroblasts in culture and induces PDGF and IL-6 
expression 35. PDGF and IL-6 can act together to increase cell proliferation and induce the 
production of collagen, respectively 35. The serine protease thrombin can also induce the 
expression of PDGF-AA and PDGFRα and is increased in bronchoalveolar lavage fluid of 
patients with SSc 72.   
There is evidence that the sera of patients with SSc may contain antibodies directed against 
PDGFR. These appear to be functional as they induce tyrosine phosphorylation of the 
downstream signalling protein ERK1/2, increase fibroblast ROS generation and induce 
fibroblast collagen production. Therefore, these antibodies are of potential pathogenic 
relevance in SSc, though independent reproduction of this data is still required to confirm 
this finding 73. 
Many partially successful anti-fibrotic agents may exert their effects through blocking PDGF 
signalling. No treatments are yet available to treat fibrosis in SSc, because, at least in 
theory, once fibrosis is established, targeting profibrotic cytokines is only likely to prevent 
progression at best, and is unlikely to mediate improvement.  
Imatinib is a protein tyrosine kinase inhibitor that can block the activity of PDGFR. It has 
been used for the treatment of chronic myeloid leukaemia and can regress bone marrow 
fibrosis in this condition. It has been trialed in animal models of SSc including the bleomycin-
induced fibrosis model and the tight skin mouse model (TSK-1) 74. These studies have given 
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different information regarding the possible utility of this agent in SSc. Imatinib was able to 
prevent the development of fibrosis in the bleomycin model but this gave no information 
about its ability to treat established fibrosis. Therefore, the investigators administered 
Imatinib to the TSK-1 mice and were able to demonstrate not only a decrease in 
myofibroblast differentiation but also a regression of established fibrosis. Imatinib drastically 
decreased the production of extracellular matrix, but no effect has been demonstrated on the 
production of enzymes that break this down e.g. MMPs. This may indicate that regression 
occurs purely by decrease in matrix production allowing the natural pool of enzymes to break 
down the fibrotic areas 74.  
The fact remains however, that although these are good models of fibrosis, they are 
incomplete models of SSc. In particular, the potentially antiangiogenic actions of Imatinib 
remain a concern in a cohort of patients who already lack angiogenesis and may have 
ischaemic symptoms 75. 
One case study in a patient with SSc treated with Imatinib exists. Fibroblasts from the patient 
were explanted and treated with TGFβ in the presence and absence of Imatinib. Imatinib 
decreased the proliferation and collagen mRNA production by fibroblasts in response to 
TGFβ. In addition, the patient demonstrated a clinical improvement 76. Interim results from 2 
trials using Imatinib in SSc were reported at the American College of Rheumatology 
meeting, 2009.  
Gordon et al reported on an open label study of Imatinib in 30 SSc patients with a primary 
endpoint of safety. They reported 156 adverse events, 24 serious adverse events and 1 
death. Only 16 patients were able to complete the study. They did however, report 
improvements in skin score, FVC, DLCO and histologic features on skin biopsy.  
Pope et al reported on a placebo-controlled, randomized, double blind, mechanistic study. 
They only enrolled 10 patients and the trial was stopped due to the high number of adverse 
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events. Only 4 patients managed to complete the study. No benefits were seen in this small 
number of patients. 
1.4.4 Interleukin-6. 
Interleukin-6 (IL-6) is increased in the serum of patients with SSc and this correlates with 
disease activity 77-83. Immunocytochemical studies reveal an increase in IL-6 staining in the 
lesional skin of patients with SSc. Unlike other pro-inflammatory cytokines, IL-6 is found in 
late as well as early biopsy specimens implying that it has a continuing role in disease 
pathogenesis 79. IL-6 is a pro-fibrotic cytokine that increases collagen and extracellular 
matrix production by fibroblasts 84. It also increases the expression of mononuclear cell 
chemokines such as MCP-1 and VEGF in fibroblasts and endothelial cells 85-88. IL-6 may 
have a role in the proliferation of synovial fibroblasts in rheumatoid arthritis 89.  However, 
these authors only found a pro-proliferative effect in one synovial sample out of 4 and further 
examination of this and other synovial samples demonstrated an anti-proliferative effect 90; 
experiments with dermal fibroblasts show that IL-6 inhibits proliferation 91.  
IL-6 can induce myofibroblast differentiation 92, and also has an activating role for endothelial 
cells, increasing the expression of cell surface leukocyte receptors, and increasing cytokine 
(IL-6) and chemokine expression (MCP-1 and IL-8) 93 94. 
IL-6 also has an important role in the transition from acute to chronic inflammation and the 
maintenance of chronic inflammation 95-97. This occurs through the activation of T-cells, 
delaying T-cell apoptosis and altering the chemokine profile from neutrophil attractants (IL-8) 
to monocyte attractants (MCP-1) 98 99. In addition, IL-6 may increase neutrophil apoptosis, 
though this is controversial 95 100-102.  
IL-6 has a role in the differentiation of B-cells towards plasma cells and may account for the 
hypergammaglobulinaemia which is a feature of SSc. Finally, IL-6 may have a role in 
promoting autoimmune phenomena which are one of the clinical hallmarks of this disease 99. 
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1.4.5 Monocyte chemoattractant protein-1 
MCP-1 is a chemokine of the C-C type that has been reclassified as CCL2. It is 
predominantly a monocyte/macrophage chemoattractant and mainly signals through the 
chemokine receptor CCR2. However, there is significant overlap: many chemokines signal 
through multiple chemokine receptors and chemokine receptors may respond to ligation by 
multiple chemokines. In addition to its effect on chemotaxis, there is additional evidence that 
MCP-1 may have a profibrotic role.  
In rat lung fibroblasts, it increases the production of collagen by increasing TGFβ 103. CCL2 
seems to have an additional direct effect on collagen mRNA levels in vitro, increasing 
transcripts for type 1 collagen in human dermal fibroblasts with kinetics that suggest that it is 
a direct phenomenon 104. The difference noted between rat lung fibroblast and human 
Fig. 5. Biological actions of interleukin-6 and interleukin-6 trans signalling in vivo and in vitro. 
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dermal fibroblast response to CCL2 may reflect the well-described phenotypic heterogeneity 
of fibroblasts. The authors, however, did not directly explore collagen protein expression in 
response to CCL2. Distler et al, in contrast, cultured both normal and SSc fibroblasts in vitro 
with CCL2 and found no increase in collagen protein expression 105. This may reflect the fact 
that the increased transcripts are not translated, or more likely may be related to differences 
in the CCL2 concentrations used. Yamamoto et al used 10ng/ml whereas Distler et al used 
100 and 400ng/ml. Serum concentrations of CCL2 are around 200pg/ml but local tissue 
concentrations are unknown.  
CCR2 was co-expressed with α-smooth muscle actin (αSMA) a myofibroblast marker, in a 
small proportion of dermal fibroblasts, and the proportion of total fibroblasts with this 
phenotype was higher in SSc than in controls. In this population of fibroblasts, specific 
inhibition of CCL2 or CCR2 attenuated the expression of αSMA implying a role for CCL2 in 
myofibroblast differentiation 106.  
CCL2 is increased in the serum and bronchoalveolar lavage fluids of patients with SSc and 
is associated with renal disease and pulmonary fibrosis 82 107 108. T-cell lines isolated from 
SSc patients express more CCL2 than controls when stimulated with PMA and ionomycin in 
vitro 82. PBMCs isolated from patients with SSc have an enhanced spontaneous production 
of CCL2 in culture 109.  
CCL2 expression is increased in the skin of patients with SSc and is almost undetectable in 
controls 105 108 110. It is localized to infiltrating monocytes, keratinocytes, fibroblasts and 
endothelial cells in patients with both limited and diffuse disease. The CCR2 is also 
increased in the skin of patients with SSc but is associated with early disease in the diffuse 
subset. It was located within myofibroblasts, pericytes, lymphocytes, macrophages and 
endothelial cells.  
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Fibroblasts in culture also spontaneously produce increased amounts of CCL2 compared to 
controls, with a dampened increase in CCL2 production in response to hypoxia 33. An 
autocrine positive feedback loop also exists, as CCL2 is shown to increase CCL2 mRNA 
expression in SSc fibroblasts but not control fibroblasts 111. Distler et al reported no increase 
in constitutive CCL2 expression by SSc fibroblasts but a greater induction of the chemokine 
in response to PDGF in SSc fibroblasts than controls 105. 
A functional single nucleotide polymorphism in the promoter region of CCL2 has been 
reported in association with SSc by 2 groups, in Germany and Slovenia 112 113. However, two 
larger European cohorts failed to demonstrate such an association 114 115. The populations 
are of similar ethnic origins, and the differences are likely to be due to sample size. 
In vitro models of SSc have shown an important role for CCL2 in monocyte chemotaxis. 
Dermal fibroblasts explanted from the skin of SSc patients or controls were co-cultured 
below an endothelial cell line monolayer (1E-7). The transmigration of mononuclear cells 
(U937) through the endothelial cells was measured. The proportion of transmigrating cells 
was much greater towards SSc fibroblasts than controls. In addition, fibroblast-conditioned 
media from SSc and control fibroblast cultures were used to stimulate transmigration through 
the endothelial cell layer, and again the conditioned media from the SSc fibroblasts had a 
more profound response. This was unrelated to any effect on leukocyte adhesion molecule 
expression on the surface of endothelial cells, but was blocked by an anti-CCL2 antibody 116. 
This data implies a role for fibroblast derived CCL2 in increasing the mononuclear cell 
infiltrate that is characteristic of SSc histology. 
1.4.6 Endothelin-1. 
Endothelin-1 is one of three closely-related vasoactive peptides, endothelin-1,2 and 3. As 
well as its prominent role in vasoconstriction, it has pleiotropic effects on fibroblasts and 
endothelial cells. Its expression is induced by TGFβ, a potent profibrotic cytokine whose role 
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in SSc is outlined above 117. In smooth muscle, endothelin-1 is associated with proliferation, 
contraction and production of profibrotic cytokines such as TGFβ, CTGF and PDGF 118-121. In 
fibroblasts, it causes myofibroblast differentiation as well as increased production of cell 
surface leukocyte adhesion molecules and the production of extracellular matrix proteins 122-
125. The effects of endothelin-1 on endothelial cells include an increase in the expression of 
leukocyte adhesion molecules and production of nitric oxide 121. Endothelin-1 also has 
actions on macrophages with an increase in the release of free radicals and the production 
of chemokines (IL-8 and CCL2) and cytokines (TGFβ) 121 126.  Endothelin-1 thus has 
interesting roles which may be relevant, not only to the vasospastic Raynaud’s phenomenon, 
but also the tissue remodeling which is a feature of the vasculopathy and fibrosis in this 
disease.  
Endothelin-1 expression is increased in the serum and bronchoalveolar lavage fluid of 
patients with SSc 127-129. Elevated levels of endothelin-1 have been found in the skin, lungs, 
blood vessels and kidney of patients with SSc 130-133. Increased endothelin receptor 
expression has been found in presclerotic and early diffuse skin lesions. 
Preliminary results with the endothelin antagonist Bosentan were initially very exciting as it 
normalized the gene expression of explanted SSc fibroblasts 134. In a large study of patients 
with primary and secondary pulmonary artery hypertension, Bosentan significantly improved 
the symptoms of patients with pulmonary hypertension and this was also true in a sub-group 
analysis of SSc patients 135. A follow up study went on to demonstrate an additional increase 
in patient survival 136. However, later studies were not so positive. Bosentan failed to make a 
difference in SSc associated pulmonary fibrosis 137 138. Trials where the primary outcome 
measure was digital ulcer healing, showed that Bosentan had no effect on digital ulcer 
healing but it did decrease the rate of new ulcer formation 139.  
Mechanistic studies have attempted to examine the effects of Bosentan on endothelial cell 
function. One study reported no change in endothelial cell dependent- and independent-
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vasodilatory responses, no changes in capillary permeability, capillary density, capillary 
structure or serum markers of endothelial dysfunction in 15 patients treated for 12 weeks 
with Bosentan 140. However, this study suffered from small sample size, especially given the 
wide variability in the techniques used and the lack of control patients.  
Another study, with a control arm showed an improvement in endothelial dependent 
vasodilatory responses in just 10 min with an endothelin receptor type A specific inhibitor 
(BQ-123) 141. These results are exciting but somewhat surprising in terms of the kinetics, and 
need to be independently reproduced. 
1.4.7 Other cytokines. 
The expression of many other cytokines have been inconsistently associated with SSc 
including IL-1β, IL2, IL4, IL8, IL10, TNFα and others. However, the roles of these cytokines 
have been less rigorously explored and therefore are not reviewed here. 
1.5 Leukocytes in SSc. 
There is significant evidence to imply a role for the immune system in SSc. Histological 
specimens consistently demonstrate an immune cell infiltrate in lesional biopsies from 
patients with SSc. This is usually reported as a mononuclear infiltrate, but one study by 
Hussein et al also implicated eosinophils and neutrophils 142. Bronchoalveolar lavage fluids 
are also associated with a leukocyte infiltrate. 
SSc is characterised by specific autoimmune phenomena, the majority of patients express 
auto-antibodies and the auto-antibody profile correlates with disease expression. Recently, 
potentially pathogenic autoantibodies have been reported e.g. anti-fibroblast antibodies, anti-
endothelial cell antibodies and antibodies directed against the PDGF receptor 10 49 73 143.  
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Recent pan-genome studies of gene expression in SSc have shown that the disease is 
strongly associated with HLA phenotype, which again implies a significant role for the 
immune system 144 145. 
Autologous stem cell transplants have been used for patients with autoimmune diseases 
including SSc, the aim of which is to ablate the cells of the adaptive immune system and 
allow them to reconstitute and develop a new concept of self, thus eliminating autoreactive T 
and B lymphocytes. Autologous stem cell transplants have, in small studies, shown clinical 
benefit in SSc, including an improvement of fibrosis on biopsy and improvement of vascular 
abnormalities on nailbed capillaroscopy. In addition, stabilisation of symptoms has been 
noted. Initial protocols have been improved to give a more favourable risk: benefit ratio and 
larger studies with control (cyclophosphamide) arms are now under way in Europe and North 
America. These studies should clarify the role for stem cell transplantation, but the fact that 
re-setting the adaptive immune system can lead to signs of clinical improvement implies a 
role for the immune system in the perpetuation if not the initiation of the disease process 146. 
1.5.1 T-lymphocytes. 
T lymphocytes are seen in the skin of patients with SSc, although there is not an increased 
number compared to healthy controls 142. However, T-cells in the skin of patients appear to 
be activated as they express higher levels of activation markers CD69 and HLA-DR 147 148. T-
cells in the peripheral blood of patients show an increase in the ratio of CD4+ T helper cells 
to CD8+ cytotoxic T-cells 142. In addition, there is a decrease in the number of regulatory T-
cells (T-reg) in patients with SSc 149. T-regs have an important role in negatively regulating 
T-cell functions and in particular in regulating autoimmune activation. Although patients with 
SSc have a smaller proportion of T-reg cells, their T-regs have an increased expression of 
CD25, implying chronic activation. Functional studies have not been performed on the Treg 
cells of SSc patients, and this would be important in the future to clarify their role in disease 
pathogenesis.  
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One of the most interesting findings is that T-cells from patients with SSc seem to show 
monoclonal or oligoclonal expansion 150. This implies antigen-driven T-cell activation, though 
the specific antigen has not yet been identified. Microchimerism, leading to a type of graft 
versus host disease, and topoisomerase 1 have been suggested as possible antigenic 
stimuli. However, inducing autoreactivity against topoisomerase 1 in mice does not result in 
a SSc like phenotype. This may reflect human/murine differences, or may reflect the fact that 
anti-topoisomerase antibodies alone are not sufficient to cause the disease phenotype. 
Some investigators propose that T-cells from the skin and circulation of patients with SSc 
show a predominantly type 2 T-helper cell phenotype and as such secrete profibrotic 
cytokines such as IL-4 and IL-13 151. However, a synthesis of the available published 
literature is rather contradictory and no clear pattern of cytokine expression emerges when 
serum or bronchoalveolar lavage fluid is analysed. This is likely to be due to the changes in 
the immune response depending on the stage and the activity of the disease, and may also 
reflect the overall heterogeneity of the disease. One group of investigators identified a novel 
subset of T-cells which were CD4+/CD8+ double positive cells in SSc 152. These cells were 
identified in both skin derived T-cell lines and in vivo in the skin of SSc patients. In culture, 
this distinct subset of cells produced very high levels of IL-4.  
T-cells from patients with SSc have an increased propensity to migrate spontaneously 
across endothelial cell layers 148. It is intriguing therefore, that investigators have found a 
decrease in the CD8+ T-cell expression of L-selectin, a T-cell adhesion molecule that is 
thought to promote adhesion of T-cells to endothelial cells and subsequent migration 153. 
However, it is not the primary molecule mediating migration and these processes are 
somewhat separate; indeed expression of adhesion molecules CD11a, CD49d, CD29 and 
CD44 were elevated in lymphocytes recovered following endothelial transmigration 148. 
Cytotoxic γδ T-cells are T-cells that have cytolytic capabilities and are not MHC restricted: 
they are capable, therefore, of interacting with intact, unprocessed self antigen. There are 
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reports that they accumulate in the lesional skin and lungs of patients with SSc and a 
polymorphism in the T-cell receptor γ gene is associated with SSc 154-156.  
Cytotoxic T-cells collected from the PBMC fraction of SSc patient blood following stimulation 
and immuno-magnetic separation were compared to similarly-isolated cells from matched 
controls. Cytotoxic T-cells isolated from SSc patients demonstrated increased adhesion to 
unstimulated endothelial cells in culture, increased proliferation when incubated with 
irradiated endothelial cells, and increased cytotoxicity towards endothelial cells but not 
fibroblasts. The cytotoxicity towards endothelial cells was reversed by anti-TCRγδ and anti-
granzyme antibodies implicating activation of the granzyme/perforin cytotoxicity mechanism 
and interactions involving the TCRγδ 157. Therefore, T-cell endothelial cell interactions may 
be important in causing the endothelial cell damage that is implicated in the pathogenesis of 
SSc. 
1.5.2 B-lymphocytes. 
B cells and plasma cells form a minor part of the mononuclear cell infiltrate seen in patients 
with SSc. However, gene expression experiments show that genes associated with B-cells 
are associated with SSc skin 145.  
Naϊve B-cells are increased in the circulation of patients with SSc but memory B-cells are 
decreased 158. B-cells in the circulation of patients with SSc express higher levels of 
activation markers (CD80, CD86 and CD95) and CD19 158. CD19 modulates B-cell function, 
and in mice, over-expression promotes autoantibody production.  
There is a generalized hypergammaglobulinaemia associated with SSc and 95% of patients 
with SSc express autoantibodies. These autoantibodies segregate with disease phenotype 
and some are thought to have potentially pathogenic roles including anti endothelial cell 
antibodies that can cause endothelial cell activation and apoptosis.  They may also have a 
role in antibody dependent cellular cytotoxicity 10 143.  
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Bleomycin administration in wild type mice induces fibrosis, but development of the 
phenotype is inhibited in CD19 deficient mice 159. B-cell depletion in neonatal but not adult 
Tsk mice resulted in decreased fibrosis as did antagonism of B-cell activating factor (BAFF) 
160 161. Finally, blockade of CD40/CD40 ligand interactions in Tsk neonatal mice inhibited 
fibrosis and autoantibody generation 162.  
Serum levels of BAFF are increased in patients with SSc and B-cells from patients express 
increased levels of BAFF receptor 163. BAFF signalling promotes B-cell survival and may be 
implicated in the rescue of autoreactive B-cells. 
In the Tsk mouse model, infusion of bone marrow derived from Tsk mice into normal 
littermates results in the development, over time, of a Tsk/SSc phenotype 164. This was not a 
graft versus host response as control mice were infused with normal littermate bone marrow, 
and sibling tissue grafts did not elicit any graft versus host response. Interestingly, 
transfusing differentiated Tsk B-cells into healthy littermates transferred antibody production 
but did not result in a fibrotic phenotype. Infusion of T-cells alone did not alter the phenotype 
at all but infusion of both T and B-cells resulted in a very mild fibrotic phenotype.  
Tsk mice crossed with CD4-/- mice had much less fibrosis but still developed autoantibodies. 
Tsk mice crossed with CD8-/- mice developed similar levels of fibrosis but fewer 
autoantibodies. Tsk mice crossed with Rag-/- mice, which are deficient in both T and B-cells, 
still develop the same fibrotic phenotype 165. These data show that the adaptive immune 
system alone is not sufficient to explain the full phenotype in animal models and that 
different subsets of immune cells may play unique roles in the pathogenesis. These findings 
may be specific to the mouse models alone but are persuasive evidence that other cell 
types, the precise environment and perhaps the genetic background may play additional and 
important roles in the disease phenotype. 
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T-bet-/- mice when exposed to bleomycin produce a florid fibrogenic response. However, 
when crossed with B and T-cell deficient mice these mice still have a fibrogenic response to 
bleomycin, arguing against a significant role for the adaptive immune system in this 
phenotype. When the same T-bet -/- mice are crossed with IL-13-/- mice no fibrotic response 
is seen in response to bleomycin, therefore arguing for an important role for IL-13. The 
source of this IL-13 remains unclear 166. 
1.5.3 Monocytes. 
Monocytes or histiocytes (monocyte derived tissue dwelling cells) are the predominant cell 
type in the mononuclear cell infiltrate of early SSc 142. There is, however, no significant 
increase in monocytes in the bronchoalveolar lavage fluid of patients with SSc compared to 
controls 142. Circulating monocytes are not increased in number, but monocytes isolated from 
the circulation have several important features when cultured ex vivo. 
Monocytes from SSc patients spontaneously, and in response to phorbol esters, produce 
increased amounts of superoxide anion in culture compared to cells isolated from healthy 
controls or patients with primary Raynaud’s phenomenon 167. Higher levels of superoxide 
generation were associated particularly with early diffuse disease. This could contribute to 
the increased oxidative stress that may be important in this disease (see later section).  
Monocytes from SSc patients spontaneously express higher concentrations of TGF1β in 
culture than healthy control cells 168. They also produce higher levels of spontaneous- and 
LPS-stimulated IL-6 in culture than control monocytes 169.  
Monocytes from patients with SSc have an increased expression of interferon-responsive 
genes 170-172, which include Siglec-1/sialoadhesin that is induced by type 1 interferons, and 
AIF1 that is induced by γ-interferon. SSc serum can induce interferon-α release from PBMCs 
especially when the sera contains anti-topoisomerase antibodies 173. This increase in 
“interferon signature” may reflect innate immune system activation via Toll like receptors 
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(TLRs). Other consequences of TLR activation in monocyte/macrophages include the 
production of IL-1, TNFα and IL-6 which may drive inflammation and fibrosis, as outlined 
above 174. 
One group has identified constitutive production of IL-1 by cultured SSc monocytes 175. 
However, others were unable to reproduce these findings, though they used unfractionated 
PBMCs in their study 176. The latter used a functional assay to measure IL-1 concentration 
and their data showed evidence for an inhibitor of IL-1 in SSc PBMC culture supernatants. 
1.6 Hypoxia in SSc. 
SSc is characterized by microvascular abnormalities and an overall capillary loss in lesional 
skin. In addition, the deposition of extracellular matrix in the lesional tissue increases the 
distance between cells and their blood supply and interrupts the diffusion of oxygen to the 
tissues. Thus, one would expect to find that the lesional tissues in SSc suffer from a degree 
of hypoxia. Two separate groups have confirmed that this is the case 62 177. Involved skin 
was found to be hypoxic and the degree of hypoxia correlated with the skin thickness, 
adding weight to the hypothesis that the laying down of extracellular matrix contributes to 
hypoxia 177. Oxygen levels in lesional (but not non-lesional) skin were found to be around 3% 
62, sufficient to induce hypoxia induced gene expression. 
Hypoxia induced gene expression frequently occurs via an increase in HIF1α stability and a 
resultant HIF1α-dependent gene transcription. Therefore, it is somewhat surprising that 
HIF1α expression is not increased in the lesional skin of patients with SSc; in fact the 
expression seems to be lower than in controls 60 62. The reason is not clear, but possible 
reasons will be explored in later chapters. What is apparent, however, is that proteins that 
are typically increased in response to hypoxia are elevated in the skin of patients with SSc, 
including VEGF, PDGF and endothelin-1, as mentioned above. It is possible that hypoxia-
independent mechanisms increase the levels of these growth factors or perhaps the 
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expression is controlled by alternative hypoxia-inducible pathways e.g. HIF2α, HIF3α or 
activating protein-1 (AP-1).  
Hypoxia may have an active role in perpetuating the disease process in SSc. Hypoxia is 
present in the skin of patients of SSc as mentioned, but is not a persistent feature of 
Raynaud’s phenomenon. Although short-term hypoxia causes adaptive responses to 
increase angiogenesis and vasculoneogenesis and changes in vascular tone to increase 
blood flow, long term hypoxia results in plastic changes. These changes include proliferation 
of smooth muscle cells that may result in intimal hyperplasia, as seen in pulmonary artery 
hypertension and SSc renal crisis and fibrosis. In addition, persistently increased levels of 
VEGF, which can be induced by hypoxia, can result in disorganised angiogenesis and 
vasculoneogenesis that can closely resemble the SSc phenotype 61. 
Hypoxia leads to an induction of collagen genes and collagen-modifying enzymes in many 
tissue types, including endothelial cells. Dermal fibroblasts express increased concentrations 
of extracellular matrix proteins in response to hypoxia in culture 178-180. This change was 
time-dependent and proportional to the degree of hypoxia. In a mouse model of normobaric 
hypoxia, increased secretion of extracellular matrix proteins occurred as soon as 24h 181. 
Antibodies against TGF1β abrogated the effects of hypoxia on fibroblast extracellular matrix 
expression in healthy control and SSc fibroblasts in culture 180. These data imply a central 
role for TGF1β in hypoxia-induced fibrosis. 
1.7 Oxidative stress in SSc. 
There is accumulating evidence that oxidative stress may be important in the pathogenesis 
and perpetuation of SSc. Ischaemia-reperfusion injury, which is presumed to occur after 
repeated episodes of Raynaud’s phenomenon, causes an increase in free radicals in the 
form of ROS and reactive nitrogen species. In addition, inflammation leads to increased 
production of reactive species. 
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 These free radicals are highly reactive and contribute to what is termed “oxidative stress”. 
Many cell types can produce ROS; phagocytes (neutrophils and macrophages) have a 
NADPH dependent oxidoreductase and the ROS are used as an antimicrobial system. Other 
cell types including endothelial cells, chondrocytes, lymphocytes and fibroblasts express 
NADPH-oxidase which can produce ROS. Endothelial cells, in addition, express xanthine 
oxidase which can produce OH., O2
.-, and H2O2.  
Free radicals can cause damage to proteins, lipids and DNA and can lead to irreversible cell 
membrane damage and cell death via necrosis or apoptosis. Endothelial cells are 
particularly vulnerable to free radical damage as they lack the protective enzyme, catalase 
182. Products of lipid peroxidation can also be cytotoxic and alter T-cell/macrophage 
interactions 183. Oxidation of lipoproteins can result in products which are chemotactic for 
monocytes, and cytotoxic to endothelial cells and smooth muscle cells 184. In addition, they 
can stimulate the formation of connective tissue and promote interactions between 
monocytes and endothelial cells 185 186.  
 
 
 
ROS also act as second messengers in many receptor ligand pathways, and can lead to the 
differentiation of many cell types including immune cells, fibroblasts, pericytes and vascular 
smooth muscle. VEGF, PDGF and TGFβ can all act through NADPH oxidase dependent 
pathways. Angiotensin II and thrombin can also activate NADPH oxidase 11. 
By-products of oxidative damage can be measured in the plasma and urine. 
Malondialdehyde (MDA) is the end product of lipid peroxidation and serum levels have been 
validated as marker of oxidant stress. Levels were found to be 10-fold higher in SSc serum 
Fig. 6. Oxidative stress in the pathogenesis of SSc. Oxidative stress leads to 
endothelial damage, perivascular immune cell infiltrate and fibrosis. The process is self 
perpetuating. This material has been removed from the abridged version but can be 
found in Simonini et al 3 Figure 1. 
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than in control serum especially in early disease 187 188. Erythrocyte MDA levels were also 
elevated in patients with SSc 188. Isoprostanes, which are products of free radical catalysed 
arachidonic acid peroxidation, can be measured in various biological fluids. They are stable 
in urine where non-invasive monitoring can be performed. Levels change in models of 
oxidant injury and in response to antioxidant treatments, but are not affected by the lipid 
content of the diet. Their levels are increased in SSc and are associated with early stages of 
the disease, but not with primary Raynaud’s phenomenon 189. They correlate with pulmonary 
fibrosis and with nailfold capillary abnormalities, but not with the degree of skin involvement 
190 191.  
Cracowski et al demonstrated that not only were the F2-isoprostanes elevated in the urine of 
patients with SSc, but that levels correlated with post-occlusive hyperaemia, a measure of 
endothelial cell function in these patients 192.  
Serum 8-isoprostane levels are increased in diffuse and limited SSc, and correlate 
negatively with lung function and positively with renal blood flow. Levels also correlated with 
serum IgG concentrations and anti-agalactosyl levels 190. This last point is of interest as 
agalactosyl IgG is thought to self-aggregate to form immune complexes 193 194. Immune 
complexes can bind to the Fc receptors of neutrophils and monocytes, activating them and 
increasing their production of ROS.  
The same authors also found elevated levels of another marker of oxidative stress, namely 
Nε-(hexanoyl)lysine (HEL), to be elevated in SSc. They did not identify any difference 
between limited and diffuse disease but again, found levels to be correlated with the anti-
agalactosyl IgG antibody concentration and rheumatoid factor titre 195. In this study however, 
they also found that patients with systemic lupus erythematosus (SLE) and dermatomyositis 
had elevated levels HEL, and in fact levels were even higher in these patients. Although 
these patients can suffer with Raynaud’s phenomenon, they do not tend to have major 
episodes of ischaemia-reperfusion as seen in SSc. This might argue against ischaemia-
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reperfusion being the main instigator of oxidative stress and may point towards inflammation 
as the cause of increased oxidative stress, as inflammation is more prominent in these 
autoimmune conditions. Equally, primary Raynaud’s phenomenon is not associated with an 
increase in markers of oxidative stress and therefore if ischaemia-reperfusion is involved in 
the generation of ROS in SSc, it is more likely to be due to the chronic ischaemia that can 
occur in this condition 11. 
One group of investigators chose to measure markers not only of lipid peroxidation (ROOH), 
but also markers of protein oxidative damage (sulphydryl and carbonyl groups) in the 
plasma. They found that the markers of lipid peroxidation were raised in SSc. While 
sulphydryl groups were decreased in the plasma, consistent with oxidative protein damage 
in SSc; carbonyl groups, however, were unchanged. Markers of lipid peroxidation correlated 
with changes measured by nailfold capillaroscopy, whereas markers of oxidative protein 
damage correlated with Rodnan’s skin score and pulmonary fibrosis (carbonyl) and 
gastrointestinal involvement (sulphydryl) 196. The reasons for these discrepancies are 
unclear, but in vitro oxidative changes to proteins occur rapidly ex vivo and therefore there 
may be non-specific changes occurring in the plasma samples, especially the samples for 
carbonyl assessment that were frozen after 1h and analysed after 24h. The study is also 
limited by the relatively small sample size, and so the associations with disease 
manifestations might be less specific were the sample size to be increased. 
Other markers of lipid peroxidation include diene-conjugates which were also raised in the 
serum of patients with SSc and were higher both in the limited form of the disease, and early 
in the disease course 3. 
Genetic polymorphisms in the glutathione-S-transferase enzyme (which acts as a free-
radical scavenger) are associated with SSc 197. The anti-oxidant capacity in SSc also 
appears to be decreased 198. Elements such as selenium and vitamins such as vitamin-C, 
vitamin-E and carotene are decreased in patients with SSc, and this does not appear to be 
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due to a dietary anomaly 19 199. Malabsorption does not seem to contribute to the decreased 
plasma levels except when there is evidence of bacterial overgrowth 200. It may simply be, 
however, that the normal anti-oxidant capacity is overwhelmed by persistent elevations in 
ROS, resulting in a consumptive decrease in detectable anti-oxidants. 
Attempts have been made to assess the total anti-oxidant capacity in venous blood from 
patients with SSc compared to controls, using a ferric reducing assay 201. It was found that 
the total anti-oxidant capacity was unchanged in SSc. The reason for this is unclear and 
appears to counter the previously published evidence that consistently shows a decrease in 
individual antioxidants. This may suggest that unmeasured antioxidants may be 
compensating for the relative lack of anti-oxidants measured in other studies. The venous 
levels of antioxidants may not be as important as the local tissue levels where ROS are 
being generated and oxidative damage is occurring. 
Exposure of endothelial cells to ROS results in damage to the cell membrane and 
degeneration and reduplication of the basement membrane, changes that can be typically 
seen on histological samples from patients with SSc. ROS also increase the expression of 
adhesion molecules and increase vascular permeability. Damage to the endothelial cell layer 
by ROS results in a loss of vascular tone control and a pro-thrombogenic state 11.  
There is evidence that ROS can cause damage to and fragmentation of antigens in a metal-
dependent manner, resulting in the exposure of neo-antigens and the promotion of SSc 
associated auto-antigen responses 202.  
Oxidative stress is reported to promote fibrosis. Fibroblasts explanted from the skin of SSc 
patients spontaneously produce more O2
- and H2O2 through the NADPH oxidase complex 
than control fibroblasts 203. Control fibroblasts can be stimulated to produce ROS in response 
to IL1-β, PDGF BB, TGFβ and H2O2 but SSc fibroblasts cannot be stimulated by these 
factors to produce any further increase in ROS, implying that they are maximally stimulated 
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already 203. Constitutive ROS generation in SSc fibroblasts was not decreased in response 
to superoxide dismutase, catalase, IL-1Ra, anti-TGFβ or anti-PDGF BB. However, it was 
decreased by the intracellular anti-oxidant N-acetyl cysteine. In addition, this anti-oxidant 
decreased the proliferative capacity and collagen mRNA expression of SSc fibroblasts 203. 
This data implies that constitutive ROS generation by SSc fibroblasts may occur via a 
positive autocrine feedback mechanism and that it may be involved in the fibrogenic 
phenotype of these cells. 
ROS can increase the release of the profibrotic cytokine TGFβ from pulmonary epithelial 
cells and can activate TGFβ by displacing it from latency-associated peptide 204 205. H2O2 can 
stimulate the Ets dependent transcription of TGFβ and collagen I synthesis 206 207. 
The hypothesis that oxidative stress has a pivotal role in SSc pathogenesis would be 
stronger if treatment with anti-oxidants resulted in evidence of improvement in clinical trials. 
However, results so far have been disappointing 208-210. This may result from the high 
turnover of ROS, which are highly reactive, the inability to control local levels of oxidant 
stress and limitation of trials to date. Clinical trials in SSc are hampered by the lack of 
dynamic, sensitive, reproducible outcome measures, the relative rarity of the condition and 
the inherent heterogeneity in the disease phenotype. Another group of therapies that may 
impact this process are vasodilators, which may decrease ROS by suppressing vasospastic 
events and therefore decreasing ischaemia reperfusion. To this end, prostacyclins have 
been associated with a normalization in oxidative stress 211. Prostacyclins also have direct 
effects on phagocyte function and therefore may have an additional affect on immune 
generated ROS.  
1.8 Neutrophils in SSc. 
Neutrophils have been largely overlooked in SSc. This may be due to the fact that 
neutrophils do not form a major part of the infiltrate in SSc lesional skin and also because 
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SSc sclerosis is not traditionally thought of as an inflammatory disease. Although SSc is not 
usually associated with a rise in inflammatory markers, inflammation, depending on the 
definition used, is very much a part of this disease, in this respect it shares many features 
with atherosclerosis. Inflammation is more prominent in the early stages of the SSc, which is 
associated with an immune cell infiltrate in lesional tissues and higher expression of pro-
inflammatory cytokines. However, inflammatory features persist throughout the disease, 
including markers of endothelial cell activation and continued tissue expression of IL-6. 
Oxidative stress continues throughout the disease and may be the result of ischaemia-
reperfusion injury and immune cell activation. Ischaemia–reperfusion is associated with a 
pronounced neutrophil activation and binding of neutrophils to endothelial cells, which then 
initiates a local inflammatory cascade.  
Neutrophils are not prominent in the immune cell infiltrate of lesional skin in SSc; however, 
Hussein et al showed that, unlike lymphocytes, neutrophils are numerically increased in the 
skin of patients with SSc 142. Endothelial cells are activated in SSc and there is an increase 
in the expression of cell adhesion molecules on the surface of endothelial cells. Therefore, it 
is likely that neutrophil adhesion to SSc endothelial surfaces will be increased. If, however 
there is no chemotactic pressure for neutrophils to infiltrate into the skin they may not form a 
significant part of the infiltrate. Endothelial cells produce increased levels of neutrophil 
chemoattractants e.g. IL-8 in SSc early in the disease 79. The role of neutrophils in 
inflammatory processes is usually an acute and relatively transient one, and therefore 
examining lesions at a single static time point may not reveal the true role for neutrophils in 
this disease. 
Neutrophils are the most abundant circulating leukocyte. They are capable of producing 
ROS in significant quantities and are a potent source of proteases. ROS from neutrophils 
could make a significant contribution to the oxidative stress seen in SSc, if ROS were 
released locally at the endothelial surface. Proteases also play complex roles in disease. 
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Proteases can be directly cytotoxic but in addition, it is becoming increasingly clear that 
proteases can play important regulatory roles in cell signalling. 
1.8.1 Neutrophil ROS and reactive nitrogen species generation in SSc 
The published literature regarding neutrophil ROS generation in SSc is highly contradictory. 
This may reflect the heterogeneity of the disease and the recruitment of different disease 
populations by different groups. However, it more likely reflects the different methodologies 
used. There are numerous methods for measuring neutrophil ROS generation but each has 
their limitations and specificity for different species of oxidant. Some methods, for instance 
only measure either intracellular (DHR-123) or extracellular ROS (horseradish peroxidase 
dependent oxidation of phenol red). Others, for instance luminol-enhanced 
chemiluminescence, are capable of measuring both intra- and extra-cellular ROS. Another 
important difference between assays is the precise nature of the ROS measured. Some 
specifically measure superoxide (cytochrome C) whilst others measure H2O2 (DHR-123, 
phenol red), and for others the precise species measured is unclear (chemiluminescence). It 
is important to note that DHR-123 can be affected by reactive nitrogen species as well as 
ROS, both of which have been implicated in SSc. The last important point to consider is 
whether and how neutrophils were separated from whole blood samples. Many isolation 
methods which rely on sedimentation over substances such as dextran, have been shown to 
activate neutrophils, and techniques using density gradients are preferable 212-214. It is 
possible to measure ROS generation in whole blood, which has many advantages; cells are 
not activated by separation procedures and the assays can reproduce the physiological 
environment preserving many of the cytokine and leukocyte interactions that occur in vivo. 
However, whole blood techniques do not discriminate which cell type is producing ROS, and 
while neutrophils have been shown to be the main producers of ROS in whole blood, this 
may depend on the exact circumstances, and other cell types in peripheral blood are 
capable of producing ROS (e.g. monocytes).  
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Some papers report an increase in ROS production by SSc neutrophils compared to 
controls. Maslen et al. in 1987 initially reported that following Percoll gradient isolation and 
using horseradish peroxidase dependent oxidation of phenol red dye to measure 
extracellular H2O2 secretion, unstimulated SSc neutrophils produced more ROS than 
controls 215. In addition, they reported that fMLP stimulated ROS production was no different 
in SSc neutrophils compared to controls when corrected for endogenous production. They 
did, however, find that the increase in ROS generation in response to immune complexes 
was greater in SSc neutrophils than in controls. They hypothesized that this may reflect an 
increase in Fc receptor expression on the surface of SSc neutrophils as immune complex 
induced ROS production is mediated by these receptors. In support of this hypothesis, they 
found that SSc neutrophils increased the proportion of EA-rosette formation for given 
concentrations of sensitizing IgG. However, they did not directly measure the Fc receptors 
(CD16 or CD32) on the neutrophil surface. The same authors went on to perform further 
studies with similar methodologies and showed that PMA stimulated neutrophils from SSc 
patients produced similar ROS levels compared to controls. 
In agreement with this study, Czirjak et al. also reported an increase in basal ROS 
production in SSc whole blood using luminol enhanced chemiluminescence, which 
measures both intracellular and extracellular ROS 216.  They also reported that zymosan 
stimulation of neutrophils resulted in a similar percentage increase in ROS generation in 
both SSc and control neutrophils. They made the assumption that the main source of ROS 
was neutrophils, but it is interesting to note that others have demonstrated an increase in 
unstimulated ROS production in SSc monocytes and the magnitude of this increase was 
much greater than that seen in SSc neutrophils 167. Therefore, it is not quite clear whether 
the assumptions regarding whole blood assays are valid. Czirjak et al. also reported that 
there were, on average, slightly higher levels of immune complexes in SSc serum compared 
to controls, but no relationship was found with the functional tests. They did not find any 
increase in EA cell binding.      
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Finally, a recent paper using whole blood to examine intracellular H2O2 production using 
DHR-123 found that basal ROS generation was actually decreased in SSc neutrophils 
compared to controls 217. This study had strengths because it benefited from the advantages 
of whole blood assay systems i.e. maintaining in vivo cellular and cytokine interactions but in 
addition it allowed the authors to explore which cell type was producing the ROS. So, ROS 
generation in this system can be measured by cellular fluorescence on a flow cytometer, 
while the different cell types can be gated separately on the flow cytometer, according to 
typical forward and side scatter properties. Then, fluorescence generation in response to 
ROS can be assessed in neutrophil and monocyte populations separately. Also, this method 
can take into account cellular heterogeneity as the fluorescence of each cell will be recorded 
and the variance in ROS generation can be assessed. The disadvantage of this system 
however, is that DHR-123 is an intracellular probe which is converted to a fluorescent 
species following interaction with cellular esterases and H2O2. Experiments have shown that 
intracellular ROS generation does not reflect production by plasma membrane NADPH 
oxidase and passive diffusion into the cell 218. In fact, scavenging of extracellular ROS 
makes no difference to ROS measurements by DHR-123. Therefore, this method does not 
account for the potentially important secretion of ROS by neutrophils.  
The decrease in ROS production seen by this group therefore may reflect the maintenance 
of important cellular and cytokine reactions or it may reflect an inability to capture ROS 
secretion that is measured by other methods. All of these studies, therefore, may reflect an 
increase in ROS secretion by NADPH oxidase and a decrease in intracellular ROS 
generation. It is also important to note that DHR-123, used in this study can also react with 
reactive nitrogen species and increased nitric oxide production by neutrophils has been 
inferred in one study 219.  
One group has reported that the adenosine receptor A2B expression is down regulated in 
SSc neutrophils compared to controls and they postulated that as adenosine is known to 
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decrease neutrophil ROS generation, that down regulation of this receptor may contribute to 
the observed increase in SSc neutrophil ROS generation 220. 
1.8.2 Other neutrophil functions. 
Other neutrophil functions have been occasionally investigated in SSc. Neutrophil 
chemotaxis and random migration have been studied by two groups: the first reported no 
differences in chemotaxis or random migration of SSc neutrophils compared to controls, the 
other reported decreased SSc neutrophil chemotaxis 216 221. The differences may reflect 
methodological differences, since they used different stimulants for chemotaxis, and the 
former group did not stipulate how long they allowed migration to take place. Both groups 
used the modified Boyden chamber and the leading-front method. In our experience, this 
method is difficult to reproduce consistently, and is operator dependent. Both groups used 
dextran sedimentation to isolate neutrophils, which can cause significant neutrophil 
activation, and therefore small but relevant changes in function may have been negated. 
The same reports also explored neutrophil phagocytosis. Neither group found any difference 
in the ability of neutrophils to phagocytose opsonised yeast, although the above comments 
about neutrophil preparation should also be taken into account 216 221. 
No group has directly compared degranulation or protease release from SSc neutrophils 
compared to controls. However, one group explored the serum levels of neutrophil elastase 
and found them to be elevated in SSc serum and to correlate with markers of SSc lung 
disease 222. 
1.8.3 Neutrophil function following treatment with Iloprost. 
Iloprost is a prostacyclin agonist that is known to be useful in the treatment of 
vascular dysfunction in SSc, not only due to short term vasodilatory effects but also 
because of longer term, immuno-modulatory effects lasting up to 3 months. It is 
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therefore extremely interesting to note that Iloprost infusions ( in vivo) have a 
profound effect on neutrophil function (ex vivo). Mazzone et al. examined neutrophil 
ROS generation and integrin expression before and 6h after a continuous infusion 
of Iloprost, and found a significant decrease in ROS generation and integrin 
expression in patients with SSc 223.  
However, this effect was not disease specific and was also seen in patients with 
ischaemia due to peripheral vascular disease, with no clinical evidence of SSc. 
Therefore, this seems to be a consequence of ischaemia rather than SSc 
specifically. Most patients with ischaemia do not generate auto-antibodies, or 
experience the widespread fibrosis that is a feature of SSc. This study implies an 
important role in endothelial dysfunction and damage, but does not suggest a wider 
role for neutrophils in the disease phenotype. The dynamics of the repeated 
ischaemia seen in SSc, however, may provoke the fibrotic and autoimmune 
phenotypes, and neutrophils may still play an important role in this.  
1.9 Summary. 
There is evidence that neutrophils could be important in the pathogenesis of SSc. 
Although, they do not form the predominant immune cell infiltrating lesional skin in 
SSc patients, they are found at increased levels in the skin compared to controls 
142. In addition, these features are only seen in skin with established fibrosis. 
Neutrophils are often an early and transient feature of immune cell infiltrates giving 
way later to chronic inflammatory cells, such as monocytes and cells of the adaptive 
immune system. 
Neutrophil chemotactins are elevated in the serum, the lesional tissue and 
bronchoalveolar lavage fluids in patients with SSc and endothelial cells express 
increased levels of leukocyte adhesion molecules 79 224-226. Therefore, it seems likely 
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that neutrophils would be attracted to endothelial cell lesions that they may be 
initiating inflammation and the resultant fibrosis in this disease. Binding of 
neutrophils to leukocyte adhesion molecules on endothelial  cells, would lead to 
neutrophil activation. 
Finally, there is some evidence to suggest that neutrophils are activated in this 
disease and in particular that they produce ROS that could contribute to the 
increased oxidative stress in SSc, which may itself contribute to perpetuation of 
endothelial injury.  
ROS generation however, is not the only feature of neutrophil biology that could 
potentially lead to endothelial injury. Neutrophils can release proteases, express 
and release cytokines, and release cytokine receptors, all of which could contribute 
to endothelial cell activation and dysfunction. Neutrophils, once thought to be rather 
limited in their immune repertoire, have recently been shown to have multiple and 
complex functions in inflammation, including their ability to interact with cells of the 
adaptive immune system via expression of MHC class II, antigen presentation and 
cytokine production 227.  
Previous studies have shown that the adaptive immune system alone is not sufficient for the 
fibrotic phenotype in animal models165, pointing to the importance of investigating the innate 
immune system in this disease, including the role of the neutrophil. 
1.10 Aims of this thesis. 
Conditions exist in SSc that are likely to promote neutrophil activation. Neutrophil derived 
mediators, including ROS, proteases, cytokines and cytokine receptors could lead to 
pathogenically relevant effects on endothelial cell activation and damage, promotion of 
chronic inflammation and fibrosis. 
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In this thesis, I aim to explore the hypothesis that: “Neutrophils are activated in SSc 
and contribute to endothelial cell activation and injury”.  
The specific aims are: 
1. To define the functional phenotype of neutrophils isolated from patients with 
SSc. This will involve measurements of ROS generation, chemotaxis, 
apoptosis, integrin expression and CD16 expression (reported in Chapter 3). 
2. To explore the ex vivo protein expression of SSc neutrophils compared to 
control neutrophils looking specifically for evidence of neutrophil priming or 
activation. The pan-proteome will be explored using the DIGE technology 
(Chapter 4) and the membrane proteome will be specifically explored using 
the iTRAQ technology (Chapter 5). 
3. To investigate a possible role for neutrophil elastase in SSc (Chapter 6). 
4. To model interactions between neutrophils and endothelial cells in vitro and 
to explore the role of neutrophil-derived mediators in these interactions 
(Chapter 7).        
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Chapter 2: Materials and methods. 
2.1 Materials. 
Annexin V-FITC (Biosource), Anti-CD11b antibody APC conjugated (Miltenyi), Anti-CD16 
antibody APC conjugated,  mitotracker red, trizol, GAPDH primers, sIL6R ELISA 
(Invitrogen), 4 Nitrophenylphosphate  disodium, mouse polyclonal anti-H3 histone antibody, 
mouse monoclonal anti-α tubulin antibody, ATP, catalase, elastase, interleukin-6, 
iodoacetamide, luminol disodium salt, lysophosphatidylcholine, MMTS, phalloidin-FITC, N-
Methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide propidium iodide, TCEP, TEAB, TritonX-100, 
CHAPS, colloidal coomassie blue, PMSF, AEBSF (Sigma), BCA protein assay kit, direct IP 
kit, Albumin/IgG dye based depletion kit (Pierce), calcein-AM, rabbit monoclonal anti-
neutrophil elastase antibody, TNF (Calbiochem), sheep polyclonal anti-S100A8 antibody 
(R&D systems), CD14 positive selection kit (Stem cell technologies), anti-CD16 antibody 
FITC conjugated (BD biosciences), CD3 positive selection beads (Dynal), anti-CD62E 
antibody APC conjugated, rabbit monoclonal anti-MHC class I antibody, anti-ICAM1 antibody 
PE conjugated, rabbit polyclonal anti SERPIN B1 antibody, rabbit polyclonal anti-interleukin-
6 antibody (Abcam), complete mini protease inhibitor tablets, GMCSF (Roche), DHR-123 
(molecular probes), human dermal microvascular endothelial cells, endothelial cell growth 
media MV (Promocell), mouse monoclonal anti eosinophil peroxidase antibody (Chemicon), 
hanging cell culture insert, Micron MWCO devices, Immobilon ECL, luminex 13plex assay kit 
(Millipore), ITRAQ multiplex kit, trypsin (Applied biosystems), PMN elastase ELISA, sICAM1 
ELISA (Bender), Polymorphprep (Axis Shields), random primers, trypsin TLCK (Promega), 
Rapid Romanowsky stain (HD supplies), RPMI+ 2mM glutamine+ 25mM HEPES (Gibco), 
Sorvall tubes 5ml, non-TC coated white 96 well plates (Fisher), Urea, Thiourea, Cy2, Cy3, 
Cy5 (GE Healthcare), MgAc, acetonitrile, ambic (BDH), 30% polyacrylamide, Bio-Lytes 3-10, 
IPG strips 17cm pH 3-10 non linear, RCDC protein assay (Bio-Rad), DTT (Melford), 
RNAeasy RNA extraction kit (Qiagen), sheep monoclonal Anti-MPO antibody (Biodesign).  
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2.2 Methods. 
2.2.1 Neutrophil isolation. 
The study was approved by the Sefton Local Research Ethics Committee, in accordance 
with the Helsinki declaration. Informed written consent was taken from patients with SSc 2 
and from healthy volunteers. 30ml of heparinised venous blood was taken from the subjects.  
Peripheral blood was separated into neutrophil and mononuclear cell fractions using 
Polymorphprep (as described in the manufacturer’s instructions). Contaminating 
erythrocytes were removed using ammonium chloride lysis buffer (KHCO3 3.4mM, NH4Cl 
155mM, EDTA 96.7µM). Neutrophils were routinely examined for purity using morphological 
analysis of cytospins after staining with Rapid Romanowsky; purity was >95% immediately 
after isolation. Neutrophils were resuspended in RPMI 1640 +25mM HEPES +2mM 
glutamine at a concentration of 5x106 cells/ml. 
2.2.2 Extraction of mRNA. 
Neutrophils were isolated from control and SSc blood as previously described and 
resuspended in RPMI 1640 +25mM HEPES +2mM glutamine at 5x106/ml. 1x107 neutrophils 
were pelleted for each sample. The supernatant was removed and 1ml of TRIzol reagent 
was added to the cell pellet. The TRIzol was mixed by pipetting until the cell pellet was 
completely lysed. The lysate was incubated for 5 min at room temperature. 200µl of 
chloroform was added in the fume hood. The mixture was agitated for 15s, and incubated for 
5 min at room temperature. The sample was centrifuged at 12000xg for 15 min at 4˚C to 
separate the sample into RNA, DNA and protein layers. The upper phase (RNA) was 
removed to a clean, RNase free microfuge tube and an equal volume of isopropanol was 
added and incubated overnight at -20˚C to precipitate the RNA. RNA precipitate was stored 
at -80˚C until required or converted immediately to cDNA for polymerase chain reaction 
(PCR).  
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2.2.3 Preparation of cDNA. 
RNA precipitate was collected by centrifugation at 12000xg for 30 min at 4˚C. The 
supernatant was discarded and the pellet washed with 70% (v/v) ethanol/ DEPC treated 
ddH2O. The pellet was recovered by centrifugation at 12000xg for 5 min, the supernatant 
removed and the pellet air dried. The sample was resuspended in RNase free H2O and 
quantified using the Nanodrop (Thermo) (OD 260/280nm). The sample was cleaned using a 
RNA extraction kit (Qiagen RNeasy) according to the manufacturer’s instructions for clean 
up. 
1µl of random primers were added to 1µl of RNA (10pg-5µg) and 1µl of 10mM dNTP mix, 
the total volume was made up to 13µl with nuclease free H2O. The reaction was incubated at 
65˚C for 5 min and then 1 min on ice. 4µl of 5x First Strand Buffer, 1µl of 0.1M DTT, 1µl of 
RNaseOUT and 1µl of SuperScript III reverse transcriptase (200u/µl) were added. The 
reaction was incubated at 25˚C for 5 min and 50˚C for 1 h, and the reaction stopped by 
heating to 70˚C for 15 min. 
2.2.4 Real Time polymerase chain reaction for quantification of mRNA. 
Primers were designed using Primer3Plus, and are listed in Table 3. cDNA was mixed with 
Quantitect at a ratio of 1:5: forward and reverse primers specific to the gene of interest were 
combined and diluted to 4µM with nuclease free H2O. 6µl of cDNA mix and 4µl of primer mix 
were combined in a nuclease free tube and the PCR reaction monitored on the RotorGene 
3000 (Corbett). Initial reactions were performed on serial dilutions of control cDNA to define 
the efficiency of the primers. Following this, relative quantification of mRNA expression was 
calculated using the modified Pfaffl equation using observed primer efficiencies and 
normalized to cyclophilin A expression.  
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Gene Forward primer Reverse primer Efficiency 
HIF1α TGCTCATCAGTTGCCACTTC TCCTCACACGCAAATAGCTG 1.2 
Interleukin 6 AGGAGACTTGCCTGGTGAAA CAGGGGTGGTTATTGCATCT 0.99 
Cyclophilin A GCTTTGGGTCCAGGAATGG GTTGTCCACAGTCAGCAATGGT 1.4 
Table 3. Primers 
2.2.5 Western blotting. 
2.2.5.1 Preparing samples for western blotting. 
Neutrophils were isolated from control and SSc blood, as previously described; 5x106 
neutrophils were pelleted, the supernatant was completely aspirated and 
10µl/5x105neutrophils of hot SDS-PAGE reducing buffer (see Appendix A) was added. The 
samples were incubated at 100˚C for 3min or until the pellet had completely lysed and then 
stored at -20˚C prior to use. 
2.2.5.2 SDS PAGE. 
Whole cell extracts were loaded onto polyacrylamide gels, the percentage acrylamide 
content varied according to the size of the protein of interest (see Table 4). 
% acrylamide content of gels Relative Molecular mass range (kDa) 
7 50-500 
10 20-300 
12 10-200 
15 3-100 
Table 4. Acrylamide content 
In general, 10µl of sample was loaded per lane but this varied according to the abundance of 
the protein of interest. Biotinylated ladders were loaded for reference. Following 
electrophoretic separation using standard running buffer (see Appendix A), proteins were 
transferred to nitrocellulose membranes using BioRad Mini Protean II Transfer apparatus 
(for transfer buffer recipe see Appendix A). Membranes were stained with Ponceau S to 
confirm successful protein transfer and were then destained with wash buffer (see Appendix 
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A). Membranes were blocked with blocking buffer (5% w/v Marvel in wash buffer) for 1h at 
room temperature. Membranes were briefly washed with wash buffer and then incubated 
with gentle agitation in primary antibody buffer (blocking buffer containing optimized 
concentration of antibody to the protein of interest) overnight at 4˚C. For details of antibodies 
used, see Table 5. Membranes were washed for 2x30s, 2x5min, 1x15min in wash buffer 
before incubation with secondary antibody buffer (blocking buffer containing HRP-
conjugated, species specific secondary antibody and an HRP conjugated anti-biotin 
antibody) for 1h at room temperature. Following thorough washing (as above) the 
membranes were treated with excess ECL reagent (Millipore) for 5 min and then imaged on 
a G-BOX (Syngene). Quantification was performed using Image-J (NIH, USA) and was 
normalized to tubulin expression. 
Protein of 
interest 
Clonality Source Concentration 
used 
Host species 
Calgranulin A/B Polyclonal R&D 1:200 Sheep 
Elastase Monoclonal Calbiochem 1:5000 Rabbit 
SERPIN B1 Polyclonal Abcam 1:5000 Rabbit 
HLA Monoclonal Abcam 1:10000 Rabbit 
Histone Monoclonal Sigma 1:10000 Rabbit 
MPO Monoclonal Biodesign 1:10000 Sheep 
Interleukin-6 Polyclonal Abcam 1:10000 Rabbit 
Tubulin A Monoclonal Sigma 1:10000 Mouse 
Table 5. Antibodies. 
2.2.5.3 Tris-Tricene SDS-PAGE for quantification of low molecular mass proteins. 
Tris-Tricene SDS-PAGE was used for the improved quantification of Calgranulin-A by 
western blotting, as compared to traditional gels they improve the resolution of low molecular 
mass proteins at the same percentage of acrylamide. In addition, the gels improve the 
resolution of hydrophobic proteins. The acrylamide concentration of traditional gels cannot 
be increased beyond 15% or the gels become too brittle to handle. Tris-Tricine gels contain 
13% glycerol in order to make them less brittle. 
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Solution component Resolving gel (mL) Stacking gel(mL) 
30% (w/v) Acrylamide: 0.8% (w/v) bis-acrylamide 7.5 0.83 
H2O 0.44 3.72 
3M Tris, 0.3% (w/v) SDS pH 8.45 5 1.55 
Glycerol 2  
10% (w/v) ammonium persulphate 0.15 0.05 
TEMED 0.005 0.005 
Table 6. Recipe for 2x 1.5mm 15% Tris-Tricene mini gels. 
Instead of standard running buffer, two separate buffers are used in the electrophoretic 
separation (see Fig. 7). The inner chamber between the two gels is filled with Inner chamber 
buffer (see Appendix A) and the outer chamber is filled with Outer chamber buffer (see 
Appendix A). Protein is separated at a constant current of 70-80 mA until the dye front runs 
off (~4h). Thereafter, the process was as per traditional western blotting. 
 
  
Fig. 7. Set up for Tris-tricene gels. 
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Chapter 3: Neutrophil function in SSc. 
3.1 Introduction 
Products of neutrophil activation including cytokines, ROS and granule enzymes could 
potentially mediate endothelial cell activation and dysfunction, which are central to the 
pathogenesis of SSc.  
Concentrations of neutrophil chemoattractants IL-8 and LTB4 are elevated in the lesional 
tissue, serum and bronchoalveolar lavage fluid of patients with SSc and endothelial cells 
from patients with SSc express higher levels of leukocyte adhesion molecules 79 224-226. 
Neutrophils are activated following binding to these molecules, and their longevity is 
increased due to a decrease in apoptosis. In addition, circulating levels of proinflammatory 
cytokines (TNFα, IL-1β) that are capable of activating neutrophils are elevated in the serum 
of some patients with SSc especially in the diffuse disease and early in the disease course 79 
82 142. SSc fibroblasts and mononuclear cells also constitutively express IL-1 in vitro: thus 
local levels of IL-1 may be significantly elevated in lesional tissue in the absence of elevated 
serum levels 35 175. 
Several studies have previously examined neutrophil function in SSc, but the results are 
somewhat contradictory 215 217 221 228. This is most likely due to methodological differences in 
the measurements of neutrophil function but also in the methods used for neutrophil 
separation. 
Neutrophils are traditionally thought to be terminally-differentiated cells with a narrow 
spectrum of biological responses and limited capacity for de novo protein expression. 
However, recent evidence demonstrates that neutrophils are capable of complex roles in the 
immune system including: cytokine production, antigen presentation and interaction with 
cells of the adaptive immune system 227 229. 
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In this Chapter, I explore a range of functions in SSc neutrophils compared to control 
neutrophils, using neutrophil separation methods which result in minimal cell activation. 
3.2 Methods. 
3.2.1 Luminol enhanced chemiluminescence. 
Two assays were used to measure chemiluminescence. Neutrophils from healthy controls at 
5x106/ml were either primed with TNF for 20min or unprimed. For the tube assay, 1x106 
neutrophils were diluted to 750µl with HBSS warmed to 37˚C. 1µl of 10mM luminol (sodium 
salt) dissolved in ddH2O was added and 250µl of either control or SSc serum was added as 
a stimulant. 1µl of fMLP (1µM, final conc.) was added to further samples as a positive 
control. Tubes were agitated and chemiluminescence was measured using a luminometer 
every 30 s over 45 cycles. 
For the microplate assay, neutrophils from patients or controls at 1x106/ml were either 
primed with TNF for 20min or unprimed. 5x104 neutrophils were added to wells of a 96-well, 
white plastic, non-coated plate. HBSS was warmed at 37˚C luminol (disodium salt) was 
added to a final concentration of 67µM, and to separate aliquots of this mixture, PMA and 
fMLP were added to a final concentration of 100ng/ml and 1µM respectively. 150µl of these 
stimulant mixtures were added to the wells and chemiluminescence was measured 
immediately on a Perkin Elmer microplate reader, every 30s for 80 cycles. 
3.2.2 Phagocytosis and phagocytosis-stimulated ROS generation. 
Neutrophils were isolated from control and SSc blood as previously described. Cells were 
resuspended in RPMI 1640 +25mM HEPES +2mM glutamine at 2x106/ml. 2x106 cells were 
transferred to a FACs tube and incubated with heat inactivated, propidium iodide (PI) 
labeled, opsonised S. aureus in the following ratios for 30min in the dark at room 
temperature; 2.5:1, 5:1, 10:1, 15:1, 25:1 bacteria: neutrophil. Cells were spun down and 
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resuspended in 250µl RPMI 1640 +25mM HEPES +2mM glutamine, ROS generation was 
assessed by incubation of the cells with 10µM DHR-123 for 15min. PI was measured on the 
PECy5 channel following excitation with the 488nm laser and rhodamine-123 was measured 
on the FITC channel following excitation with the 488nm laser on a Dako CyAn ADP flow 
cytometer. 
3.2.3 Neutrophil chemotaxis. 
Neutrophils were isolated from control and SSc blood, as previously described, and were 
resuspended at 5x106/ml in RPMI 1640 +25mM HEPES +2mM glutamine. Disposable 
chemotactic chambers (Millipore) with a 3µm PTFE membrane were used (Fig. 8). The 
bottom chamber was filled with 800µl of RPMI 1640 +25mM HEPES +2mM glutamine 
±10nM fMLP. The top chamber was filled with 200µl (1x106 cells) of freshly-isolated 
neutrophils. The chambers were covered and incubated at 37˚C without agitation for 90min. 
The top chambers were removed from the bottom chamber and placed into an empty 24well 
plate. The medium in both chambers was agitated by pipetting up and down 3 times to 
dislodge loosely adherent cells. The number of cells in each chamber was then counted on a 
coulter counter. Cells moving from the top to the bottom chamber in the absence of a 
chemotactic gradient represent the random motility of the cells. Cells moving from the top to 
the bottom chamber along a fMLP chemotactic gradient have undergone chemotaxis. Often, 
the total number of cells in the bottom and top chambers did not account for all the cells 
entering the system. This was interpreted as cells adherent to the membrane or plastic-ware. 
Page 66 of 236 
 
 
 
3.2.4 Assessment of neutrophil apoptosis using annexin-V staining. 
Neutrophils were isolated from control and SSc blood as previously described and 
resuspended at 5x106 in HBSS. 100µl of neutrophil suspension was transferred to a FACs 
tube and incubated with 1µl of annexin V-FITC for 15min in the dark at room temperature. 
Annexin V labels phosphatidylserine residues exposed on the cell surface during apoptosis. 
Samples were made up to 1ml and analysed on the flow cytometer using the FITC channel, 
following excitation with the 488nm laser. Apoptosis was expressed as the percentage of 
annexin V labeled cells. 
3.2.5 Labelling neutrophils for surface expression of CD16, CD11b and CD18 by flow 
cytometry. 
Neutrophils were isolated from SSc and healthy control blood as previously described. Cells 
were resuspended in RPMI 1640 +25mM HEPES +2mM glutamine at 5x106/ml. 100µl of 
cells were placed in a flow cytometry tube and excess PBS EDTA was added, cells were 
centrifuged at 1000xg for 3min and resuspended in 200µl of PBS 2%BSA. Cells were then 
incubated for 30min in the dark at 4˚C with 2µl of allophycocyanin (APC)-conjugated anti-
Fig. 8. Chemotaxis chamber set up. 
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CD16 antibody, 2µl of APC-conjugated anti-CD11b antibody or 4µl of PE-conjugated anti-
CD18 antibody. Cells were washed x1 with PBS and analysed on the flow cytometer. Cells 
were gated to include only neutrophils according to characteristic forward and side scatter 
characteristics. APC emission was measured at 660nm following excitation with the 635nm 
laser; PE was measured at 575nm following excitation with the 488nm laser. When labeling 
for CD16-APC a simultaneous assessment of eosinophil number was made measuring 
spontaneous fluorescence on the PE-Cy5 channel, which is characteristic of eosinophils. 
This assessment was made because eosinophils are reportedly increased in the circulation 
of patients with SSc 142 and would fall inside the neutrophil gate on forward and side scatter 
but would not express CD16. 
3.2.6 The role of ROS in neutrophil: endothelial cell co-cultures. 
HDMECs were cultured in 48 well plates in microvascular endothelial cell medium 
(Promocell). Cultures were used in passage 4-8 when they reached 90% confluence. Under 
these conditions, cell phenotype is guaranteed up to passage 14 (Promocell). 
3.2.6.1 Preparation of serum samples. 
Serum samples were collected in clot-activating tubes (Vacutainer) and centrifuged at 340xg 
for 15min to precipitate the clot. Serum was aspirated and flash frozen in liquid nitrogen. 
Samples were thawed and filtered through a 0.4µm filter to remove particulate material that 
could interfere with confocal microscopy. Serum samples were kept on ice until used. 
3.2.6.2 Preparation of neutrophil: endothelial cell co-cultures. 
Endothelial cell culture medium was removed and replaced with 450µl of fresh medium or 
neutrophil suspension, and 150µl of SSc or healthy control serum. 1.5µl of annexin V and 
2.5µl of a 1:10 dilution of the E-selectin antibody were added to each well. Co-cultures were 
incubated for 24h at 37˚C, in a 5% CO2, humidified atmosphere. 
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3.2.6.3 Confocal microscopy. 
Confocal images were taken using an LSM-710 (Zeiss) confocal microscope using the Zen 
2009 software. Annexin V-FITC was excited using the 488nm laser while APC was excited 
using the 633nm laser. Images were taken using the optimum separation of emission 
spectra mode. Duplicate images were taken for each experimental variable. A z-stack of 13 
images was taken over a distance of 9.91µm, focusing from the endothelial cells to the 
neutrophils. Images were taken using a 10x fluar 0.5 NA objective.  
Images were analysed using Image J software (NIH, USA) and those representing the 
maximal fluorescence values for red and green fluorescence were measured for total 
fluorescence intensity. Values were corrected for fluorescence intensity of cells cultured in 
media alone.  
In order to assess the role of ROS in these co-cultures, 2000U/ml catalase was added to 
wells to catalyse the reaction H2O2        O2+H20. 
As previous experiments had shown a role for interleukin-6 (IL6) in endothelial cell activation 
and apoptosis in neutrophil-endothelial cell co-cultures (Chapter 7), AB serum spiked with 
200ng/ml recombinant IL-6 was added to co-cultures instead of patient or control serum in 
the presence or absence of catalase, to determine if the observed effect of IL-6 was 
mediated by ROS. 
In addition, co-cultures were incubated with 8µM DHR-123 for 24h. This probe is taken up 
freely by cells and is oxidised by H2O2 into the fluorescent product rhodamine-123. 
Fluorescence was then measured and localized by confocal microscopy following excitation 
with the 488nm laser.  
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3.3 Results. 
3.3.1 Unstimulated neutrophil ROS generation is lower in patients with SSc compared 
to controls. 
Total unstimulated chemiluminescence, calculated as the area under the curve, corrected to 
healthy controls was decreased on average by 25% in SSc neutrophils (p=0.0007, n=13). 
(Fig. 9.) 
 
3.3.2 PMA stimulated neutrophil ROS generation is greater in patients with SSc 
compared to controls. 
However, the total increase in chemiluminescence in response to PMA stimulation was 
greater in SSc neutrophils compared to healthy control neutrophils, both when unprimed 
(p=0.02) and when TNF-primed (p=0.01). Healthy control neutrophils increased total 
chemiluminescence 4.9 fold (unprimed) and 5.0 fold (TNF primed) as compared to SSc 
neutrophils which increased 6.3 fold (unprimed) and 6.7 fold (TNF primed)(Fig. 10.). This 
resulted in similar levels of PMA stimulated chemiluminescence in both patients and 
controls, given that unstimulated levels of chemiluminescence were lower prior to the 
addition of PMA. 
Fig. 9. Baseline reactive oxygen species 
generation, measured by luminol enhanced 
chemiluminescence, in neutrophils isolated from 
patients with SSc is significantly lower than in 
control neutrophils. 
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3.3.3 Formyl-met-leu-phe (fMLP) stimulated ROS generation is greater in unprimed 
SSc neutrophils compared to controls. 
Neutrophil responses to fMLP usually require priming with agents such as TNF and GMCSF. 
However, the average increase in total chemiluminescence in response to fMLP in SSc 
neutrophils was 2-fold. This was significantly increased compared to healthy controls, which 
increased on average 1.7 fold (p=0.046) (Fig. 11). This suggests that neutrophils, isolated 
from SSc patients are primed in vivo. The response of TNF primed neutrophils from SSc 
patients was not significantly different to healthy controls. 
Fig. 10. PMA stimulation (100ng/ml) resulted in a greater increase in reactive oxygen 
species generation (measured by luminol enhanced chemiluminescence) in SSc 
neutrophils, in both unprimed and TNF primed cells, compared to controls. (N=13). 
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3.3.4 Soluble factors in SSc serum do not effect neutrophil ROS generation. 
One possible explanation for the decreased ROS generation of SSc neutrophils is that 
neutrophils are activated in vivo and are therefore exhausted ex vivo. To explore this 
possibility, healthy control neutrophils were exposed to SSc or healthy control serum and 
ROS generation was measured by chemiluminescence. No differences were found in the 
total chemiluminescence of either unprimed or TNF primed neutrophils in response to SSc 
serum, compared to healthy control serum (Fig. 12). 
Fig. 11. Unprimed SSc neutrophils generate more reactive oxygen species 
(measured by luminol enhanced chemiluminescence), in response to fMLP (1µM) 
than control neutrophils. Following TNF priming, however, this effect was negated. 
N=13. 
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3.3.5 ROS generation in neutrophil: endothelial cell co-cultures. 
SSc serum increased endothelial cell apoptosis (annexin-V staining) and activation (E-
selectin expression) in neutrophil: endothelial cell co-cultures at 24h (p=0.006 and 0.00004 
respectively, n=17) (see Chapter 7). Addition of catalase to the co-culture media did not 
significantly decrease this effect (n=8) (Fig.13). However, for 3 individual patients with the 
greatest response to SSc serum, the addition of catalase to the media resulted in a marked 
decrease in the endothelial cell activation (Fig.14). There were no distinguishing clinical 
Fig. 12A. Healthy control neutrophils were primed with TNFα (10ng/ml) for 20min and 
then stimulated with healthy control serum, SSc serum or fMLP as a positive control. 
Reactive oxygen species were measured by luminol enhanced chemiluminescence. 
Neither control nor SSc serum were able to stimulate reactive oxygen species 
generation by neutrophils. A representative trace from 3 independent experiments is 
shown. B. Shows a close up of the patient and control serum samples. 
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features in these 3 patients. Of note, in single cell neutrophil cultures, sera from these 
individuals did not increase neutrophil ROS generation (data not shown). 
 
 
 
 
 
Fig. 13. Human dermal microvascular endothelial cells (HDMECS) were co-cultured with 
healthy control neutrophils for 24h in the presence of 25% healthy control or SSc serum. 
Apoptosis was measured using annexin V FITC and E-selectin expression was 
measured using an APC conjugated monoclonal antibody. Mean fluorescence was 
measured by confocal microscopy and expressed as a fold change in mean 
fluorescence corrected to media alone. Catalase was added to cultures to scavenge 
ROS. N=8. 
 
p=0.11 
p=0.37
5 
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3.3.6 Catalase does not abrogate IL-6 induced endothelial cell apoptosis and 
activation in neutrophil: endothelial cell co-cultures. 
Studies (Chapter 7) have indicated that IL-6 has a role in the effect of SSc serum on 
increasing endothelial cell apoptosis and activation in neutrophil: endothelial cell co-cultures. 
However, catalase did not abrogate this effect, indicating that IL-6 does not mediate its effect 
by increasing ROS generation. 
3.3.7 SSc serum increases intracellular ROS generation in neutrophils as measured 
by conversion of DHR-123 to rhodamine-123. 
Of the 3 patient sera with a marked response to SSc and abrogation of the effect by 
catalase, one was used at 25% to stimulate neutrophil: endothelial cell co-cultures. 
Intracellular ROS generation was measured at 24h by the conversion of DHR-123 to 
rhodamine-123; fluorescence was quantified and localised by confocal microscopy. For this 
Fig. 14. Human dermal microvascular endothelial cells (HDMECs) were cultured with 
healthy control neutrophils in the presence of 25% control or SSc serum for 24h. E-
selectin expression was measured using an APC conjugated monoclonal antibody. 
Mean fluorescence was measured by confocal microscopy and expressed as a fold 
change in mean fluorescence corrected to media alone. Each line represents single 
experimental repeats. N=8. E selectin expression was higher in the presence of SSc 
serum, but on average, catalase did not abrogate the effect of SSc serum. However, in 
three patients with the greatest increase in E-selectin expression, catalase markedly 
decreased the E-selectin expression. 
 
Page 75 of 236 
 
serum sample, ROS generation was increased compared to healthy control serum, and the 
fluorescence increase was located to the neutrophils (Fig. 15).  
 
 
 
 
 
Fig. 15. Neutrophil: endothelial cell co-cultures in the presence of 25% A. control or B. SSc 
serum were incubated with DHR-123 for 24h. Conversion of DHR-123 to fluorescent 
rhodamine-123 (red) by ROS was measured as mean fluorescence intensity (MFI) using 
confocal microscopy. The results of 3 technical repeats are shown in C (mean ± SE). D. 
Rhodamine-123 was located within neutrophils. SSc serum resulted in more intracellular ROS 
generation in co-cultures than control serum. 
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3.3.8 Neutrophil chemotaxis. 
Fewer neutrophils isolated from SSc patients migrated towards fMLP compared to control 
neutrophils. In addition, in the absence of a chemotactic gradient, fewer SSc neutrophils 
were found in the bottom chamber of the chemotaxis chamber compared to control 
neutrophils indicating a decrease in random motility. More SSc neutrophils were 
unaccounted for in either chamber, likely to be due to increased adhesion of neutrophils to 
the membrane or the plastic of the chemotaxis chamber (Fig. 16) via increased 
adhesiveness of unstimulated SSc neutrophils compared to controls. Increased adhesion to 
plastic surfaces was confirmed by inspection of the plastic ware following removal of the 
neutrophil suspension and washing of the plastic ware with excess PBS. 
 
 
 
 
Fig. 16. SSc neutrophils showed lower random migration and chemotaxis down an fMLP 
gradient (10 nM) than control neutrophils. Random movement or chemotaxis was 
measured over 90min. 
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3.3.9 Neutrophil CD11b and CD18 expression 
Given the suggestion above that SSc neutrophils are more adhesive than control 
neutrophils, cell surface expression of the neutrophil integrin proteins CD11b and CD18 was 
measured by flow cytometry. CD11b is increased on the neutrophil surface on priming, but 
there was no difference in CD11b expression between control or SSc neutrophils. CD18 
expression changes very little upon priming, and so the ratio of CD11b to CD18 was 
calculated. There was no difference in the ratio of CD11b:CD18 in SSc neutrophils 
compared to controls (N=11) (Fig.17). 
 
 
 
3.3.10 Neutrophil apoptosis. 
There was no difference in neutrophil apoptosis between freshly isolated SSc and control 
neutrophils, as measured by annexin V FITC labeling of surface phosphatidylserine 
expression and flow cytometry (Fig. 18). 
Fig. 17.There was no difference in the cell surface expression of (A) CD11b (B) CD18 
or (C) the ratio of CD11b:CD18 in SSc neutrophils compared to controls as assessed 
by flow cytometry (N=11). 
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3.3.11 Neutrophil phagocytosis. 
A dual phagocytosis: ROS production flow cytometry assay was used to correlate these two 
events. In control and SSc neutrophils, depending on the ratio of bacteria: neutrophils, a 
proportion of neutrophils were dim for phagocytosis and ROS generation. However, there 
were no differences in the proportion of dim neutrophils between SSc and controls at any 
concentration of bacteria (Fig. 19). There was no significant difference in mean phagocytosis 
of PI-labeled S. aureus or ROS generation at any ratio of bacteria: neutrophils between SSc 
and control neutrophils (Fig. 20 and Fig. 21). There was a tendency for SSc neutrophils to 
have a higher ROS generation in response to phagocytosis but this was not significant. At 
high ratios of bacteria: neutrophils this trend was reversed. 
Fig. 18. Neutrophil apoptosis of freshly-isolated cell is no different in SSc compared to 
controls. Apoptosis was measured by annexin V-FITC binding to surface 
phosphatidylserine expression. 
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Fig. 19. The proportion of neutrophils which were dim for phagocytosis of S. 
aureus PI and for ROS generation (DHR) were no different between SSc and 
controls but did vary according to the ratio of bacteria: neutrophils. DHR 
staining of ROS generation was also measured at baseline in the absence of 
phagocytosis. 
 
Fig. 20. Mean phagocytosis of PI labeled S. aureus did not differ between SSc 
and control neutrophils at any ratio of bacteria: neutrophils. 
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There was no difference in the ratio of ROS generation to phagocytosis between control and 
SSc neutrophils at any bacterial concentration (Fig. 22). 
 
 
 
Fig. 21. Mean ROS generation in response to phagocytosis of PI labeled S. aureus did 
not differ between SSc and control neutrophils at any ratio of bacteria: neutrophils. 
However, at most bacterial concentrations there was a tendency for SSc neutrophils to 
produce more ROS. At high concentrations of bacteria (25:1) this was reversed. 
 
Fig. 22. There was no significant difference in the ratio of ROS generation to level of 
phagocytosis between control and SSc neutrophils at any ratio of bacteria: neutrophils. 
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3.3.12 Neutrophil CD16 expression. 
There was no difference in mean or median CD16 expression on control or SSc neutrophils. 
CD16 expression on control and SSc neutrophils was divided into bright and dim expression. 
An increased proportion of SSc neutrophils were CD16 dim compared to control neutrophils 
(Fig. 23). 
 
 
 
 
Fig. 23. Increased proportion of CD16 dim SSc neutrophils compared to controls. The top 
panel shows a representative flow cytometry trace. R1 contains CD16 dim neutrophils. 
R2 contains CD16 bright neutrophils. The unfilled trace represents SSc neutrophils. The 
filled trace represents control neutrophils. The hashed trace shows the isotype control. 
The bottom panel represents the mean and SD of 12 experimental repeats. 
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SSc patients have been reported to have an elevated eosinophil count compared to controls 
142. Eosinophils are likely to be a contaminant of the neutrophil preparation procedure as 
polymorphprep does not separate neutrophils from eosinophils. Eosinophils do not express 
CD16 and autofluoresce in the PECy5 channel. Simultaneous examination for CD16 
expression (APC) and autofluorescence in the PECy5 channel reveals that the CD16 dim 
population of cells did not autofluoresce and therefore are not eosinophils (Fig. 24). 
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Fig. 24. CD16 dim cells in the SSc neutrophil samples are not eosinophils. The top 
panel plots CD16 expression (APC) against autofluorescence (PECy5). CD16 dim cells 
(R2) are marked in red. These cells did not have an increased autofluorescence in the 
PECy5 channel (bottom panel) showing that they do not represent eosinophils. 
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3.4 Discussion. 
SSc neutrophils are hypofunctional in terms of spontaneous ROS generation and 
chemotaxis in vitro. This may represent a primary functional deficit in SSc neutrophils or may 
reflect in vivo activation and hence in vitro “exhaustion”. 
To explore this further, control neutrophils were exposed to SSc serum to see if this would 
stimulate ROS production. However, no such effect was seen. In addition, although 
unstimulated neutrophils were hypofunctional in terms of ROS production, they were capable 
of producing similar levels of ROS to control neutrophils in response to stimulants such as 
fMLP and PMA. This would suggest that the neutrophils are not fundamentally 
hypofunctional.  
ROS generation in response to fMLP requires prior priming to increase the 
expression/affinity of the fMLP receptor on the neutrophil surface. SSc neutrophils produced 
more ROS in response to fMLP when unprimed suggesting that neutrophils are primed in 
vivo. This could be confirmed by measuring the surface expression of the fMLP receptor in 
SSc and control neutrophils by flow cytometry but time did not permit these experiments.  
Priming can occur in response to a number of different stimuli including cytokines TNFα, 
GMCSF and IL-8. Interestingly, IL-8, which has been found in increased concentrations in 
SSc serum, is capable of priming ROS not only in response to fMLP but also in response to 
PMA unlike other priming agents 230. Therefore, IL-8 exposure in vivo may explain the 
increased response to both fMLP and PMA of SSc neutrophils. It is however, evident that 
further priming in vitro can be achieved from the more powerful priming agent TNFα. 
Luminol enhanced chemiluminescence was used here to measure ROS generation. This 
method measures both extracellular (secreted) and intracellular ROS generation due to the 
cell permeability of luminol. My data is in agreement with another recently published paper 
which uses an alternative and exclusively intracellular probe DHR-123, which demonstrated 
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a decrease in basal ROS production using a whole blood assay with neutrophil ROS 
generation measured by FACS gated for neutrophils only 217. They also did not demonstrate 
a greater ROS generation in SSc neutrophils compared to controls in response to PMA, but, 
although the authors did not specifically report this, the data seems to suggest a greater fold 
change in ROS in SSc neutrophils in response to PMA 217.  
The study described above used whole blood, therefore maintaining neutrophil interactions 
with serum cytokines and also leukocyte-leukocyte interactions. It is interesting, therefore, 
that they still demonstrated a hypoactive neutrophil phenotype, indicating perhaps that if in 
vivo neutrophil activation does occur, then it is not driven by a blood borne factor.  
There are, however, other interactions that occur in vivo, including important interactions 
with activated endothelium that may cause neutrophil activation. My preliminary data 
suggests that over 24h neutrophils may produce more intracellular ROS in co-cultures with 
endothelial cells when exposed to SSc serum compared to control serum. This data needs 
to be repeated and if confirmed, the factors mediating this phenomenon will need to be 
systematically investigated. 
The literature contains several reports of increased ROS generation by SSc neutrophils in 
vitro in direct contradiction to my results 215 216 228. The discrepancies may be explained by 
different methodologies, as described below.  
Czirjak et al used a whole blood assay using luminol to measure ROS generation. They 
were unable to discriminate which cells were producing the ROS but made the assumption 
that neutrophil ROS was so dominant that it would be most likely responsible for the 
increase 216. However, the same authors also demonstrated an increase in mononuclear cell 
ROS production in SSc and therefore the validity of this assumption is questionable 231. 
Maslen et al and Stevens et al described an increase in ROS generation in unstimulated 
SSc neutrophils compared to controls 215 228. Both authors used Percoll gradients for 
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neutrophil separation, which can cause more neutrophil activation than Polymorphprep. Both 
of these studies measured only extracellular ROS generation. The luminol method used in 
my study measures both intra and extracellular ROS generation. It is possible that there is 
an increase in extracellular ROS production (as described by Maslen and Stevens) and a 
decrease in intracellular ROS production (as described by Foerster et al 217) so the overall 
effect is a decrease in total ROS generation, as reported here. 
My data also demonstrated that SSc neutrophils are hypofunctional in terms of chemotaxis 
towards fMLP, compared to control neutrophils. There was also a trend towards a decrease 
in SSc neutrophil random motility compared to control neutrophils, but this did not reach 
statistical significance. The method that I used, however, was able to measure not only the 
number of cells that had migrated but also the number that remained in the top chamber. 
This allowed me to calculate the number of cells that were unaccounted for. These cells 
were assumed to be either in the membrane or stuck to the plastic ware. The number of cells 
unaccounted for were significantly greater in SSc. This was taken to reflect an increase in 
cell adhesiveness. 
Previous literature has also shown that neutrophils from SSc patients are hypofunctional in 
terms of chemotaxis 216 221. Czirjak et al demonstrated a decrease in neutrophil chemotaxis 
towards zymosan conditioned media. Spisani et al found no significant difference in random 
motility or chemotaxis towards casein. However, there was a trend for SSc neutrophils to 
migrate a shorter distance in the leading front assay, at all concentrations of casein tested. 
The lack of a statistically significant result is likely to reflect the small number of samples 
tested and the assay technique used. In my hands the leading front assay is difficult to 
reproduce and somewhat subjective. 
Because the migration assay suggested that SSc neutrophils were more adhesive I went on 
to explore the expression of the predominant leukocyte adhesion molecule Mac-1 
(CD11b/CD18). Leukocyte adhesion is an essential part of leukocyte migration especially 
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through endothelial surfaces. The first stage in leukocyte migration involves the rolling of 
neutrophils along activated endothelial surfaces. This is mediated by transient leukocyte 
attachments to the endothelial cell surface mediated via L-selectin (neutrophil) and Sialyl-
Lewisx, E-selectin (endothelial cell). Following this, L-selectins are shed by a proteolytic 
mechanism and firm adhesion of the neutrophil to the endothelial surface is mediated by the 
binding of neutrophil integrins to their ligands. Thereafter, neutrophils undergo diapedesis, 
the process of deformation and movement between endothelial cells into tissues. This is 
mediated by cytoskeletal changes and interaction of neutrophils with endothelial cell 
adhesion molecules (ICAM 1,2, PECAM-1, JAMs) (Fig. 25) 232. 
 
 
The main neutrophil integrins are Mac-1 (CD11b/CD18) and LFA-1 (CD11a/CD18). The up-
regulation of neutrophil integrin expression is mediated by priming factors that enable the 
Fig. 25. Neutrophil migration. This process is triphasic involving initial rolling, followed by 
firm adhesion and then diapedesis. 
Page 88 of 236 
 
translocation of intracellular integrin stores to the neutrophil surface. Expression is transient 
and localized to the leading front of the cell and activation may be mediated by the actin 
cytoskeleton 218. 
Mac-1 is involved in the adhesion of complement-coated particles to phagocytes, neutrophil 
self-aggregation and binding to endothelial cells. It also binds fibrinogen. Ligation stimulates 
neutrophil activation and it constitutes the major neutrophil integrin. LFA-1 is involved in 
binding to cytotoxic T-cells. ICAM-1 is also a ligand for LFA-1 218. 
I did not demonstrate any difference in the expression of CD11b or CD18 in SSc neutrophils 
compared to controls nor in the ratio of CD11b to CD18. However, Mac-1 is only one of 
several molecules that can make neutrophils more adhesive. In addition Mac-1 activation 
does not only rely on an increase in cell surface expression but can be mediated by a 
change in configuration to increase the affinity of Mac-1 for its ligands. Mediators of such 
conformational change are incompletely defined but include cytoskeletal molecules that 
increase local concentrations of Mac-1 as well as increasing Mac-1 affinity. L-Plastin is one 
such example and I present evidence in Chapter 5 that L-plastin expression at the plasma 
membrane is increased in SSc neutrophils 233 234. 
It is interesting to note that Mazzone et al reported that Iloprost (prostacyclin) infusions 
decrease the expression of Mac-1 on SSc neutrophils 6h after infusion 223. Iloprost is known 
to improve Raynaud’s phenomenon and digital ulceration in SSc patients not only during the 
infusion but for a prolonged period after the infusion. However, they reported similar changes 
in patients without SSc who had Iloprost for peripheral vascular disease. 
I also noted in neutrophil: endothelial cell co-cultures (see Chapter 4) that cell-cell 
aggregates containing endothelial cells and neutrophils are increased in response to SSc 
serum. This may indicate that a soluble factor in SSc serum increases the adhesiveness of 
neutrophils either directly or indirectly via endothelial cell activation. 
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Finally, I have frequently observed that neutrophils isolated from patients with SSc often 
form cell aggregates, in common with previous studies. Lau et al. used cell aggregation as a 
surrogate marker for neutrophil activation 235. They found that SSc neutrophils more readily 
underwent aggregation when stimulated with fMLP compared to control neutrophils, when 
read on a particle volume analyser. 
To take these observations forward, I would ideally like to assess the adhesiveness of SSc 
neutrophils compared to control neutrophils using an adhesion assay. The most meaningful 
assay would be to assess neutrophil adhesion to TNFα activated endothelium. Similarly, I 
would like to formally quantify neutrophil aggregation in SSc as this may have pathological 
relevance by occluding microvessels and contributing to prolonged ischaemia. This could 
also be done by assessing neutrophil singlets, doublets and triplets by flow cytometry, using 
differences in forward and side scatter to separate and quantify the different sized cell 
aggregates. 
Like previous authors, I did not observe any difference in the phagocytic activity of SSc 
neutrophils compared to controls 216 221. 
I found that neutrophils isolated from patients with SSc had a higher percentage of CD16 
dim cells compared to controls. CD16, also known as FcγIIIb, is a cell surface expressed 
member of the immunoglobulin gene superfamily. It is a low affinity receptor for IgG and is 
not a transmembrane receptor but is attached to the neutrophil surface by a GPI linkage. It 
exists not only on the cell surface but also preformed in intracellular stores. By virtue of the 
GPI-linkage, it can be cleaved from the surface by enzymes such as metalloproteinases, 
elastase, pronase and PI-phospholipase C 236 237. The main function of CD16 ligation 
appears to be ROS generation in response to ligation by soluble immune complexes in 
primed neutrophils 238.  
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The control of surface expression is via a combination of proteolytic cleavage and 
mobilization of intracellular stores 236. Different substances control surface expression by 
different mechanisms: GMCSF increases proteolytic cleavage but also increases 
mobilization to maintain cell surface expression whereas sodium butyrate decreases 
proteolytic cleavage with little effect on mobilization 239. Loss of CD16 expression correlates 
with apoptosis and other cell surface markers of apoptosis like phosphatidylserine 
expression 240-242. However, studies have shown that these events are controlled 
independently 243. Proteolytic cleavage of CD16 from the cell membrane in vitro does not by 
itself increase apoptosis and does not appear to mark cells for phagocytosis 244. A decrease 
in CD16 is not specific for apoptosis, as neutrophils incubated with LPS undergo delayed 
apoptosis but have decreased surface CD16 expression 241. In addition, actin polymerization 
can induce shedding of CD16 245. 
As there were more CD16 dim neutrophils in SSc, I also quantified apoptosis at baseline by 
annexin-V binding to phosphatidylserine residues and found no increase in apoptosis. 
Therefore, the significance of the increase in CD16 dim cells is unknown. It maybe that SSc 
neutrophils have defective mobilization of intracellular stores or increased proteolytic 
cleavage of CD16. Interestingly, soluble CD16 (sCD16) is found in the circulation and 
proteolytic cleavage from neutrophils is thought to be the major source 246. Serum levels of 
sCD16 are elevated in autoimmune inflammatory disorders such as Sjögrens syndrome, 
systemic lupus erythematosus (SLE) and rheumatoid arthritis 247-249. This is thought to 
represent increased shedding of CD16 during increased neutrophil apoptosis in these 
diseases. However, although neutrophil apoptosis is increased in SLE, neutrophil apoptosis 
is delayed in rheumatoid arthritis 250-252. Therefore, the increased shedding may serve some 
other purpose and may occur independently of apoptosis in vivo. Accordingly sCD16 has 
many attributed roles in immune function 253.  
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Future work could explore the levels of sCD16 in the serum of patients with SSc, could 
quantify the intracellular stores of CD16 in SSc neutrophils and assess the ability of 
intracellular stores to be mobilized by TNFα. 
In conclusion, SSc neutrophils have an abnormal functional phenotype ex vivo compared to 
control neutrophils. They are hypofunctional in terms of unstimulated ROS generation but 
are stimulated to produce a greater increase in ROS in response to fMLP and PMA. The 
former observation may indicate exhaustion following in vivo activation and the latter may 
indicate in vivo priming. IL-8 could be a candidate priming agent. In support of this theory, 
SSc neutrophils are also hypofunctional in terms of chemotaxis but appear to be more 
adhesive ex vivo. This may indicate exposure to neutrophil chemotactins such as interleukin-
8 in vivo. Although SSc neutrophils do not express more cell surface Mac-1 proteomic 
studies do suggest that they express more L-plastin (see Chapter 5), which can lead to Mac-
1 activation by promoting focal accumulations of Mac-1 and by increasing its binding affinity. 
IL-8 can induce L-plastin function 254.  
Neutrophil activation at the endothelial surface could have important ramifications for the 
pathogenesis of SSc. The release of cytokines, proteases and ROS could directly contribute 
to the endothelial cell injury and activation, which is thought to be central to the 
pathogenesis. ROS and proteases, in addition to endothelial cell activation, are all profibrotic 
phenomena and therefore could be enhancing and perpetuating the main pathological 
features of this disease. Finally, neutrophils have a role in promoting mononuclear cell 
recruitment, which may lead to the typical chronic inflammatory cell infiltrates that are 
typically seen in this disease. 
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Chapter 4: Neutrophil proteomics. 
4.1 Introduction. 
Functional studies (Chapter 3) have revealed that neutrophils have a distinct phenotype in 
patients with SSc. To shed further light on this phenotype a study of the neutrophil proteome 
was undertaken to look for changes in protein expression in these cells compared to healthy 
controls. It was anticipated that information would be gained from differences in the pattern 
of protein expression which would shed light on the underlying processes resulting in this 
change in phenotype. 
Proteomic techniques are often limited by the fact that there is significant gel to gel variation 
making comparisons between samples (e.g. patient and control) very difficult. In order to 
overcome this problem, I used the DIGE technology (GE Healthcare) 255. This uses 3 
fluorescent, cyanine-based dyes, the first of which is used to label the patient sample and 
the second to label the healthy control sample. The third dye is used to label a mixture of 
equal volumes of the patient and healthy samples to act as an internal control to 
compensate for loading variance. All three samples are then run on the same gel in order to 
eliminate gel to gel variation. The fluorescence emission of each dye is read separately on a 
fluorescence scanner giving a highly sensitive measure of protein abundance (sensitivity 
0.25-0.95ng, linear dynamic range 1-10000ng). Changes in expression as low as 10% can 
be accurately measured using this method 255. 
4.2 Methods. 
4.2.1 Protein extraction and preparation for 2D PAGE 
5 x 106 neutrophils were lysed using 200µl of a hypertonic lysis buffer (7M urea, 2M thiourea, 
30mM Tris, 1% Triton X-100, 4% CHAPS, 5mM MgAc, protease inhibitors 5mM PMSF). 
Samples were centrifuged at 14000xg for 10 min at 4ºC in order to remove insoluble 
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material. The protein concentration of the supernatant was quantified using the RCDC assay 
according to the manufacturer’s instructions. Samples were made up to 320μl with 
rehydration buffer (8M urea, 2M thiourea, 4% CHAPS, 1.5mM DTT, 0.8% Bio-Lytes 3-10). 
3.2μl ASB14 (5mg in 100μl H2O) was added, and the mixture incubated at room temperature 
for 1h. 
4.2.2 2D-PAGE of underivatised proteins. 
Initially, the conditions for the 2D PAGE of neutrophil samples were optimised by running 
2D-gels, and visualising spots by silver staining 256. The optimised conditions were then used 
for running 6 replicate samples on DIGE gels (see below). Following analysis of the DIGE 
results, the differentially expressed proteins were identified by tandem MS following trypsin 
digestion of spots removed from comparator colloidal-Coomassie or silver-stained gels of 
underivatised protein 256 257. IEF was performed using a Protean IEF cell (Bio-Rad) with a 
17cm IPG ReadyStrip pH 3-10 non-linear (BioRad).   
For analytical gels, 100μg of protein sample in rehydration buffer, in a total volume 300μl, 
was applied to the IPG strip, whereas for gels to be Coomassie blue stained, 300μg-1mg of 
protein in 300μl of buffer was applied to yield sufficient protein for MS analysis. Proteins 
were applied using the cup loading technique to improve resolution of the basic proteins 258. 
Strips were actively rehydrated at 50V for 12h and then proteins were focused at 250V for 
30min (linear ramp), 10000V for 3h, 10000V to 40000V/h (linear ramp). Strips were 
equilibrated in equilibration buffer [50mM Tris, pH 6.8, 6M urea, 2% (w/v) SDS, 30% (w/v) 
glycerol, bromophenol blue] containing 20mM DTT for 15min, then in equilibration buffer 
containing 25mM IAA for 15min. 
Strips were then loaded onto 12.5% SDS-PAGE gels and run at 15mA/gel for 30min and 
then 30mA/gel until the dye front had just run off the gel. Gels were scanned in a Bio-Rad 
GS-710 densitometer using PDQUEST 7.31 2D software package (Bio-Rad). Spots of 
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interest identified by DIGE electrophoresis (below) were matched to spots on comparator 
gels by eye. 
4.2.3 DIGE electrophoresis. 
Samples were adjusted to pH 8.5 and were labelled using the fluorescent cyanine dyes 
developed for DIGE (GE Healthcare), following the manufacturer’s protocol (Fig.26). 50μg of 
neutrophil protein extracts from patients with SSc were labelled with Cy3 dye, 50μg of 
neutrophil protein extracts from healthy controls with Cy5 dye and an internal loading control 
(25μg of patient protein plus 25μg of healthy control protein) with Cy2 dye. In each case, 
400pmol of amine-reactive cyanine dye, freshly dissolved in anhydrous dimethyl formamide 
was used and the reaction incubated in the dark at 4ºC for 30min. The reaction was stopped 
with lysine (1mM final concentration). The samples were then pooled and incubated with 
rehydration buffer, total volume 320μl plus ASB14 for 15min at 4ºC and then frozen 
overnight at -70ºC. 
Samples were thawed and loaded onto IPG strips using the cup loading technique and 
subjected to 2D electrophoresis using the conditions given above. Cyanine-dye-labelled 
proteins were visualised on a Typhoon scanner (GE Healthcare). Protein profiles were 
analysed using DeCyder software (GE Healthcare) with spot filters set as slope >1.1, area 
<100, peak height <100 and peak volume<10000. Individual filtered proteins were then 
filtered manually to check that the spots were genuine. Relative protein abundance between 
patients and healthy controls was analysed using one-way ANOVA with correction for 
multiple analyses. 
 
 
Page 95 of 236 
 
 
 
 
 
4.2.4 Trypsin digestion and mass spectrometry. 
In-gel trypsin lysis was performed on spots excised from comparator gels. Supernatants 
were analysed using an UltiMate nano-liquid chromatograph (LC Packings) connected to a 
Waters (Manchester, UK) Q-TOF Micro electrospray tandem mass spectrometer, operating 
in positive ion mode. Chromatography was performed using a μ-Precolumn C18 cartridge 
Fig. 26. DIGE workflow. On each gel, 2 protein samples can be compared. Each protein 
extract is labeled with a different cyanine based dye. An internal standard, comprising 
equal quantities of each protein sample, is labeled with the third dye. All 3 samples are 
then run simultaneously on one gel. Each dye is imaged separately and image analysis 
using DeCyder software assesses the differential protein expression in each sample 
compared to the internal standard.  
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(LC Packings) connected to a PepMap C18 column (3μm 100Ǻ packing; 15cmx 75μm i.d.), 
using a linear gradient of 5% (v/v) solvent B [0.1% v/v formic acid in 80% (v/v) acetonitrile in 
water] in solvent A [0.1% (v/v) formic acid in 2% (v/v) acetonitrile in water] to 100% solvent B 
over 60min at a flow rate of 200nl/min. The spectrometer was operated in Data Directed 
Analysis (DDA) mode, where a survey scan was acquired from m/δ 400-1500, with switching 
to MS/MS on multiply charged ions. MS/MS mass spectrum acquired over mass range 80-
2000Da. 
4.2.5 Database searching and protein identifications. 
For the MS/MS data, peak lists were created using Masslynx (version 4), and necessary 
subtraction was performed with the following parameters: polynomial order 15, 50% below 
curve, tolerance 0.01. Smoothing of the peak list was performed using the Savitzky Golay 
method to 2 smooths. The data were centred using the centroid top method at 80%. MS/MS 
ion searches of the NCBI MSDB database (20060831) restricted to the Homo sapiens 
entries (total proteins searched 148148) were undertaken using the MASCOT search engine 
version 2.3 (http://www.matrixscience.com) to yield protein identifications. Searches were 
performed without restriction of protein Mr or pI. Searches were restricted to trypsin cleavage 
products and one trypsin miscleavage was allowed. Searches took into account the following 
post-translational modifications: fixed carbamidomethylation at cysteine residues, variable 
oxidation of methionine, and variable phosphorylation at serine, threonine and tyrosine. 
Peptide mass tolerance and fragment mass tolerance were set to 2.0Da and ±0.8Da, 
respectively. Peptide matches were assigned following statistically significant MASCOT 
probability scores (<0.05). Protein identifications were assigned if 2 or more peptide matches 
were made. False discovery rates were derived by searching against a decoy database and 
the false discovery rate was zero. 
 
Page 97 of 236 
 
4.2.6 Staining of intracellular F-actin using phalloidin-FITC. 
Actin exists in 2 major pools within the cell, G-actin (unpolymerised) and F-actin 
(polymerised). Many cellular functions involve increased actin polymerisation, which can be 
detected using Phalloidin, which binds to F-actin but not G-actin. Phalloidin can be 
conjugated to the fluorescent probe FITC which, when measured on the flow cytometer can 
give a relative quantification of the F-actin content of the cell. 
2x106 neutrophils were placed in FACs tubes, spun down and resuspended in 3.7% 
formaldehyde with 200μg/ml phosphatidylcholine. Cells were incubated at 4°C for 15min to 
fix and permeabilise the cells. The cells were washed 3 times and resuspended in 500μl 
PBS. Cells were incubated with FITC-Phalloidin at 2.5ng/ml for 30mins in the dark at 4°C. 
Cells were washed 3 times and fluorescence detected by flow cytometry (FITC channel) or 
by confocal microscopy. On the confocal microscope Z-stacks of 30 images were taken 
focussing from the top to the bottom of the neutrophils.  
As a positive control, patient and control neutrophils were stimulated with 1nM fMLP for 1min 
prior to pelleting the cells, and labelling with Phalloidin as above.  
4.2.7 Western blotting. 
Western blotting was undertaken as indicated in the General Methods Chapter. 
4.2.8 Statistical methods. 
Comparisons between means were assessed using the student t test. Multiple comparisons 
were made using ANOVA. Where appropriate, in the assessment of actin expression, the 
paired t test was used to compare differences between paired control and SSc samples from 
the same experimental repeat. 
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4.3 Results. 
4.3.1 Differential protein expression by DIGE. 
In this section of the work, protein expression in 6 SSc patients was compared by DIGE with 
6 healthy controls. For patient characteristics please see Table 7. Equal amounts of protein 
from both types of extracts were combined and used as an internal control in the DIGE 
analysis. Up to 2136 different protein spots were resolved on the gels.  
Characteristic Patient (n=6) Control (n=6) 
Age/yrs (median, IQR) 47 (42,57) 42 (38,49) 
Male: Female ratio 1:5 1:5 
Limited disease (%) 5/6 (83) N/A 
Diffuse disease (%) 1/6 (17) N/A 
Pulmonary fibrosis (%) 2/6 (33) N/A 
Pulmonary artery hypertension (%) 1/6 (17) N/A 
Disease duration/yrs (median, IQR) 4 (3,6) N/A 
 
42 proteins were differentially expressed (statistical significance <0.05) between patients 
with SSc and healthy controls. Positive protein identifications were made for 24 of these 
(57%) (Fig.27). This is in keeping with previous studies which found that only 60% of 
proteins identified by DIGE could be identified by matching with comparator gels stained with 
colloidal Coomassie, due to differences in the dynamic ranges of the two different stains 255. 
It was possible to locate 70% of the 42 differentially expressed proteins by visual matching of 
the DIGE and the comparator gels. Of these, some spots did not yield identities due to the 
strict criteria set for protein identification, coupled with their low abundance. One of the 4 
observed down-regulated proteins yielded identification (Table 8). 
Table 7. Patient characteristics. Characteristics of patients and controls in whom neutrophil 
proteinexpression was compared. 
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MW 70 kDa 
10 kDA 
pH 3 pH 10 
Fig.27. DIGE gel showing proteins that were differentially expressed between systemic 
sclerosis patients and healthy control samples. Protein (50μg) from the neutrophils of patients 
with systemic sclerosis, healthy controls, or mixtures of both protein extracts (internal loading 
control) were labelled with Cy dyes (see Methods) separated on a pH3-10 non-linear IPG strip 
in the first dimension and by 12.5% acrylamide SDS-PAGE in the second dimension. The 
resulting gel was scanned using a Typhoon fluorescence scanner and the results analysed 
using DeCyder software. 38 proteins were up-regulated (unmarked) whereas 4 proteins were 
down-regulated (marked *) in systemic sclerosis patients compared to healthy control samples. 
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      Fold change 
Protein ID Database source Accession number Theoretical mW (kDa) Estimated mW (kDa) Magnitude Anova (p) No. of peptides matched Max MOWSE score Sequence coverage (%)
Lactoferrin MSDB Q5EK51 76 72 1.8 0.014 23 453 21
Glutathione disulfide reductase MSDB P00390 52 52 1.4 0.045 4 102 9
Actin gamma MSDB P63261 41 40 1.7 0.00077 7 211 12
Phosphoglycerate kinase MSDB P00558 44 40 1.5 0.014 4 149 10
Ficolin 1 MSDB Q5VYV5 35 34 1.4 0.027 6 138 16
Annexin 3 MSDB P12429 36 34 1.5 0.04 21 545 38
Bacteriocidal permeability-increasing protein fragment MSDB Q5JRQ5 34 34 1.5 0.0066 2 57 4
Actin related peptide 2/3 complex subunit 2 MSDB Q53R19 34 33 1.7 0.0043 7 142 22
Purine nucleoside phosphorylase MSDB P00491 32 32 1.4 0.0092 11 310 27
Chloride intracellular channel protein 1 MSDB O00299 27 32 1.5 0.0035 6 139 20
Actin capping protein MSDB Q5VV25 31 31 1.4 0.018 14 321 30
Elastase inhibitor MSDS P30740 42 30 2 0.023 4 87 5
Actin gamma fragment MSDB Q6PJ43 29 28 1.8 0.0018 21 289 22
Annexin 3 MSDB P12429 36 28 1.8 0.0019 2 64 5
Triosephosphate isomerase MSDB P60174 26 28 1.8 0.034 4 240 21
Beta haemoglobin MSDB P68871 16 27 1.3 0.033 4 133 35
PYD and CARD domain containing protein MSDB Q9ULZ3 21 24 1.6 0.0095 10 506 45
Actin related peptide 2/3 complex subunit 5 MSDB O15511 16 17 1.8 0.0006 4 122 15
GAPDH fragment MSDB P00354 36 17 1.6 0.0067 9 259 18
Allograft inflammatory factor 1 MSDB P55008 16 15 1.8 0.033 2 74 12
Calgranulin B MSDB P06702 13 13 2.1 0.00025 4 111 32
Calgranulin B MSDB P06702 13 13 2.1 0.0069 3 92 25
Calgranulin A MSDB P05109 11 11 1.8 0.0043 5 161 45
Calgranulin A MSDB P05109 11 11 1.8 0.038 25 244 68
Beta haemoglobin fragment MSDB Q3LR79 11 11 0.2 0.037 6 72 32
                                          Identification                                                                                                             
 
Table 8. Differentially expressed proteins in SSc neutrophils. 
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Differentially expressed proteins fell into 2 main categories; neutrophil granular proteins and 
proteins involved in actin turnover. Table 8 also shows that some of the proteins, although 
securely identified, ran on the gels at lower than the predicted molecular mass, implying that 
they have been cleaved in vivo or in vitro. The fact that there was an increase in the 
abundance of such cleavage products in patients compared to healthy controls, despite the 
presence of excess protease inhibitors in the lysis buffer, may suggest that the proteins may 
have been cleaved in vivo. This may have resulted from an increase in the amount or activity 
of intracellular proteases or perhaps a functional deficit in antiproteinases.  
The proteins were increased 1.4 to 2-fold, (Table 8) in keeping with previously reported 
changes in protein expression on neutrophil activation 259. Fig.28 shows the individual levels 
of four proteins in 6 patients and healthy controls. Each dotted line represents one DIGE gel 
and the continuous line represents the average of all 6 gels. Clearly, there was statistically 
significant up-regulation of the three proteins in the patients, although this was not 
apparently observed in all the individual patients. Also shown is a 3-D representation of the 
abundance of the protein spots on the DIGE gels. 
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Fig.28. Standardised abundance of selected proteins in individual systemic sclerosis 
patients and healthy controls. The individual levels of four proteins in 6 patients and 6 
healthy controls are shown. Each dotted line represents the standardised quantification 
from one DIGE gel and the continuous line represents the average of all 6 gels. Also 
shown is a 3-D representation of the abundance of the protein spots on the DIGE gels. 
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Attempts were made to validate the proteomic studies by assessment of F-actin turnover 
and western blotting of calgranulin B and SERPIN B1. Calgranulin was chosen for validation 
because it showed the greatest fold change by DIGE. SERPIN B1 was also chosen for 
validation because changes in protease activity especially neutrophil elastase may be 
relevant to tissue fibrosis.  
4.3.2 F-actin turnover measured by Phalloidin-FITC staining. 
F-actin turnover was assessed by measuring phalloidin-FITC staining before and after 
stimulation with fMLP by flow cytometry and by confocal microscopy. Flow cytometry 
experiments showed that there was no significant difference in F-actin expression between 
control and SSc neutrophils at baseline (Fig.29).  
 
 
When imaged by confocal microscopy, less SSc neutrophils were weakly stained and SSc 
neutrophils appeared to have more focal accumulations of F-actin i.e. the cells were more 
frequently polarised indicating activation (Fig.30).  
Fig.29. Neutrophils were isolated 
from patients with SSc or healthy 
controls. F-actin was labeled with 
Phalloidin-FITC. Neutrophils were 
stimulated with fMLP (1nM for 
1min). Mean fluorescence 
intensity (MFI) was measured by 
flow cytometry. No significant 
differences in F-actin content were 
identified (n=7). 
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To further investigate this, stacks of 30 slices were taken through the neutrophils over 
9.91µm by confocal microscopy. fMLP was used as a positive control. Control neutrophils 
are uniformly stained with Phalloidin-FITC and on treatment with fMLP they form focal actin 
aggregates. Untreated SSc neutrophils have focal actin aggregates similar to those seen on 
fMLP treatment (Fig. 31). 
Fig.30. Healthy control (A) and SSc (B) neutrophils were stained with Phalloidin-FITC to 
label F-actin content and were visualized by confocal microscopy. A representative image 
is shown. There are less weakly stained SSc neutrophils and SSc neutrophils appear to 
have more focal concentrations of F-actin (arrows). 
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Fig. 31. Untreated control neutrophils 
(A) stain uniformly with Phalloidin-
FITC which label F-actin. On treatment 
with fMLP (1nM 1min) control 
neutrophils form focal actin 
aggregates and cells polarize and 
decrease in size (B). Untreated SSc 
neutrophils (C) display a similar 
phenotype to fMLP treated control 
neutrophils. Images represent 
consecutive slices through the 
neutrophil taken by confocal 
microscopy. 
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4.3.3 Calgranulin B and SERPIN B1 expression by western blotting. 
Western blots of calgranulin B showed an increase in calgranulin B expression in SSc 
neutrophils compared to controls, however this did not reach significance (Fig.32).  
 
 
 
 
SERPIN B1 expression as assessed by western blotting, was decreased in SSc neutrophils 
compared to controls, with an increase in the 29kDa fragment. The 29kDa fragment is 
thought to arise by proteolytic cleavage of SERPIN B1 by neutrophil elastase and therefore 
this result may imply an increase in intracellular elastase activity in SSc neutrophils (Fig.33).  
The western blot studies concur with the DIGE studies in that the direction of change in 
protein expression is similar. However, the magnitude of change is much smaller when 
assessed by western blotting and does not reach statistical significance. 
Fig.32. There was no significant increase in calgranulin B expression in SSc neutrophils 
compared to healthy controls. Neutrophil lysates were prepared for control and SSc 
neutrophils. These were analysed for calgranulin B expression by western blotting using 
Tris-tricene gels. Protein expression was quantified and corrected for histone expression. 
Histone was used for normalisation as gels were optimised for low molecular weight 
proteins. N=5 (p=0.097). 
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Further investigations into neutrophil elastase expression and function are detailed in 
Chapter 6. 
 
 
Fig.33. There was a non-significant decrease in SERPIN B1 expression in SSc neutrophils 
compared to healthy controls (p=0.15), and a non-significant increase in the 29kDa fragment 
of SERPIN B1 (p=0.09). Neutrophil lysates were prepared for control and SSc neutrophils. 
SERPIN B1 expression was quantified using conventional western blotting. Protein 
expression was corrected for tubulin expression. N=5. 
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4.4 Discussion. 
These data show that DIGE is a powerful technique to compare protein profiles of disease 
and control human samples and allow a novel insight into potential disease mechanisms. 
We have identified clear and statistically-significant changes in expression of key neutrophil 
proteins in a disease state (SSc), which may help uncover mechanisms whereby neutrophils 
are activated in vivo and contribute to pathology.   
 
The actin cytoskeleton in the neutrophil is a dynamic cellular component which has roles in 
motility, phagocytosis receptor affinity, apoptosis, cell cycle and cell signalling 260. Actin 
exists in the cell as both G-actin (unpolymerised) and F-actin (polymerised into fibrils). 
Neutrophil activation results in an increase in the cellular F-actin content 260. Many 
associated proteins are involved in the regulation of actin polymerisation. The rate limiting 
step in actin polymerisation is nucleation, where monomers of G-actin form trimers which 
serve to seed F-actin formation.  
 
Actin related peptide (ARP 2/3 complex) is involved in the promotion of actin nucleation 
thereby promoting actin polymerisation 261. I found ARP 2/3 complex expression to be 
increased in SSc neutrophils compared to controls. Following nucleation, actin filaments 
grow by the addition of G-actin at the “barbed” end of the filament. However, in the resting 
state, most of the barbed ends are “capped” by capping proteins such as actin capping 
protein (CapZ). This serves to regulate actin polymerisation by preventing filament 
extension. On activation, capping proteins are cleaved from the barbed ends allowing 
filament extension 262. I found an increase in the abundance of CapZ in SSc neutrophils 
compared to controls. This may indicate cleavage of CapZ from the barbed ends of actin 
filaments as a result of neutrophil activation. In SSc, these proteins are upregulated and may 
indicate increased neutrophil motility as a result of activation. Finally, G-actin forms 
complexes with actin-sequestering proteins that bind G-actin with high-affinity and prevent it 
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from polymerising. Sequestering proteins include thymosin β4 and profilin. G-actin is 
released from the binding proteins during activation (Fig.34) 260.  
 
 
 
We have found an increase in cellular actin in SSc neutrophils compared to controls. This 
may represent release of G-actin from the sequestering proteins during neutrophil activation 
as total cellular actin is not thought to vary. It is however, difficult to interpret the changes in 
actin levels as polymerised actin would be insoluble and would therefore not be loaded onto 
a 2D gel.  
 
Experiments examining the F-actin concentration by Phalloidin-FITC staining do not confirm 
the hypothesis that there is increased F-actin content in SSc neutrophils at baseline. 
However, imaging studies do suggest an increase in neutrophil polarisation in SSc and 
Fig.34. The control of actin polymerization. ARP 2/3 promotes nucleation of actin 
filaments. Actin capping proteins prevent filament growth. Actin binding proteins 
sequester G-actin. 
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although this is not accompanied by an increase in Phalloidin-FITC staining, it does mimic 
the changes induced by neutrophil activation with fMLP.  
 
The demonstrated increase in protein fragments including elastase inhibitor (SERPIN B1) 
may indicate an increase in neutrophil proteases or a deficit in anti-proteinases. In this study, 
I have not identified any change in the expression of the neutrophil proteases, elastase and 
cathepsin G. This is likely to be due to the basic pI of these proteins (8.7 and 11.37, 
respectively). The IEF strips used had a range of pH3-10, but they are expanded in a non-
linear fashion with maximum resolution in the range pH4-7. Therefore, to optimally resolve 
these basic proteins, it would be necessary to use strips with a more basic pH range. I did 
conduct repeat experiments using pH7-10 strips, but no significant differences in protein 
abundance were detected. However, cathepsin G would obviously not be identified on such 
strips and even elastase would be towards the basic limit of resolution of these gels.  
 
Basic proteins are notoriously difficult to resolve using 2D protein electrophoresis due to the 
difficulties in maintaining the solubility of such proteins. The 29kDa fragment of SERPIN B1 
is the result of elastase dependent proteolytic cleavage, which occurs during binding of 
elastase to its endogenous inhibitor (SERPIN B1). Elastase expression and activity are 
further explored in Chapter 6. 
 
Annexin 3, actin gamma fragment, elastase inhibitor and calgranulins A and B were 
increased in SSc neutrophils. In a previous proteomic study, an increase in the levels of 
annexin 3, actin gamma fragment and elastase inhibitor was found when neutrophils were 
exposed to lipopolysaccharide, a substance known to activate neutrophils in vitro. The 
magnitude of the proteomic changes seen in the latter study were similar to those found in 
my study 259. There were some discrepancies between the two studies however; ficolin 
expression was decreased, but in my study is increased. The reason for this discrepancy is 
not known. In addition, unpublished proteomic studies from our laboratory have shown that 
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calgranulin levels are increased in neutrophils following in vitro exposure to TNF (personal 
communication J. Allen). Calgranulins will be further discussed in Chapter 5.  
The inability to validate the findings of DIGE using western blotting to estimate protein 
expression is disappointing. Western blotting is a powerful technique for exploring changes 
in protein expression in one sample exposed to several different conditions. However, it has 
major limitations in assessing differences between samples from different donors taken at 
different times. It is extremely difficult under these circumstances to ensure equal protein 
loading. Although correction can be made to so called “house-keeping” genes, the variability 
in expression of these proteins in disease settings has not been explored. Finally, but most 
fundamentally, although western blotting is extremely sensitive, it is not very precise, that is 
it is semi-quantitative at best 263.  
 
The direction of change in both calgranulin B expression and SERPIN B1 29kDa fragment 
were, however, the same as those seen in DIGE experiments and were approaching 
statistical significance (p=0.09) and therefore western blot data was consistent with evidence 
of neutrophil activation. 
 
A limitation of this study has been the difficulty in matching DIGE gels. DIGE was designed 
to decrease the effects of gel-to-gel variation and, indeed, within one gel this can be very 
effective. However, in order to increase the statistical power of this study it was necessary to 
compare 6 DIGE gels. The number of spots resolved on the gels ranged from 1279 to 2136 
and the number of spots matched on all 6 gels was 768. Gel spots included within the results 
were rigorously analysed on an individual basis to check that they represented true proteins 
and that the spot represented the same protein on all gels analysed. This will, however, have 
led to some spots being excluded from the analysis that may have been differentially 
expressed.  
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An even greater limitation is that comparator gels used for protein identification were stained 
with colloidal Coomassie or silver. The dynamic ranges of these stains are much lower than 
the dynamic range of DIGE and therefore matching of low abundance spots was often 
difficult. Further attempts were made to increase the number of protein identifications by 
preparing overloaded silver stained gels and overloaded lava Purple (GE Healthcare) 
stained gels following removal of the high abundance low molecular weight proteins by using 
a 10kDa centrifugal filter device (Millipore). The gels were however so different in overall 
appearance that it was difficult to match proteins by eye. Overloaded lava purple stained 
gels were then prepared from the complete neutrophil protein lysate as lava purple has a 
wider dynamic range than silver or Coomassie colloidal staining and the digital images of the 
lava purple stained gels could be scanned into and matched to the original DIGE images 
using the Decyder software. However, this approach did not lead to any further protein 
identifications.  
 
These limitations will have led to missing proteins of interest, however, they do not detract 
from the positive results already discussed above. 
 
Chapter 5 explores the use of cellular fractionation and gel-free shotgun techniques (iTRAQ) 
to further investigate the neutrophil proteome in SSc. This technique is able to overcome 
some of the limitations outlined above. In addition, iTRAQ, potentially, allows differences in 
post-translational modifications between SSc and control to be explored. Although, mass 
spectrometry is capable of detecting post-translational modifications to peptides, in this 
experiment a single sample loaded onto the comparator gel is used to generate the peptide 
identification and therefore differences between patient and control post-translational 
modifications will be missed.  
 
DIGE technologies require spot matching for relative quantification and therefore if a protein 
is expressed, but is absent from one of the two samples being compared this will not be 
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picked up. iTRAQ however will still be able to quantify proteins which are present in at least 
one sample even if it is absent from the others. 
 
In conclusion, circulating neutrophils from SSc patients exhibit an activated phenotype. It is 
possible that these activated neutrophils may release proteases and ROS that contribute to 
endothelial cytotoxicity in SSc. Neutrophils have a complex role in the immune system, being 
capable of antigen presentation, cytokine and chemokine release 264. Therefore, if 
neutrophils are activated in the peripheral blood in SSc, they may drive ongoing 
inflammation and endothelial cytotoxicity, leading to fibrosis-the characteristic clinical feature 
of this disease. 
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Chapter 5: Membrane proteomics. 
 
5.1 Introduction. 
Functional studies of neutrophils isolated from patients with SSc indicate that the neutrophils 
may be primed in vivo (Chapter 3). Neutrophil priming is defined as the process of 
enhancing ROS generation in response to an activating agent by prior treatment with a 
priming agent (Fig.35). This two stage process increases control over neutrophil activation 
which can result in the production and release of potentially tissue damaging ROS 1 230. 
 
 
Neutrophil priming can be caused by substimulatory concentrations of cytokines which are 
known to activate neutrophils at higher concentrations. At these low concentrations, 
however, these cytokines are not capable of stimulating the neutrophil per se. However, 
incubation with these substimulatory concentrations of cytokines results in an enhanced 
Fig.35. Neutrophil priming by inflammatory mediators results in enhanced superoxide 
production (reproduced from Condliffe et al 1998 1). 
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capacity for cellular functions, such as ROS generation in response to activating substances 
such as fMLP, C5a and LTB4 218. 
Neutrophil priming is not strictly limited to the potentiation of ROS production. It can also 
involve the de novo synthesis of many proteins and also changes in protein subcellular 
localization. For example, priming increases the plasma membrane expression of the fMLP 
receptors, CR1, CR3 and cytochrome b molecules necessary for ROS generation and 
adhesion. In addition, there are changes in cell shape and changes in cytoskeletal re-
arrangements. The increased expression of proteins on the plasma membrane may not 
require de novo synthesis but instead involve the mobilisation of proteins from intracellular 
stores. This involves movement of the stores via changes in the cytoskeletal network and 
fusion of intracellular membrane bound stores with the plasma membrane 1 218 230. 
Some changes in primed neutrophils however, do not reflect an increase in the number of 
membrane proteins but rather a change in ligand-binding affinity, for example binding to 
endothelial surfaces by integrin- dependent mechanisms 218. 
Neutrophil priming is essential for, amongst other things, neutrophil mediated endothelial 
damage. In the presence of activating agents, fMLP, C5a or LPS, neutrophils cause only 
minimal damage to endothelial cells. However, if neutrophils are first primed, significant 
damage to endothelial cells ensued in response to the same activating substances 265. 
Finally, priming increases neutrophil survival. Potentially injurious neutrophils usually 
undergo apoptosis after 12-18h in the circulation. This programmed cell death allows 
efficient removal without the release of potentially toxic substances from the cell. However, 
primed neutrophils are not only more active following stimulation but they have increased 
survival 1 218 230. 
Priming is not a homogenous process. Different priming agents result in different effects on 
neutrophil function. Although, by definition, all priming agents increase ROS generation 
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following stimulation with agents such as fMLP, other priming functions differ. For example, 
interleukin-8, in contrast to TNFα and GMCSF, increases oxidative burst in response to 
PMA. Priming agents also have differing effects on degranulation and on membrane protein 
expression 230. 
The proteomic studies undertaken previously (Chapter 4) using gel-based techniques are 
limited because membrane proteins which are highly hydrophobic proteins are poorly 
resolved in such systems. In this study, I undertook further proteomic experiments on the 
plasma membrane fraction of SSc and control neutrophils. The purpose was to; examine for 
differences in membrane protein expression between control and SSc neutrophils; identify 
patterns which are consistent with neutrophil priming in vivo; identify a cytokine or other 
priming agent signature. 
5.2 Methods. 
5.2.1 Neutrophil isolation. 
Neutrophil isolation was performed as per Chapter 2. Cells were resuspended in RPMI 1640 
+25mM HEPES and 2mM glutamine at a concentration of 1 x 107 cells per ml. 
5.2.2 Neutrophil fractionation. 
A nitrogen decompression chamber was used to disrupt the neutrophils as this conferred 
several advantages over alternative methods. Firstly, disruption could occur in any medium, 
allowing compatibility with down-stream processing including iTRAQ labelling and MS/MS. 
Secondly, the disruption of cells occurs without any heating of the sample and in the 
absence of oxygen, thereby decreasing degradation or oxidative damage of proteins. Finally, 
nitrogen disruption produces a highly reproducible and homogenous cell lysate. 
Neutrophils were centrifuged (at 1000xg for 3min) to pellet the cells and resuspended in 
relaxation buffer (100mM KCl, 3mM NaCl, 3.5mM Mg2Cl, 1mM ATPNa2 (store aliquots at 
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50mM, -20°C and add just prior to use) 10mM PIPES, pH 7.2) containing complete protease 
inhibitor cocktail (Roche). Cells were placed on ice and transferred to a 45ml nitrogen 
disruption chamber (Parr). The cells were equilibrated at a pressure of 350Psi for 20min 
before releasing the cells into 100mM Na EGTA to give a final concentration of 25µM. Bomb 
pressures were optimized to give maximal cell disruption whilst giving minimal nuclear and 
granule disruption (determined experimentally). 
Cell lysates were centrifuged at 1500xg for 10min to pellet unlysed cells and nuclei. The 
supernatants were centrifuged at 7000xg for 1h to pellet the microsomal fraction. Optimal 
centrifugation speeds were confirmed by western blot for myeloperoxidase (granule 
enzyme), histone (nuclear protein) and HLA (membrane protein marker). The presence of 
the membrane protein fraction in the supernatant was also confirmed by measuring latent 
and non-latent alkaline phosphatase activity in pellets and supernatant. The supernatants 
were centrifuged at 250000xg for 4h to pellet the membrane fraction. The pellet was washed 
with 50mM ambic pH 8 and re-centrifuged at 250000xg for 4h. 
5.2.3 Measuring alkaline phosphatase activity.  
The alkaline phosphatase activity in supernatants and resuspended post 7000xg pellets was 
assayed using the alkaline phosphatase dependent production of p-nitrophenol, from 2mg/ml 
nitrophenol phosphate (NPP). The coloured product was measured by absorption at 405nm. 
The assay was performed in a buffer at pH10 (100mM 2-amino-2-methyl-1 propanol, 1mM 
MgCl2) at 37˚C and read after 30min. The assays were repeated in the presence and 
absence of 0.4% Triton X-100 to assess latent and non-latent activity. 
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5.2.4 iTRAQ. 
5.2.4.1 Sample preparation. 
The membrane pellet was resuspended in non-reducing sample buffer (3% SDS, 10% 
glycerol, 62.5mM Tris-HCl pH 6.8). Samples were quantified using the BCA assay (Pierce). 
50µg aliquots were taken of 4 patient samples and 3 healthy control samples. An internal 
control was prepared by combining 12.5µl of each of the patient and control samples. The 
protein was precipitated overnight at -20˚C by adding 6 vol of ice cold acetone. The 
precipitate was pelleted by centrifugation at 1000xg for 5min at 4˚C. The supernatant was 
removed.  
5.2.4.2 ITRAQ labeling. 
The pellet was dissolved in labeling buffer (8M urea, 25mM TEAB, 2% Triton-X100, 
0.1%SDS, pH8.5). The sample was reduced using 50mM TCEP (2µl per 20µl sample) at 
room temperature for 1h. Cysteine blocking was performed using MMTS 200mM in 
isopropanol (1µl per 20µl sample) at room temperature for 10min with agitation. Trypsin was 
added to the protein samples in a ratio of 1:20 and incubated at 37˚C overnight. Samples 
were centrifuged at 1000xg for 5min, and the supernatant was removed to a clean tube and 
dried in a Speedvac. The samples were resuspended in 25µl 1M TEAB and 60µl isopropanol 
pH 8.5 then each was transferred to a separate vial of iTRAQ label and incubated with 
agitation for 2h at room temperature. 100µl of H2O was added and incubated at room 
temperature for 2h with agitation. All samples were combined, dried in a Speedvac and 
resuspended in 3ml of loading buffer/buffer A for cation exchange (10 mM KH2PO4 in 25% 
acetonitrile at pH 3.0). Cation exchange was performed over a gradient of 100% buffer A to 
50% buffer A (50% acetonitrile). A total of 59 fractions were collected. Acetonitrile was 
evaporated off prior to loading peptides on to the mass spectrometer. 
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5.2.4.3 Mass spectrometry. 
Mass spectrometry experiments were performed using a QTof  Premier (Waters, Milford, 
Massachucetts) quadrupole time-of-flight hybrid instrument.  The QTof was operated either 
in MS mode or MS/MS mode, in a data-dependent manner.  Separation of peptides was 
performed by reverse-phase chromatography using a nanoAcquity HPLC pump, at a flow 
rate of 300nl/min and a Waters C18 nanoAcquity UPLC column (BEH 130 C18, 1.7µm 
particle size, 75µm i.d. x 150mm).  Peptides were loaded onto a trap column (Waters 
Symmetry C18, 5µm particle size, 180µm i.d. x 20mm) from the autosampler using 0.1% 
formic acid for 5 min at a flow rate of 5µl/min. After this period the valve was switched to 
allow elution of the peptides onto the analytical column.  Solvent A was 1% acetonitrile + 
0.1% formic acid and solvent B was 99% acetonitrile + 0.1% formic acid.  The gradient 
employed was 1-50% B in 112 min. 
In MS mode, data were collected from m/z 350-1600.  For data dependent mode, MS/MS 
data were collected between m/z 50-2000.  Briefly, peptides were selected for MS/MS based 
on charge-state recognition (2+ and 3+), providing the ion counts were above 10 counts.  
MS/MS data was collected for a total of 3s, before the instrument was switched back to MS. 
5.2.4.4 Data processing. 
All data was processed in ProteinLynx Global Server 2.3.  Text files (.pkl) were generated 
which contained precursor ion m/z values and associated fragment ion m/z values. 
Processed files were submitted to the Mascot search algorithm 2.2.0 (Matrix Science, 
London UK) and searched against forward and reverse ipi.HUMAN.v3.38.fasta database for 
protein identification, using fixed modification of MMTS (C) and variable modifications of 
oxidation (M), iTRAQ8plex (K),iTRAQ8plex (N-term) and iTRAQ8plex (Y).  
Mascot search results were processed using Mascot Percolator (Markus Brosch, Sanger 
Institute) to calculate q-values (estimated false discovery rate). Quantitation of reporter ions 
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was calculated in centroided mode using iSPY (Phil Charles, PhD student, unpublished). 
Protein identifications and corresponding reporter ion quantitation were then coupled using 
iSPY with an ion count threshold of 15 and application of ratiometric normalistion. Finally, 
results were filtered by q-value using a false discovery rate of 1% per run. 
5.3 Results. 
5.3.1 Optimisation of bomb pressure. 
Well-validated markers of membrane subfractions were used to optimise the bomb pressure 
used for nitrogen cavitation. In keeping with previously published data266, a bomb pressure 
of 350Psi resulted in the optimal recovery of the membrane fraction while limiting 
contamination with granular or nuclear proteins (Fig.36). 
 
 
 
5.3.2 Optimisation of centrifugation steps. 
The same markers of neutrophil subcellular fractions were used to optimize the 
centrifugation steps to recover the membrane fraction with minimal contamination from the 
Fig.36. The amount of MPO in the supernatant progressively increases with increasing 
bomb pressure. The lower the bomb pressure the greater the number of unlysed cells 
(larger pellet). Therefore, a bomb pressure of 350PSI was chosen to maximise the 
number of cells lysed but minimise the granule disruption. 
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granular and nuclear proteins. Protein markers by western blot and enzymatic assays of 
alkaline phosphatase activity revealed that an initial centrifugation step of 7000xg for 30min 
(Fig.37 and 38) followed by a second centrifugation step of 250000xg for 4h (Fig.39) gave 
the optimal separation of the plasma membrane fraction. This is in agreement with 
previously published data 266. 
 
 
 
 
Fig.37. Centrifugation of the supernatant at speeds of greater than or equal to 6000xg 
resulted in the removal of granular proteins (MPO) and centrifugation at speed greater 
than or equal to 7000xg resulted in the optimal removal of nuclear proteins (histone). 
Although some membrane proteins (HLA) were lost at these speeds there was no 
difference in HLA recovery between 6000 and 7000xg. Therefore 7000xg was chosen 
as the appropriate centrifugation speed. 
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Fig.38. Alkaline phosphatase activity is a marker for membrane proteins. Latent activity 
represents secretory vesicle alkaline phosphatase activity whilst non-latent alkaline phosphatase 
activity represents plasma membrane protein levels. Latent activity is revealed in the presence of 
0.4%TritonX-100 and non-latent activity is calculated by subtracting the latent activity from the 
total activity. Whilst lower centrifugation speeds give greater non-latent (membrane) activity there 
is in addition, latent activity indicating contamination with intracellular membrane bound 
organelles (secretory vesicles). Centrifugation at 7000xg gives the optimal recovery of non-latent 
alkaline phosphatase in the supernatant with no latent contamination. 
 
Fig.39. Centrifugation of the 7000xg supernatant for 250000xg for 4h results in 
pelleting of the membrane fraction (HLA-I) with no detectable contamination of the 
supernatant by western blot. This pellet was therefore used for membrane 
proteomics. 
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5.3.3 Patient characteristics. 
The characteristics of the 4 patients used in the iTRAQ experiments are summarised in 
Table 9. 
Male: Female 0:4 
Median disease duration (mths) 42 
Median Raynaud’s duration (yrs) 5 
Median Rodnan skin score 14.5 
Clinical feature Number (%) 
Limited subtype 3/4 (75) 
Diffuse subtype 1/4 (25) 
Lung involvement 0/4 (0) 
Pulmonary artery hypertension 1/4 (25) 
Renal involvement 0/4 (0) 
ANA positive 1/4 (25) 
Anticentromere positive 1/4 (25) 
Anti Scl70 positive 1/4 (25) 
Anti RNP positive 0/4 (0) 
DMARDs 2/4 (50) 
       Mycophenolate mofetil 1/4 (25) 
       Sildenafil 1/4 (25) 
Table 9. Patient characteristics. 
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              Control SSc   
Protein description 
Gene 
name Accession no. No. of peptides† Internal control‡ Average protein∆ 
% 
Differenceᶲ Average SD Average SD p value 
Myosin-9 MYH9 http://www.uniprot.org/uniprot/P35579 29 1.20 1.23 1.77 1.13 0.15 1.30 0.49 0.61 
Keratin KRT1 http://www.uniprot.org/uniprot/P04264 16 0.99 1.18 19.35 0.97 0.69 1.34 0.76 0.54 
Keratin KRT9 http://www.uniprot.org/uniprot/P35527 13 1.40 2.86 104.53 1.17 0.58 4.14 6.20 0.46 
Glycogen phosphorylase PYGL http://www.uniprot.org/uniprot/P06737 13 1.36 1.76 29.21 1.33 0.78 2.09 0.72 0.24 
Major vault protein MVP http://www.uniprot.org/uniprot/Q14764 13 0.90 1.11 23.30 0.69 0.11 1.43 0.56 0.08 
Matrix metalloproteinase 9 MMP9 http://www.uniprot.org/uniprot/P14780 12 0.83 0.89 7.73 0.60 0.34 1.11 0.41 0.14 
Cathepsin G precursor CTSG http://www.uniprot.org/uniprot/P08311 10 4.90 4.37 10.75 4.77 0.63 4.08 2.09 0.61 
Ras GTPase-activating-like protein  IQGAP1 http://www.uniprot.org/uniprot/P46940 9 2.55 1.37 46.04 1.98 1.10 0.92 0.57 0.15 
Keratin 10 KRT10 http://www.uniprot.org/uniprot/P13645 9 1.12 0.69 38.55 0.77 0.39 0.63 0.18 0.53 
Histone HIST2H4A http://www.uniprot.org/uniprot/P62805 7 2.10 2.65 26.10 1.68 1.22 3.37 2.75 0.37 
Plastin-2 LCP1 http://www.uniprot.org/uniprot/P13796 7 1.14 0.86 24.24 0.40 0.08 1.21 0.48 0.04 
Calgranulin A S100A8 http://www.uniprot.org/uniprot/P05109 6 1.84 2.07 12.88 2.43 0.31 1.80 0.79 0.26 
Talin-1 TLN1 http://www.uniprot.org/uniprot/Q9Y490 6 0.95 1.34 40.88 1.38 0.25 1.32 0.23 0.77 
Leukocyte elastase precursor ELA2 http://www.uniprot.org/uniprot/P08246 6 5.46 5.40 1.13 5.45 0.87 5.35 2.07 0.94 
Phosphoglycerate kinase 1 PGK1 http://www.uniprot.org/uniprot/P00558 5 1.68 1.50 10.44 1.00 0.20 1.88 1.76 0.44 
Actin-related protein 3 ACTR3 http://www.uniprot.org/uniprot/P61158 5 2.65 1.73 34.76 0.60 0.04 2.58 1.88 0.14 
Brain acid soluble protein 1 BASP1 http://www.uniprot.org/uniprot/P80723 5 1.07 2.80 160.31 2.03 1.32 3.37 5.11 0.68 
Protein-arginine deiminase type-4 PADI4 http://www.uniprot.org/uniprot/Q9UM07 5 0.92 1.50 63.51 1.04 0.51 1.85 1.10 0.29 
Adenylosuccinate synthetase isozyme 2 ADSS http://www.uniprot.org/uniprot/P30520 5 0.88 1.11 26.77 1.09 0.48 1.13 0.66 0.93 
Keratin KRT2 http://www.uniprot.org/uniprot/P35908 5 0.77 1.20 56.61 0.63 0.31 1.63 2.18 0.48 
Bactericidal permeability-increasing protein precursor BPI http://www.uniprot.org/uniprot/P17213 4 1.29 2.18 68.13 1.33 0.44 2.81 2.66 0.39 
Isoform 1 of Dedicator of cytokinesis protein 2 DOCK2 http://www.uniprot.org/uniprot/Q92608 4 1.05 1.08 2.38 0.47 0.16 1.53 0.85 0.09 
Leukocyte elastase inhibitor SERPINB1 http://www.uniprot.org/uniprot/P30740 4 0.90 0.69 23.02 0.44 0.18 0.89 0.46 0.17 
T-complex protein 1 subunit epsilon CCT5 http://www.uniprot.org/uniprot/P48643 4 0.67 1.51 123.86 1.18 0.86 1.76 1.54 0.59 
Isocitrate dehydrogenase [NADP] cytoplasmic IDH1 http://www.uniprot.org/uniprot/O75874 4 2.48 1.53 38.22 1.17 0.62 1.81 1.37 0.50 
Cofilin-1 CFL1 http://www.uniprot.org/uniprot/P23528 4 0.80 2.09 159.61 1.62 1.23 2.44 2.47 0.63 
Myeloblastin precursor PRTN3 http://www.uniprot.org/uniprot/P24158 3 1.10 1.01 7.85 1.10 0.06 0.95 0.66 0.70 
Lysozyme C LYZ http://www.uniprot.org/uniprot/P61626 3 0.82 1.03 24.96 0.51 0.14 1.42 0.43 0.02 
Cathelicidin antimicrobial protein CAMP http://www.uniprot.org/uniprot/P49913 3 1.71 1.46 14.40 0.78 0.14 1.97 1.25 0.17 
Catalase CAT http://www.uniprot.org/uniprot/P04040 3 2.13 1.94 9.09 0.85 0.89 2.75 0.72 0.03 
Calgranulin B S100A9 http://www.uniprot.org/uniprot/P06702 3 0.42 1.66 297.96 2.58 0.22 0.96 1.35 0.10 
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Vacuolar ATP synthase catalytic subunit A ATP6V1A http://www.uniprot.org/uniprot/P38606 2 0.75 0.51 32.35 0.47 0.06 0.53 0.40 0.80 
Alpha-centractin ACTR1A http://www.uniprot.org/uniprot/P61163 2 0.72 1.98 175.30 1.25 0.10 2.53 3.20 0.53 
Coronin-1A CORO1A http://www.uniprot.org/uniprot/P31146 2 1.75 2.44 39.14 2.00 0.85 2.77 2.01 0.57 
T-complex protein 1 subunit beta CCT2 http://www.uniprot.org/uniprot/P78371 2 0.56 2.18 290.12 1.52 1.45 2.67 1.43 0.35 
Aminopeptidase N ANPEP http://www.uniprot.org/uniprot/P15144 2 0.74 1.04 40.70 0.62 0.02 1.35 1.57 0.46 
1,4-alpha-glucan-branching enzyme GBE1 http://www.uniprot.org/uniprot/Q04446 2 1.29 3.41 164.69 2.39 0.51 4.18 5.12 0.58 
Synaptic vesicle membrane protein VAT-1 homolog VAT1 http://www.uniprot.org/uniprot/Q99536 2 3.92 1.53 60.91 0.42 0.02 2.36 2.49 0.24 
Cytochrome b-245 light chain CYBA http://www.uniprot.org/uniprot/P13498 2 1.36 3.52 158.60 1.95 0.40 4.70 3.38 0.23 
L-lactate dehydrogenase B chain LDHB http://www.uniprot.org/uniprot/P07195 2 3.06 1.79 41.65 0.82 0.09 2.51 1.60 0.13 
Cytochrome b-245 heavy chain CYBB http://www.uniprot.org/uniprot/P04839 2 1.20 1.38 15.28 1.65 1.00 1.18 0.15 0.38 
Myeloid cell nuclear differentiation antigen MNDA http://www.uniprot.org/uniprot/P41218 2 1.07 1.58 47.77 1.78 1.74 1.43 1.21 0.76 
Aspartyl-tRNA synthetase DARS http://www.uniprot.org/uniprot/P14868 2 3.68 2.03 44.98 0.95 0.32 2.83 1.55 0.10 
Copine-3 CPNE3 http://www.uniprot.org/uniprot/O75131 2 0.41 1.47 263.60 0.67 0.25 2.08 2.51 0.39 
Importin subunit beta-1 KPNB1 http://www.uniprot.org/uniprot/Q14974 2 3.54 1.39 60.67 0.30 0.11 2.21 2.51 0.26 
 Isoform 1 of L-lactate dehydrogenase A chain LDHA http://www.uniprot.org/uniprot/P00338 2 4.60 2.81 38.92 1.35 0.31 3.90 2.22 0.11 
Integrin-linked protein kinase ILK http://www.uniprot.org/uniprot/Q13418 2 2.81 1.33 52.84 0.82 0.41 1.71 1.66 0.41 
Arachidonate 5-lipoxygenase-activating protein ALOX5AP http://www.uniprot.org/uniprot/P20292 2 2.68 3.35 24.95 1.78 0.63 4.52 4.68 0.37 
 
Table 10. Membrane proteomics. Shows proteins identified from the membrane fraction of neutrophils isolated from SSc patients and healthy 
controls based on >1 matched peptide. †Indicates the number of unique peptides matched to each protein. ‡Indicates the relative abundance 
of the protein in the internal control. ∆ Indicates the average relative protein abundance in all samples. ᶲ Indicates the difference between ∆ and 
ᶲ as a percentage of ∆. P value is calculated for  difference between mean protein abundance in SSc neutrophils and healthy controls using the 
student T test. ANOVA analysis with Bonferroni correction revealed no significant differences between SSc and control.
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            Control SSc   
Protein description Gene name Accession no. Internal control Calculated % Difference Average SD Average SD 
p 
value 
fMet-Leu-Phe receptor FPR1 http://www.uniprot.org/uniprot/P21462 0.23 0.79 315.00 1.20 0.90 0.48 0.73 0.30 
Dynein heavy chain, cytosolic DYNC1H1  http://www.uniprot.org/uniprot/Q14204 1.41 0.64 95.65 0.16 0.09 1.00 0.89 0.17 
Proteasome subunit alpha type-2 PSMA2 http://www.uniprot.org/uniprot/P25787 0.40 1.64 364.00 2.84 2.24 0.73 0.31 0.11 
Zinc finger protein 677 ZNF677 http://www.uniprot.org/uniprot/Q86XU0 1.66 1.17 95.20 1.45 0.94 0.96 0.81 0.49 
Peptidoglycan recognition protein PGLYRP1 http://www.uniprot.org/uniprot/O75594 0.26 0.88 315.00 0.76 0.54 0.97 0.68 0.68 
Protein unc-13 homolog D UNC13D http://www.uniprot.org/uniprot/Q70J99 0.69 1.06 85.00 0.87 0.12 1.20 1.22 0.66 
N-acetylglucosamine kinase NAGK http://www.uniprot.org/uniprot/Q9UJ70 0.30 1.27 387.00 1.76 1.30 0.90 0.98 0.36 
HSPA5 protein HSPA5 http://www.uniprot.org/uniprot/Q2KHP4 0.51 2.72 487.00 2.70 0.87 2.74 2.12 0.98 
Zinc finger protein 428 ZNF428 http://www.uniprot.org/uniprot/Q96B54 1.68 7.27 263.00 1.71 0.86 11.44 19.35 0.43 
NULL     0.00 0.17 NA 0.03 0.06 0.27 0.54 0.49 
 26S proteasome non-ATPase regulatory subunit 2 PSMD2 http://www.uniprot.org/uniprot/Q13200 0.51 0.74 93.00 0.53 0.22 0.90 0.63 0.38 
Immunoglobulin superfamily member 2 IGSF2 http://www.uniprot.org/uniprot/Q93033 2.09 2.01 113.11 1.76 0.26 2.19 0.67 0.34 
Integrin beta chain, beta 2 variant ITGB2 http://www.uniprot.org/uniprot/P05107 0.35 0.98 243.00 1.08 0.80 0.90 0.91 0.79 
Uncharacterised C6orf10 http://www.uniprot.org/uniprot/Q5SRN2 0.00 0.39 NA 0.37 0.34 0.39 0.48 0.95 
Ret finger protein-like 4B RFPL4B http://www.uniprot.org/uniprot/Q6ZWI9 1.08 3.34 200.00 1.26 0.05 4.90 7.48 0.45 
cAMP-dependent protein kinase type I-alpha regulatory subunit PRKAR1A http://www.uniprot.org/uniprot/P10644 0.25 1.09 407.00 1.88 1.46 0.49 0.54 0.13 
Heat shock 70kDa protein 12A HSPA12A http://www.uniprot.org/uniprot/O43301 0.53 2.94 496.00 1.48 2.29 4.04 4.44 0.41 
Epiplakin EPPK1 http://www.uniprot.org/uniprot/P58107 4.26 8.28 231.44 3.84 0.34 11.62 10.83 0.28 
Puromycin-sensitive aminopeptidase NPEPPS http://www.uniprot.org/uniprot/P55786 0.62 2.63 360.00 4.23 3.09 1.44 2.03 0.20 
Vasodilator-stimulated phosphoprotein VASP http://www.uniprot.org/uniprot/P50552 0.84 2.45 205.00 4.31 3.29 1.05 0.62 0.10 
Coatomer subunit beta COPB1 http://www.uniprot.org/uniprot/P53618 0.55 0.74 80.00 0.45 0.13 0.95 0.87 0.38 
Actin-like protein (Fragment) P704P NA 0.43 1.55 318.00 2.81 2.27 0.61 0.60 0.11 
T-complex protein 1 subunit beta TCP1 http://www.uniprot.org/uniprot/P17987 1.90 4.24 34.00 1.70 0.14 6.15 8.52 0.42 
Annexin A1 ANXA1 http://www.uniprot.org/uniprot/Q05BR2 8.31 2.59 799.59 0.76 0.17 3.97 3.72 0.21 
Calpain-1 catalytic subunit CAPN1 http://www.uniprot.org/uniprot/P07384 0.50 0.74 97.00 0.49 0.10 0.92 1.06 0.52 
Eukaryotic initiation factor 4A-III EIF4A3 http://www.uniprot.org/uniprot/P38919 1.10 1.59 34.00 0.95 0.09 2.08 2.24 0.43 
Regulator of G-protein signalling 19 RGS19 http://www.uniprot.org/uniprot/P49795 0.39 0.75 151.00 0.35 0.09 1.04 1.42 0.45 
Keratin, type II cytoskeletal 5 KRT5 http://www.uniprot.org/uniprot/P13647 0.61 0.80 69.00 0.82 0.06 0.78 0.53 0.91 
Proteasome 26S non-ATPase subunit 8 PSMD8 http://www.uniprot.org/uniprot/P48556 0.47 0.79 121.00 0.43 0.11 1.07 1.38 0.47 
Short palate, lung and nasal epithelium carcinoma-associated protein 2 precursor C20orf70 http://www.uniprot.org/uniprot/Q96DR5 7.49 2.87 710.56 0.67 0.42 4.52 6.93 0.39 
Cytidine deaminase CDA http://www.uniprot.org/uniprot/P32320 10.21 4.78 973.95 1.05 0.24 7.58 8.40 0.25 
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Glucose-6-phosphate isomerase GPI http://www.uniprot.org/uniprot/P06744 3.32 0.48 317.66 0.17 0.02 0.71 0.61 0.20 
Osteoclast-stimulating factor 1 OSTF1 http://www.uniprot.org/uniprot/Q92882 1.34 0.60 89.70 0.22 0.05 0.89 0.79 0.21 
Retinoblastoma-associated protein RB1 http://www.uniprot.org/uniprot/P06400 0.14 0.98 662.00 1.86 1.57 0.31 0.35 0.11 
CDNA FLJ34945 fis, clone NT2RP7008454 NA NA 0.68 0.48 3.00 0.43 0.37 0.51 0.60 0.84 
Actin-related protein 2/3 complex subunit 2 ARPC2 http://www.uniprot.org/uniprot/O15144 2.09 0.97 162.06 1.20 0.78 0.80 0.67 0.50 
55kDa protein NA NA 1.10 1.06 13.44 1.17 0.39 0.98 0.28 0.48 
CDNA FLJ36836 fis, clone ASTRO2011149 NA NA 2.24 8.77 167.00 2.70 0.56 13.32 19.79 0.41 
MYL6 11kDa protein MYL6 http://www.uniprot.org/uniprot/P60660 0.08 0.20 241.00 0.19 0.27 0.21 0.31 0.96 
Short palate, lung and nasal epithelium carcinoma-associated protein 2 precursor C20orf70 http://www.uniprot.org/uniprot/Q96DR5 1.32 1.58 12.90 1.23 0.01 1.84 0.46 0.08 
Calnexin precursor CANX http://www.uniprot.org/uniprot/P27824 0.68 0.04 62.23 0.00 0.00 0.07 0.09 0.30 
Serine/threonine-protein kinase OSR1 OXSR1 http://www.uniprot.org/uniprot/O95747 0.47 0.69 97.00 0.51 0.14 0.82 0.78 0.53 
MET 24 kDa protein MET http://www.uniprot.org/uniprot/P08581 2.00 1.56 121.83 0.86 0.75 2.08 3.19 0.55 
IGHV4-31 Immunoglobulin heavy variable 4-31 IGHV4-31 NA 0.00 6.03 NA 7.46 12.92 4.97 9.93 0.78 
Heat shock protein HSP 90-beta HSP90AB1 http://www.uniprot.org/uniprot/P08238 0.27 0.92 311.00 0.31 0.06 1.38 1.88 0.38 
Proteasome subunit alpha type-5 PSMA5 http://www.uniprot.org/uniprot/P28066 0.51 0.59 65.00 0.17 0.00 0.91 1.38 0.41 
Macrophage migration inhibitory factor MIF http://www.uniprot.org/uniprot/P14174 4.26 2.15 375.65 0.52 0.11 3.38 4.77 0.36 
Uncharacterized protein ENSP00000382129 NA NA 0.61 1.72 223.00 2.89 2.62 0.84 0.73 0.19 
Eukaryotic translation elongation factor 1 epsilon-1 EEF1E1 http://www.uniprot.org/uniprot/O43324 1.53 1.24 73.00 1.32 0.58 1.17 0.61 0.76 
Isoform 1 of NLR family CARD domain-containing protein 4 NLRC4 http://www.uniprot.org/uniprot/Q9NPP4 0.09 0.10 106.00 0.11 0.02 0.10 0.02 0.56 
Annexin A11 ANXA11 http://www.uniprot.org/uniprot/P50995 0.41 1.67 364.00 1.59 0.41 1.74 0.76 0.77 
Profilin-1 PFN1 http://www.uniprot.org/uniprot/P07737 1.05 0.32 75.05 0.08 0.01 0.49 0.50 0.22 
Cytokine receptor-like factor 3 CRLF3 http://www.uniprot.org/uniprot/Q8IUI8 0.35 1.42 374.00 2.27 1.54 0.79 1.09 0.19 
Protein phosphatase 1 regulatory subunit 3D PPP1R3D http://www.uniprot.org/uniprot/O95685 1.08 2.71 142.00 3.02 2.07 2.47 0.79 0.64 
60S ribosomal protein L18 RPL18 http://www.uniprot.org/uniprot/Q07020 1.19 1.50 6.00 0.94 0.15 1.92 1.56 0.34 
Olfactomedin-4 precursor OLFM4 http://www.uniprot.org/uniprot/Q6UX06 0.37 0.44 80.00 0.30 0.16 0.54 0.52 0.47 
Threonyl-tRNA synthetase, cytoplasmic TARS http://www.uniprot.org/uniprot/Q5M7Z9 0.29 0.65 200.00 0.35 0.08 0.88 0.72 0.28 
Hexokinase-3 HK3 http://www.uniprot.org/uniprot/P52790 4.01 1.55 362.63 0.50 0.03 2.33 2.16 0.21 
Galectin-3 LGALS3 http://www.uniprot.org/uniprot/Q6FGL0 0.64 1.49 166.00 0.59 0.07 2.16 2.99 0.42 
Uncharacterized protein ENSP00000382574 NA NA 0.23 0.31 111.00 0.21 0.08 0.39 0.22 0.25 
Myosin IG MYO1G http://www.uniprot.org/uniprot/B0I1T2 0.69 1.13 94.00 0.60 0.07 1.53 1.90 0.45 
7 kDa protein CALCOCO1 http://www.uniprot.org/uniprot/Q9P1Z2 1.75 5.04 112.00 1.50 0.20 7.69 8.81 0.29 
High mobility group protein B2 HMGB2 http://www.uniprot.org/uniprot/P26583 1.71 4.83 111.00 2.23 1.16 6.77 11.18 0.52 
Uncharacterized protein ENSP00000368456 NA NA 1.42 2.01 1.45 0.98 0.34 2.77 3.33 0.41 
Inosine-5'-monophosphate dehydrogenase 2 IMPDH2 http://www.uniprot.org/uniprot/P12268 0.09 0.38 403.00 0.59 0.45 0.23 0.29 0.25 
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Leukocyte surface antigen CD53 CD53 http://www.uniprot.org/uniprot/P19397 0.87 0.96 24.00 0.70 0.18 1.16 0.40 0.13 
Neutrophil collagenase precursor MMP8 http://www.uniprot.org/uniprot/P22894 2.51 0.74 221.31 0.22 0.06 1.12 1.15 0.24 
Exportin-1 XPO1 http://www.uniprot.org/uniprot/O14980 0.63 2.15 281.00 3.65 2.96 1.02 0.91 0.15 
Isoform 1 of Spatacsin SPG11 http://www.uniprot.org/uniprot/Q96JI7 1.02 1.07 3.00 0.62 0.44 1.41 1.10 0.29 
40S ribosomal protein S13 RPS13 http://www.uniprot.org/uniprot/P62277 0.35 1.08 274.00 1.71 1.42 0.60 0.83 0.25 
Pentraxin-related protein PTX3 precursor PTX3 http://www.uniprot.org/uniprot/P26022 0.00 0.19 NA 0.04 0.06 0.30 0.61 0.49 
Centromere protein F CENPF http://www.uniprot.org/uniprot/P49454 1.26 0.52 85.33 0.18 0.01 0.77 0.68 0.21 
Ficolin-1 precursor FCN1 http://www.uniprot.org/uniprot/O00602 2.14 1.30 152.79 1.49 1.06 1.16 1.32 0.74 
Receptor-type tyrosine-protein phosphatase eta precursor PTPRJ http://www.uniprot.org/uniprot/Q12913 0.62 2.10 280.00 3.52 2.55 1.04 0.69 0.11 
Talin-related protein (Fragment) NA http://www.uniprot.org/uniprot/Q9Y4A1 1.11 2.26 92.00 2.34 0.26 2.20 0.67 0.76 
Isoform alpha-enolase of Alpha-enolase ENO1 http://www.uniprot.org/uniprot/P06733 0.98 5.35 450.00 3.30 3.75 6.88 3.43 0.24 
26S proteasome non-ATPase regulatory subunit 3 PSMD3 http://www.uniprot.org/uniprot/O43242 0.38 1.34 312.00 2.06 1.48 0.81 1.12 0.25 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 67 kDa subunit 
precursor RPN1 http://www.uniprot.org/uniprot/P04843 0.82 2.99 284.00 5.32 4.95 1.24 0.64 0.15 
Uncharacterized protein ENSP00000381431 NA NA 0.71 1.54 147.00 1.35 1.08 1.69 0.93 0.68 
Isoform 1 of Immunoglobulin superfamily member 10 precursor IGSF10 http://www.uniprot.org/uniprot/Q6WRI0 2.26 4.63 21.02 2.20 0.85 6.45 8.90 0.46 
Glial maturation factor gamma GMFG http://www.uniprot.org/uniprot/O60234 1.46 1.38 51.41 1.43 0.15 1.35 0.46 0.79 
60S acidic ribosomal protein P2 RPLP2 http://www.uniprot.org/uniprot/Q6FG96 1.67 0.58 132.66 0.15 0.01 0.91 0.81 0.18 
40S ribosomal protein S5 RPS5 http://www.uniprot.org/uniprot/P46782 3.21 0.91 293.12 0.23 0.02 1.42 1.34 0.19 
CDNA FLJ32372 fis, clone SALGL1000005 RILPL2 http://www.uniprot.org/uniprot/Q969X0 0.35 1.36 350.00 2.11 1.59 0.80 1.15 0.26 
CD59 glycoprotein precursor CD59 http://www.uniprot.org/uniprot/P13987 0.42 0.43 60.00 0.26 0.03 0.56 0.59 0.42 
LOC442501 Uncharacterized protein ENSP00000382470 NA NA 1.74 4.63 91.00 2.73 0.62 6.04 8.26 0.53 
FACT complex subunit SPT16 SUPT16H http://www.uniprot.org/uniprot/Q9Y5B9 1.07 1.67 49.00 1.87 0.23 1.52 0.44 0.27 
Adenosylhomocysteinase AHCY http://www.uniprot.org/uniprot/P23526 0.27 1.51 538.00 0.39 0.19 2.35 2.58 0.26 
Ras-related protein Rab 8B RAB8B http://www.uniprot.org/uniprot/Q92930 0.58 1.98 282.00 3.35 2.48 0.96 0.73 0.12 
Azurocidin precursor AZU1 http://www.uniprot.org/uniprot/P20160 0.49 0.74 101.00 0.37 0.18 1.02 1.03 0.34 
Eosinophil peroxidase EPX http://www.uniprot.org/uniprot/P11678 5.52 2.38 508.44 0.32 0.03 3.92 4.87 0.27 
Alpha-actinin-4 ACTN4 http://www.uniprot.org/uniprot/O43707 0.57 0.98 112.00 0.62 0.06 1.25 1.25 0.44 
U4/U6.U5 tri-snRNP-associated protein 1 SART1 http://www.uniprot.org/uniprot/O43290 1.85 0.97 132.14 1.31 0.96 0.71 0.73 0.38 
14-3-3 protein epsilon YWHAE http://www.uniprot.org/uniprot/P62258 0.00 0.09 NA 0.00 0.00 0.16 0.33 0.44 
Tubulin alpha-4 chain TUBA4B http://www.uniprot.org/uniprot/Q9H853 0.74 1.02 65.00 0.79 0.07 1.20 0.66 0.34 
26S protease regulatory subunit 6A PSMC3 http://www.uniprot.org/uniprot/P17980 1.24 2.05 42.00 1.25 0.28 2.65 2.64 0.41 
Glycogen phosphorylase PYGB http://www.uniprot.org/uniprot/P11216 2.30 3.43 80.62 1.94 0.46 4.55 5.66 0.47 
Resistin precursor RETN http://www.uniprot.org/uniprot/Q9HD89 0.50 1.06 160.00 0.42 0.01 1.54 1.80 0.34 
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FMLP-related receptor I FPRL1 http://www.uniprot.org/uniprot/P25090 0.60 2.40 338.00 3.58 2.59 1.52 2.28 0.31 
Alpha-actinin-2 ACTN2 http://www.uniprot.org/uniprot/P35609 1.00 1.66 65.00 1.01 0.16 2.14 2.14 0.41 
Phosphorylase b kinase regulatory subunit alpha PHKA2 http://www.uniprot.org/uniprot/P46019 0.17 0.93 542.00 1.59 1.13 0.43 0.55 0.13 
Protein-arginine deiminase type-2 PADI2 http://www.uniprot.org/uniprot/Q96DA7 0.99 0.63 34.45 0.43 0.07 0.79 0.43 0.22 
Ras GTPase-activating-like protein IQGAP3 IQGAP3 http://www.uniprot.org/uniprot/Q86VI3 0.81 0.72 8.00 0.48 0.46 0.90 0.35 0.22 
Interferon gamma precursor IFNG http://www.uniprot.org/uniprot/P01579 0.99 4.39 345.00 8.18 6.87 1.55 1.41 0.11 
Laminin subunit alpha-5 precursor LAMA5 http://www.uniprot.org/uniprot/O15230 0.74 2.96 324.00 0.84 0.31 4.54 6.70 0.39 
 
Table 11. Membrane proteomics. Shows proteins identified from the membrane fraction of neutrophils isolated from SSc patients and healthy 
controls based on only 1 matched peptide. No significant differences were found in protein expression between SSc patients and controls.
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5.3.4 iTRAQ. 
iTRAQ identified 48 proteins using more than one peptide (Table 10) and 105 proteins by 1 
peptide identification in the neutrophil membrane fraction (Table 11). Proteins based on only 
1 peptide identification were discounted in further analyses. An internal control was included 
which contained equal volumes of each protein sample. Therefore, assuming correct 
quantification, the relative quantity of each protein in the internal control should equal the 
sum of the quantity of that protein in each sample divided by the number of samples (N=7). 
The percentage difference between these 2 quantities was calculated and reflects the 
accuracy of the quantification in each case. The variation ranged from 1.13% (leukocyte 
elastase) to 297.96% (calgranulin B). Proteins that varied from the control more than 63% 
(75th centile) were disregarded in further analysis (Fig.40). 
 
 
 
Fig.40. Assessment of the reliability of protein quantification using iTRAQ. Each point 
on the scatter graph represents one protein identified in the neutrophil membrane 
proteome. The difference between the average protein abundance across samples 
compared to the internal control abundance is plotted as a percentage of the internal 
control abundance. The smaller the difference the more reliable the quantification data 
for that protein. Proteins that lie above the 75th percentile for % difference (63%) are 
regarded as too unreliable and quantification data for these proteins is discarded 
(n=11). 
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Membrane proteomic data shows no membrane proteins are differentially expressed in SSc 
neutrophils compared to controls with statistical significance. There is a trend to significance 
for the expression of several proteins but due to the multiple comparisons made, the 
application of the stringent Bonferroni correction meant that no changes were significant. 
iTRAQ is also limited by the fact that a maximum of 7 samples can be compared in one 
experiment (the 8th being reserved for internal control, a mixture of equal quantities of all 7 
samples used for validation of quantification (see above)). Therefore only 3 control and 4 
SSc samples could be compared. Therefore, it is unsurprising that results did not reach 
statistical significance. However, the study served its purpose by indicating potential 
differentially expressed proteins which can be explored further using other techniques such 
as flow cytometry which can be carried out in greater numbers of patients. As has often been 
the case in patients with SSc, the protein abundance is often highly variable (more variable 
than abundance in healthy controls), likely to reflect the heterogeneity of the disease.  
5.3.5 Calgranulin expression is decreased in the plasma membrane fraction of 
SSc neutrophils compared to controls. 
Proteins of interest include membrane-expressed calgranulin A (S100A8), which is down 
regulated in 3 of the patients with SSc (Fig.41). Total neutrophil calgranulin was elevated in 
SSc compared to controls (Chapter 4), therefore it is interesting to find a down regulation in 
its localisation within membranes. N.B. The membrane fraction may contain intracellular 
membrane proteins in addition to plasma membrane proteins. Proteins associated with the 
plasma membrane are not necessarily orientated to the outside of the membrane, as many 
are associated with the intracellular surface of the plasma membrane where they are 
involved in signal transduction and cytoskeletal organisation. 
Calgranulin B (S100A9), the heterodimer partner of calgranulin A, was also found to be 
down-regulated in 3 of the SSc neutrophil membrane samples (Fig.42) However, the 
average protein abundance varied widely from the internal control abundance (>63%) and 
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so this apparent down-regulation is questionable. However, the 2 proteins are most stably 
expressed as a heterodimer which is responsible for many of the protein’s functions. As both 
proteins were found to be down-regulated in the same patients when the majority of other 
proteins were upregulated or remained constant in SSc, the down-regulation may be 
genuine.  
 
Fig.41. Calgranulin A (S100A8) abundance in 3 control neutrophil and 4 SSc neutrophil 
membrane samples.    and    represent individual patient and control samples respectively. 
In addition, median and interquartile range are shown. 
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Fig.42.Calgranulin B (S100A9) abundance in 3 control neutrophil and 4 SSc neutrophil 
membrane samples.    and    represent individual patient and control samples 
retrospectively. In addition, median and interquartile range are shown.  
 
5.3.6 Specific granule proteins are upregulated in the plasma membrane of 
SSc neutrophils compared to controls. 
Lysozyme C is also upregulated (Fig.43), it is consistently upregulated in all patient samples 
compared to control levels.  
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Fig.43. Lysozyme C protein abundance in 3 control and 4 SSc neutrophil membrane 
samples.    and    represent individual patient and control samples retrospectively. In 
addition, median and interquartile range are shown.  
 
5.3.7 The anti-oxidant enzyme catalase is increased in the plasma membrane 
fraction of SSc neutrophils compared to controls. 
Median catalase expression in the plasma membrane fraction is also increased in patients 
compared to controls (Fig.44).  
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Fig.44. Catalase protein abundance in 3 control and 4 SSc neutrophil membrane samples.     
Symbols    and    represent individual patient and control samples retrospectively. In 
addition, median and interquartile range are shown.  
 
5.3.8 Proteins involved in the control of actin polymerisation are increased in 
the plasma membrane fraction of SSc neutrophils compared to controls. 
L-plastin, otherwise known as actin-bundling protein, is increased in the plasma membrane 
fraction of 3/4 SSc neutrophils compared to controls (Fig.45). L-plastin is a multifunctional 
protein, involved not only in the control of actin polymerisation but is also an important 
signalling molecule. 
Actin-related peptide is involved in the control of actin polymerisation. It is important in the 
nucleation of actin monomers necessary for the subsequent propagation of polymerisation. 
Actin-related peptide was increased in the plasma membrane fraction of 3/4 SSc patients 
compared to controls (Fig.46). 
Page 136 of 236 
 
 
 
 
Fig.45. L-plastin protein abundance in 3 control and 4 SSc neutrophil membrane samples.     
Symbols    and    represent individual patient and control samples retrospectively. In 
addition, median and interquartile range are shown.  
 
Fig.46. Actin-related peptide abundance in 3 control and 4 SSc neutrophil membrane 
samples.     and    represent individual patient and control samples, retrospectively. In 
addition, median and interquartile range are shown.  
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It is interesting to note that in many cases one of the patient samples did not fit with results 
seen in the rest of the disease group but had protein expression levels more similar to the 
control group. This patient is a patient with long standing limited SSc, has pulmonary artery 
hypertension and is on Sildenafil. The other patients had much shorter disease duration and 
have progressive symptoms. 
5.4 Discussion. 
5.4.1 Calgranulin. 
It is potentially interesting to find differential expression in both the whole cell and membrane 
levels of calgranulin A (S100A8) and B (S100A9) and that similar changes were seen in both 
proteins. The functions of S100A8 and S100A9 have been the subject of a great deal of 
recent research. S100A8 and S100A9 are members of the S100 family of proteins, are 
expressed by monocytes and neutrophils and also can be induced in keratinocytes during 
inflammation. Their expression is up-regulated in a wide range of malignancies and also in 
inflammatory disease 267. They can be found as monomers but frequently form homo- and 
hetero-dimers and higher order oligomers. They are found in high abundance within the 
neutrophil cytoplasm constituting up to 45% of the neutrophil cytoplasmic protein 268 but they 
can also be found associated with the plasma membrane on activation 269. They may be 
secreted into the extracellular space in an energy-dependent, microtubule mediated process, 
separate from the classical Golgi dependent secretion process 270. S100A8 and S100A9 
appear to have distinct functions in all 3 locations and function is also dictated by 
dimerisation and post-translational modification 271. The complex functions of these proteins 
have been difficult to untangle, not least because the mouse homologues do not always 
function in an analogous fashion 270 271. Therefore, extensive studies using mouse knock-out 
models have sometimes given results that are contradictory to human in vitro investigations. 
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5.4.1.1 Effects on the endothelial cell.  
Treatment of endothelial cell lines with the heterodimer of S100A8 and S100A9, calprotectin 
results in an increase in endothelial cell ICAM, VCAM and thrombospondin expression and 
an increase in the production of chemokines IL-8, MCP-1272. This phenotype is reflected in 
SSc, where there is evidence of increased serum levels of soluble ICAM and soluble VCAM, 
which correlate with increased endothelial expression of these molecules 16. There is also, in 
SSc serum, an increase in the serum levels of thrombospondin and serum levels of all 3 
markers of endothelial activation correlate with disease severity 16 19. MCP-1 and IL-8 levels 
are also increased in SSc serum and an increased expression of MCP-1 is found in 
histological samples from SSc skin and in explanted SSc endothelial cells grown in vitro 33 80 
82 105 108 110 273.  
Calprotectin can also result in functional changes at the endothelial surface resulting in a 
prothrombogenic phenotype with increased endothelial cell permeability and a decrease in 
monolayer integrity, all changes which are mirrored in SSc 272. Calprotectin may increase 
endothelial cell detachment and initiate caspase-dependent and -independent endothelial 
cell apoptosis, also features of the SSc endothelium 274. 
Extracellular calprotectin binds to heparan sulphate proteoglycans and carboxylated glycans 
on endothelial cells 275. Calprotectin also binds arachidonic acid and may act as carrier 
protein to translocate arachidonic acid to the endothelial cell. It is of interest to note that 
endothelial cells utilise endogenous and exogenous arachidonic acid for transcellular 
production of thromboxane, an eicosanoid which acts as a powerful vasoconstrictor 276. 
Thromboxane A2 is elevated in SSc and levels correlate with disease severity 
19. It is 
tempting to hypothesise that locally-generated thromoboxanes may be acting in a paracrine 
fashion to cause vasoconstriction resulting in Raynaud’s phenomenon which is a prominent 
symptom in SSc. 
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5.4.1.2 Effects on leukocytes. 
S100A8/9 (calprotectin) increases the activity of neutrophil NAPDH oxidase, increasing the 
production of ROS 277. This involves intracellular interaction with components of the oxidase 
and the binding of arachidonic acid is essential for oxidase assembly 278-280. Arachidonic acid 
has previously been established as a cofactor for NAPDH oxidase and it may be that 
calprotectin with its arachidonic-binding capability provides this by interacting with the 
NADPH oxidase complex. 
Murine S100A8 is chemotactic for neutrophils and monocytes, but the data for human 
S100A8 and 9 in neutrophil adhesion and chemotaxis is somewhat confused. In part, this 
may be due to the improper folding of recombinant forms of human S100A8 and A9 used in 
these experiments. Also, posttranslational oxidation and nitrosylation of S100A8 and A9 
have profound effects on their function and if not controlled could yield disparate results in in 
vitro systems.  S100A8, A9 and the heterocomplex have been shown to increase neutrophil 
adhesion to fibrinogen, by increasing the activity and expression of Mac-1 (CD11b/CD18) 281. 
Others, however, have shown that human S100A9 increased neutrophil adhesion but that 
this was inhibited in the presence of S100A8, presumably due to heterocomplex formation 
282. Others have confirmed that S100A9 and the heterodimer have a role in increasing 
neutrophil adhesion to fibronectin but failed to show any inhibitory effect of S100A8 283.  
Sroussi et al 284 found that S100A8 and A9 had no chemotactic activity for neutrophils; in fact 
they found the proteins to cause fugetaxis (repulsion of cells). This activity was abolished by 
various post-translational modifications of S100A8 and A9 284. Others however, have shown 
that S100A8, A9 and the heterodimer are chemotactic to neutrophils 281.  
S100A9 and the heterodimer, promote transendothelial migration of monocytes and 
monocytes expressing the heterodimer on their cell surface represent a cohort of monocytes 
which preferentially migrate across endothelial cell layers 285. 
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In summary, there is contradictory evidence for the role of S100 proteins in leukocyte 
recruitment, but studies have consistently shown that they can increase neutrophil adhesion 
via activation of Mac-1 and that they promote the transendothelial cell migration of 
monocytes. In addition, the effect of S100 proteins on endothelial cells is likely to further 
promote leukocyte recruitment as a result of an increase in the expression of ICAM and 
VCAM. A monocytic infiltrate in lesional skin is typically found in histologic samples from SSc 
patients. 
5.4.1.3 S100 proteins in the innate immune system and amplification of 
inflammation. 
S100A8 and A9 are specifically expressed in leukocytes of the innate immune system 
(neutrophils and monocytes) but not by lymphocytes. The innate immune system comprises 
the first line of defence in response to invading pathogens. Monocytes and neutrophils 
respond non-specifically to a range of invading pathogens through receptor systems that are 
ligated by pathogen associated molecular patterns (PAMPs) e.g. lipopolysaccharide (LPS). 
Engagement of these receptor systems e.g. Toll like receptors (TLRs) results in the release 
of cytokines which amplify the inflammatory response and recruit cells of the adaptive 
immune system 267.  
In addition to responding to invading pathogens, the innate immune system can respond to 
cell damage in a similar way. In this case, damage associated molecular patterns (DAMPs) 
are released and can engage with similar receptors to amplify the inflammatory response. In 
fact, TLR4 seems to respond to PAMPs and DAMPs. S100A8 and A9 appear to function as 
DAMPs and can ligate TLR4 and possibly RAGE expressed on monocytes 267. 
5.4.1.4 S100 proteins and autoimmunity. 
Elevated S100A8 and A9 serum levels are associated with several autoimmune disorders 
including rheumatoid arthritis, SLE and systemic onset juvenile idiopathic arthritis 267.  
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A recent study has shown that, Quinoline-3-carboxamides, which are in development for the 
treatment of autoimmune diseases e.g. MS, SLE and type I diabetes, may exert their actions 
by binding to S100A9 and preventing ligation of TLR4 and RAGE by S100A9 286.  
In a recent study in rheumatoid arthritis, elevated serum S100A8 and A9 concentrations 
were associated with the presence of anti-CCP and RhF 287. 
5.4.1.5 S100 proteins role in oxidative stress. 
S100A8 and A9 have interesting roles in oxidative stress, acting as scavengers for reactive 
oxygen and nitrogen species. It is thought that in this way, they may contribute to protecting 
phagocytes from intracellular ROS. However, as mentioned above, they can also interact 
with the intracellular portion of NADPH oxidase of phagocytes and increase ROS production. 
Extracellular S100A8 and A9 can act as ROS scavengers and therefore may decrease 
oxidative stress 271 288.  
S100A8 and A9 are susceptible to cysteine oxidation and s-nitrosylation. These post-
translational modifications can lead to completely different protein functions and can promote 
dimerisation, which in turn can alter the functionality. In fact, most known functions of S100 
proteins are mediated by homo- or hetero-dimers 271. There is evidence of increased 
oxidative stress in SSc; this may be as a result of inflammation or recurrent hypoxia-
reperfusion 3 11 198 289. Whatever the cause, oxidative stress may result in post-translational 
modification of S100A8 and A9 resulting in increased dimerisation and a specific functional 
repertoire.  
5.4.2 Specific granule proteins. 
Lysozyme C is found in the primary and secondary neutrophil granules. Other granule 
proteins are found expressed on the plasma membrane surface at increased concentrations 
after degranulation, reflecting the fusion of granule membrane with the plasma membrane 
Page 142 of 236 
 
(e.g. CD11b, CD63, cytochrome b245, lactoferrin, fMLP receptor). One hypothesis for the 
increased membrane expression of lysozyme C in SSc is that this may represent a similar 
insertion of granule protein into the membrane and may reflect degranulation. Further 
experiments would be required to confirm this. 
Neutrophil granules tend to discharge in a predefined order with increasing concentrations of 
activating or priming stimuli: secretory vesicles are mobilized first, followed by gelatinase-
containing granules, secondary granules and finally primary granules (Fig.47) 218. 
It is also interesting to note that different priming agents have differential effects on 
neutrophil degranulation. For instance TNFα, PAF and LPS all cause degranulation of 
secretory vesicles, secondary and gelatinase-containing granules, whereas GMCSF is 
capable of mobilising secretory vesicles only. Interleukin-8 results in degranulation of only 
secretory vesicles and secondary granules at priming doses 230. 
Fig.47. Neutrophil granules. Granules are mobilised hierarchically with increasing stimulant 
concentrations: secretory vesicles first, followed by gelatinase-containing granules, 
secondary granules, and finally primary granules. 
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Other markers of specific granule degranulation were identified in this study but were 
excluded from the analysis due to the unreliability of the data. Cytochrome b-245 light chain 
was increased in 3/4 patient samples but, it was excluded from analysis because variability 
compared to the internal control was greater than 63% (158%). In addition, the cytochrome 
b-245 heavy chain was not increased in SSc samples and the data was more reliable as the 
variation from internal control was only 15%. β-integrin and the fMLP receptor were both 
detected in the sample but only 1 peptide of each were detected and the information 
available was insufficient to allow meaningful quantification.  
5.4.3 Cytoskeletal proteins. 
L-plastin (LCP-1) is an actin-bundling protein that consists of two actin-binding domains and 
a head-piece that contains two calcium-binding EF hand motifs (Fig.48). 
 
Fig.48. Structure of L-plastin. ACT=actin-binding domains. HP=head-piece. Shaded areas in 
head-piece represent calcium binding EF hand motifs. 
L-plastin is calcium regulated and its actin cross linking functions are inhibited by rises in 
calcium in the physiological range. However, in addition to its actin-bundling activity, it is also 
involved in signal transduction. L-plastin is phosphorylated in response to stimulation with 
inflammatory cytokines, PMA, chemotactic peptides and immune complex ligation of FcγRII 
when bound to solid surfaces 254 290-293. 
An intact cytoskeleton is essential for many signal transduction pathways, likely providing a 
scaffold for signal transduction molecules, keeping them within the vicinity of receptors. 
Focal adhesions are aggregates of actin, actin-binding proteins and signal transduction 
molecules. In motile leukocytes, these foci are called podosomes 294.  
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L-plastin phosphorylation occurs at a serine residue (Ser5) in the head-piece. Cell permeant 
peptides derived from the head-piece and containing the phosphorylated serine are capable 
of inducing neutrophil adhesion through activation of αMβ2 integrins. This can be abrogated 
by blocking the actions of phosphoinositol 3-kinase and protein kinase C. However, if the 
peptide was exogenously phosphorylated at serine 5, the peptide induced adhesion and this 
action was not blocked by kinase inhibitors. This integrin activation however, is not 
accompanied by an increase in calcium mobilisation or ROS generation 233.  
Activation of integrins involves two distinct processes; first, there is an increase in integrin 
diffusion as a result of release from cytoskeletal constraints allowing integrin clusters to form; 
secondly, there is a conformational change within the integrin resulting in increased affinity 
for the ligand. L-plastin has been implicated in both these roles. The cell permeant L-plastin 
peptides described above were shown to mediate their effects on αvβ3 integrins through actin 
depolymerisation, presumably to increase integrin diffusion, and by co-operating with Arg-
Gly-Asp ligand to change the conformation of the integrin to a higher affinity form 234.  
This is interesting in the light of data presented in Chapter 4 which describes a decrease in 
F-actin content but an increase in focal adhesions in SSc neutrophils compared to controls. 
Although other activating stimuli are associated with an increase in F-actin, L-plastin-
dependent signalling results in a decrease in F-actin but an increase in focal adhesions as 
seen in SSc neutrophils. Taken together with the increase in L-plastin expression, this may 
imply that SSc neutrophils have been activated by a stimulus that acts through L-plastin and 
as a result is likely to increase integrin function and adhesion, though not necessarily 
through an increase in integrin expression. This reflects the SSc neutrophil phenotype which 
I have observed to be more “sticky” (see Chapter 3) and the effect of SSc serum on healthy 
neutrophils which induces cell-cell interactions and the formation of multi-cellular aggregates 
(see Chapter 7). 
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An upregulation of membrane L-plastin has not previously been described and therefore the 
functional implications are not fully known. However, it is speculated that phosphorylation of 
L-plastin may regulate its molecular location, specifically, localisation to podosomes on the 
cell membrane 291. 
Neutrophils of L-plastin knock-out mice have defective adhesion-dependent respiratory burst 
and hence a decreased capacity to kill S. aureus despite normal phagocytosis. This effect 
was due to markedly decreased integrin dependent syk activation. However, unlike β2 
integrin knockouts, L-plastin knockout murine neutrophils have normal adhesion to 
fibrinogen, fibronectin and vitronectin 295.  This result is, however, somewhat confusing since 
β2 integrins do not bind to fibronectin or vitronectin. A recent study showed that engagement 
of β2 integrins induce surface expression of β1 integrins, which do bind to extracellular matrix 
components, but this does not explain the findings outlined above 296. Knockout models may 
have their limitations since murine integrins may not faithfully represent the functions of 
human integrins and knock-outs may also disrupt epigenetic phenomena. The normal 
adhesion and spreading of L-plastin knockout neutrophils, does not rule out an important 
role for L-plastin in the regulation of integrin function, as many other interactions contribute 
to neutrophil adhesion. The neutrophils in this study were also stimulated with TNFα (1nM 
for 30min). 
Phosphorylation of L-plastin has also been implicated in activation of neutrophil NADPH-
oxidase but further studies are needed to confirm this 297.  
It is interesting to note that integrin-linked protein kinase is increased in 2/4 patients with 
SSc. This protein is found in the podosomes and is involved in integrin-dependent signalling. 
It is implicated in cytoskeletal reorganization and inside-out integrin signalling. It 
phosphorylates the cytoplasmic domain of the β-integrins and may be implicated in integrin 
ligand avidity. 
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5.4.4 Catalase expression. 
Catalase is an important anti-oxidant in neutrophils. It catalyses the decomposition of 
hydrogen peroxide into water and oxygen. It is predominantly found in the organelles of 
neutrophils. To my knowledge, there are no reports of plasma membrane expression of 
catalase.  
There are two important mechanisms in the neutrophil that protect them from oxidative 
damage. The first is catalase, the second is the cytosolic glutathione reductase system 
which reduces hydrogen peroxide by oxidising NADPH, itself regenerated by the hexose 
monophosphate shunt. Neutrophils express less glutathione and glutathione peroxidise than 
monocytes and macrophages but higher concentrations of catalase 298. Experiments on 
neutrophils from acatalasemic patients have revealed that the glutathione reductase system 
is sufficient to protect neutrophils from endogenous ROS, but insufficient to protect from 
exogenous oxidative stress 299. Catalase in neutrophils affords them protection against 
exogenous oxidative stress and the higher levels of catalase found in neutrophils compared 
to other inflammatory cells means that they are more resistant to extracellular oxidative 
damage 298. 
In other cell types such as liver and endothelial cells, oxidative stress can induce the 
expression of catalase 300 301, but it is not known whether this is also the case in neutrophils. 
This could explain the apparent upregulation found in this proteomic study. An alternative 
explanation is that catalase is translocated to the plasma membrane under conditions of 
exogenous oxidative stress, but this remains to be confirmed. Finally, although my 
experiments would imply an increase in the plasma membrane expression of catalase, the 
possibility cannot be excluded that there is contamination of the membrane sample. 
Catalase is primarily located in the cytoplasmic compartment and is co-localised with lactate 
dehydrogenase (LDH) 302. LDH was also found in the membrane fraction, indicating some 
contamination from the cytoplasmic fraction is possible and there was a tendency for this 
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contamination to be greater in the SSc neutrophils. All samples were treated in exactly the 
same manner so there is no reason to suspect that the increased contamination with 
catalase and LDH occurred for methodological reasons. It is more likely that these proteins 
have an increased association with the plasma membrane fraction in SSc neutrophils either 
due to a specific increase in plasma membrane expression or due the increased expression 
of other membrane proteins which lead to increased adhesion of LDH and catalase 
indirectly. Other cytoplasmic proteins are not differentially expressed between SSc and 
controls in the plasma membrane samples. 
The overall signature of the neutrophil phenotype in SSc cannot be confirmed from these 
data, predominantly due to the small number of samples examined. However, the data do 
point to some membrane proteins of potential interest for examination using other 
techniques (e.g. flow cytometry) which will allow examination of a larger number of patients. 
There is insufficient evidence from these proteomic studies to confirm or refute in vivo 
neutrophil priming in SSc. However, if further work can confirm that lysozyme C is a marker 
of degranulation and that lysozyme C is increased on the plasma membrane of SSc 
neutrophils, this will provide tantalising evidence of neutrophil priming in SSc. Priming is not 
an all or nothing response but rather a continuous spectrum of responses depending on the 
concentration of the priming agent. In addition, different priming agents have different effects 
on neutrophil phenotype. These factors, coupled with the heterogeneity of SSc, may go 
some way to explain the high degree of variation seen in SSc neutrophil protein expression.  
Despite the obvious limitations of this approach, it does have some great strengths. It allows 
for an unbiased examination of the changes in membrane protein expression, and it has 
revealed important but unexpected changes, such as the down-regulation of membrane 
calgranulins and the up-regulation of L-plastin and catalase. These changes may give 
important clues to the factors in SSc which give rise to the change in neutrophil phenotype. 
For instance, the increase in catalase expression, if confirmed, could imply activation by 
Page 148 of 236 
 
exogenous oxidative stress which is well established in SSc. The increase in membrane L-
plastin may reflect translocation to the membrane following phosphorylation. L-plastin is 
phosphorylated in response to interleukin-8, which also acts as a neutrophil priming agent 
resulting not only in specific granule degranulation but in the priming of ROS generation not 
only in response to fMLP but also to PMA which may tie in the functional changes seen in 
chapter 3. Interleukin-8 is raised in the serum and in lesional skin of patients with SSc and is 
associated with early disease 34 79 224. 
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Chapter 6: Neutrophil elastase. 
6.1Introduction. 
Neutrophil elastase is a serine protease that is stored in the azurophilic granules of 
neutrophils. It predominantly functions as an intracellular anti-microbial protein and is 
released into the phagolysosome following phagocytosis to mediate bacterial digestion. 
However, in addition it is secreted by the cell. Azurophilic granules are the most resistant to 
exocytosis and therefore release of elastase into the extracellular environment is usually 
limited 303. Secretion of elastase is thought only to be significant in frustrated phagocytosis or 
when excess neutrophil apoptosis overwhelms the phagocytic capacity to remove 
neutrophils, leading to secondary necrosis and the release of intracellular proteins 304 305. In 
the extracellular environment it has anti-microbial activities and can break down extracellular 
matrix.  
It is apparent however, that neutrophil elastase has additional functions in the regulation of 
inflammation and it is implicated in inflammatory and fibrotic conditions, including fibrotic 
lung disease 306 307. Elevations in serum elastase have previously been reported in patients 
with SSc and were associated with lung disease 222.  
Serum elastase activity is regulated by serine protease inhibitors. The main intracellular 
inhibitor of elastase is SERPINB1, while the main extracellular inhibitor of neutrophil elastase 
is α1-protease inhibitor (α1PI) and additional inhibition is mediated by α2-macroglobulin, elafin 
and secreted leukocyte proteinase inhibitor (SLPI) 308.  
Neutrophil elastase can also be expressed on the neutrophil membrane, where it occupies 
low and high affinity binding sites. Membrane expression is increased by neutrophil 
activation with cytokines such as TNFα and IL-8 303. The increase in membrane expression 
is more significant than the amount secreted extracellularly during typical activation. Plasma 
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membrane bound elastase has the same catalytic functions as soluble elastase but there is 
some evidence that the membrane bound enzyme is relatively resistant to α1PI 
309 310. 
Previous work in my thesis has implied neutrophil activation in SSc. Since, neutrophil 
elastase has established roles in other inflammatory and fibrotic disorders I hypothesised 
that neutrophil elastase could be an important mediator in the pathogenesis of SSc. 
To explore this hypothesis, I measured the concentration and catalytic activity of neutrophil 
elastase in SSc serum compared to controls. I also examined the levels of membrane 
expression of elastase in SSc neutrophils compared to controls and studied clinical 
correlates. 
6.2 Methods. 
6.2.1 Neutrophil elastase concentration. 
Neutrophil elastase concentrations were assessed in SSc and control whole cell lysates by 
western blotting, as outlined in Chapter 2.  
6.2.2 Serum elastase concentrations. 
Neutrophil elastase levels were measured in SSc patient and control serum using a PMN 
elastase ELISA (Bender, Vienna) according to the manufacturer’s instructions. 
6.2.3 Neutrophil elastase concentrations in neutrophil culture supernatants. 
Neutrophils were isolated from SSc and healthy control blood as previously described, and 
were cultured for 6h with gentle agitation at 37˚C at a density of 107cells/ml in RPMI 1640 
+25mM HEPES +2mM glutamine. Cells were precipitated by centrifugation (1000xg for 
5min) and the neutrophil elastase concentration in the supernatants was measured by 
ELISA (Bender, Vienna). 
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6.2.4 Serum neutrophil elastase enzymatic activity. 
Following experiments to optimise substrate concentration and length of incubation, serum 
elastase activity was measured using a colorimetric assay. In 96 well clear plastic plates, 
150µl of elastase buffer (0.1M HEPES, 0.5M NaCl, pH7.5) was added to 50µl serum 
samples from patients with SSc and healthy controls. The substrate (15mM methoxy-
succinyl- alanyl-alanyl-prolyl-valyl-p-nitroanilide) was added to a final concentration 750µM. 
The reaction was incubated in the dark at 37˚C for 6h. The elastase dependent conversion 
of colourless methoxy-succinyl- alanyl-alanyl-prolyl-valyl-p-nitroanilide to yellow p-nitroanilide 
was measured as a change of absorbance at 405nm on a plate reader. Standards of known 
concentration were used to generate a calibration curve (data not shown). 
6.2.5 Clinical data. 
Clinical data was collected on all patients as a part of routine clinical care and included: 
Rodnan skin score; neutrophil count; autoantibody profile; medications; major organ 
involvement and disease duration (defined as time since onset of first non-Raynaud’s 
symptom). 
6.2.6 Serum SERPINB1 levels. 
As no ELISA kits were available, serum SERPINB1 concentrations were estimated by 
western blotting as detailed earlier. Serum samples were depleted of the albumin and IgG 
using an Albumin/IgG dye based depletion kit (Pierce, Rockford, USA) in order to minimise 
distortion of the western blot. 
6.2.7 Neutrophil membrane elastase expression. 
Neutrophil membrane elastase expression was measured by flow cytometry. Neutrophils 
were isolated from SSc and healthy control blood as previously described. Cells were 
resuspended in RPMI 1640 +25mM HEPES +2mM glutamine at 5x106/ml. 100µl of cells 
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were placed in a flow cytometry tube and excess PBS EDTA was added. Cells were then 
centrifuged at 1000xg for 3min and resuspended in 200µl of PBS 2%BSA, and incubated for 
30min in the dark at 4˚C with 2µl elastase monoclonal antibody raised in rabbit 
(Calbiochem), following experiments to find the optimal antibody dilution (data not shown). 
The cells were washed 3x in PBS and resuspended in PBS 2%BSA and 2µl FITC-
conjugated anti-rabbit IgG secondary antibody. Cells were incubated for 30min at 4˚C in the 
dark. Cells were washed 3x in PBS, resuspended in PBS and analysed on the flow 
cytometer on the FITC channel. Mean fluorescence readings were corrected for secondary 
antibody controls. 
6.2.8 Statistical methods. 
The data was non-normally distributed and so means were compared using the Mann-
Whitney U test. The strength and significance of bivariate correlations were made using 
Spearman’s Rho. 
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6.3 Results. 
6.3.1 Clinical characteristics. 
 Median (IQR) 
Disease duration/mths 40 (21-96) 
Neutrophil count x109/l 4 (2.4-4.8) 
Rodnan skin score 6 (3-10) 
 Number (%) 
Limited SSc 29/33 (88) 
Diffuse SSc 4/33 (12) 
ANA 26/31 (84) 
Anticentromere 13/31 (42) 
Anti RNP 9/31 (29) 
Anti Scl70 9/31 (29) 
Lung involvement 10/33 (30) 
PAH 5/33 (15) 
DMARDs 14/33 (42) 
       HCQ 3/33 (9) 
       MMF 4/33 (12) 
       MTX 1/33 (3) 
       CYC 1/33 (3) 
       Pred 3/33 (9) 
       Aza 1/33 (3) 
Bosentan 1/33 (3) 
Sildenafil 3/33 (9) 
Table 12. Patient characteristics. HCQ=hydroxychloroquine, MMF= Mycophenolate mofetil, 
MTX= methotrexate, CYC= cyclophosphamide, Pred= prednisolone, Aza= azathioprine. 
 
6.3.2 Neutrophil elastase is not increased in SSc neutrophils compared to 
controls. 
Neutrophil elastase expression was unchanged in SSc neutrophils compared to controls in 
neutrophil whole cell lysates, by western blotting (Fig.49). 
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6.3.3 Serum neutrophil elastase levels were equivalent in patients with SSc 
compared to controls. 
There was no significant difference between SSc patient and control serum levels of 
neutrophil elastase (p=0.11) (Fig.50). 
Fig.49. Neutrophil elastase expression is equivalent in SSc neutrophils compared to 
controls by western blotting corrected for tubulin expression. The graph indicates the 
mean ±SD. 
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6.3.4 Neutrophil elastase concentrations in control and SSc neutrophil culture 
supernatants are equivalent. 
There was no difference in the levels of neutrophil elastase in supernatants following 6h 
culture of control and SSc neutrophils in RPMI1640 +25mM HEPES +2mM glutamine 
(p=0.53) (Fig.51). 
 
 
 
Fig.50. No differences were found 
in serum elastase concentrations 
between SSc patients and 
controls. Serum neutrophil 
elastase concentrations were 
measured by ELISA. Graph 
indicates median and IQR 
(p=0.11).  
Fig. 51. No differences were found in 
the levels of neutrophil elastase 
secreted by control and SSc 
neutrophils in 6h. Neutrophils isolated 
from SSc patients and healthy 
controls were cultured for 6h and 
elastase concentrations in the culture 
supernatant were measured by 
ELISA. Graph indicates median and 
IQR (p=0.53). 
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6.3.5 Serum neutrophil elastase activity is equivalent in SSc patients and 
controls. 
The serum neutrophil elastase activity was measured in SSc patients and controls by the 
elastase dependent conversion of methoxy-succinyl-alanyl-alanyl-prolyl-valyl-p-nitroanilide to 
p-nitroanilide. No difference in serum elastase activity was found between SSc patients and 
controls (p=0.91) (Fig. 52). However, there was a proportion of patients 6/18 (33%) which 
had high serum elastase activity (>0.15U/ml) compared to 1/9 (11%) controls. These 
patients had either early disease <36mths or a higher Rodnan skin score >9. 
 
 
 
6.3.6 Serum neutrophil elastase concentration correlates with serum 
neutrophil elastase activity: this relationship is stronger in controls than in 
SSc. 
As expected the serum neutrophil elastase concentrations correlated closely with the serum 
neutrophil elastase activity (Spearman’s Rho= 0.62, p=0.0006). However, in SSc patients 
Fig. 52. There was no difference in serum elastase activity in SSc patients compared to 
controls. Elastase activity was measured by the conversion of methoxy-succinyl- alanyl-
alanyl-prolyl-valyl-p-nitroanilide to p-nitroanilide. Graph indicates median and IQR (p=0.91). 
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the relationship was weaker (Spearman’s Rho =0.67, p=0.003) compared to controls 
(Spearman’s Rho= 0.85, p=0.006) despite the larger number of patients (Fig. 53). This 
indicates a significant difference between the ratio of serum elastase concentration: activity 
(p=0.03) (Fig. 54). There were no distinguishing clinical features in the patients with a low 
serum elastase concentration: activity ratio (<50000). 
 
 
 
Fig.53. The correlation between serum elastase concentration and serum elastase 
activity is stronger in (B) controls (Rho=0.85 p=0.006) compared to (A) SSc 
patients (Rho=0.67, p=0.003). 
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6.3.7 Serum SERPIN B1 levels are not different between SSc and control 
serum. 
Serum SERPIN B1 levels are not significantly different between SSc patients and controls; 
neither is the 66kDa complex of SERPINB1 with elastase or the 29kDa fragment of 
SERPINB1 caused by elastase dependent cleavage (Fig.55-57). 
Fig.54. There is a lower ratio of serum elastase concentration to serum elastase activity 
in SSc patients compared to controls. This may indicate a decrease in elastase 
inhibitors in SSc serum compared to controls (p=0.03). 
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Fig.55. Serum SERPIN B1 levels are not different in SSc patients compared to 
controls. Measured by western blot on albumin/IgG depleted serum samples. 
Fig.56. Serum SERPIN B1 levels, the 66kDa complex of SERPIN B1 and the 29kDa 
fragment caused by elastase dependent cleavage of SERPIN B1 are not significantly 
different between SSc patients and controls as measured by western blot of albumin/IgG 
depleted serum samples. Graphs show mean±SD. N=6. 
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6.3.8 Clinical correlations with serum neutrophil elastase concentration and 
activity. 
Disease subtype, disease duration, major organ involvement, neutrophil count or DMARD 
use did not correlate with either serum neutrophil elastase concentration or activity. Serum 
elastase concentration was significantly lower in RNP and ANA positive patients compared 
to antibody negative patients (p=0.03 and p=0.003 respectively) (Fig. 58-59). In addition, 
serum elastase activity was significantly lower in RNP antibody positive patients (p=0.02) 
(Fig. 60). 
Fig.57. Total serum SERPINB1 concentration is not different between SSc patients 
and controls, as measured as the total lane density on western blot of albumin/IgG 
depleted serum. Graphs show mean±SD. N=6. 
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Fig.58. Serum elastase concentrations are lower in RNP positive patients compared 
to RNP negative patients. Serum elastase concentrations were measured by ELISA. 
Graphs indicate median and IQR (p=0.03). 
Fig.59. Serum elastase concentrations are lower in ANA positive patients compared to 
ANA negative patients. Serum elastase concentrations were measured by ELISA. 
Graphs indicate median and IQR (p=0.003). 
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6.3.9 Neutrophil count correlates with Rodnan skin score. 
Peripheral blood neutrophil count correlated with Rodnan skin score in SSc patients 
(Spearman’s Rho=0.39, p=0.04) (Fig.61). The 3 outliers with low Rodnan skin score and a 
relatively high neutrophil count were either antibody negative (1/3) or RNP positive (2/3), No 
other clinical correlations were however noted. 
Fig.60. Serum elastase activity was lower in RNP positive patients compared to RNP 
negative patients. Serum neutrophil elastase activity was measured in SSc patients and 
controls by the elastase dependent conversion of methoxy-succinyl-alanyl-alanyl-prolyl-
valyl-p-nitroanilide to p-nitroanilide. Graphs indicate median and IQR (p=0.02). 
 
Page 163 of 236 
 
 
6.3.10 Membrane expression of neutrophil elastase. 
No difference was found in the membrane expression of neutrophil elastase between SSc 
and control neutrophils (Fig. 62). 
 
 
 
 
Fig.61. Peripheral neutrophil 
count correlates with Rodnan skin 
score in SSc patients. Rho=0.39, 
p=0.04. 
Fig. 62. Membrane expression of 
neutrophil elastase was not 
different between controls and 
SSc neutrophils. Membrane 
expression of neutrophil elastase 
was measured by flow cytometry. 
Mean±SD shown. n=9 (p=0.63). 
Page 164 of 236 
 
6.4 Discussion. 
In this study I indentified no difference in serum elastase concentration or catalytic activity in 
SSc patients compared to controls. This contradicts a previous study by Hara et al which 
observed an increase in serum elastase concentration in both limited and diffuse SSc 
patients 222. However, an examination of their data reveals that the serum elastase levels 
measured in my study were similar in magnitude and variation to their observations in SSc 
patients. In my study however, I found some higher concentrations and greater variance in 
concentration in the control cohort whereas the previous study showed consistently low 
levels in all controls. The previous study did not examine elastase activity. 
Hara et al also reported that serum elastase levels were more likely to be outside the normal 
range in patients with joint involvement, and they observed that most patients who were anti-
centromere antibody positive were likely to have normal levels of elastase 222. I did not 
record joint involvement as a clinical outcome in my cohort. It is interesting to note, however, 
that I observed lower serum elastase levels in RNP positive patients, since these patients 
would be expected to have higher rates of joint involvement. Hara et al, did not record RNP 
antibody status in their study. 
It may seem somewhat surprising that Hara et al described such an increase in serum 
elastase levels since only 2% of serum elastase is released during neutrophil activation and 
raised serum levels are usually only found in situations where there is pronounced neutrophil 
infiltration, frustrated phagocytosis or excess neutrophil apoptosis which overwhelms 
phagocytic clearance 303-305. As none of these are implicated in SSc, I would not expect to 
find elevated serum levels, an expectation confirmed in my studies. Certainly, direct 
observations do not show significant neutrophilic infiltration and there is no evidence of 
excessive neutrophil apoptosis. Therefore, the most likely explanation for increased 
secretion would be frustrated phagocytosis and a search for a potential stimulus should be 
undertaken. An alternative explanation for the data reported by Hara et al could be that 
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serum elastase is protected from degradation in SSc patients leading to increased serum 
levels.  
I did not find any change in the neutrophil elastase concentration in SSc neutrophils. Since 
elastase is only transcribed at the promyelocytic stage of neutrophil development, I would 
not have expected to find an increase in cellular content of neutrophil elastase 311. The fact 
that neutrophil elastase concentrations were not decreased in SSc neutrophils could be used 
to argue against in vivo secretion, but western blot analysis is relatively insensitive to small 
changes in large concentrations.  
I did not observe any increase in the membrane expression of elastase on SSc neutrophils. 
Secretion of azurophilic granule contents during degranulation or activation by cytokines 
results in the increased expression of neutrophil elastase at the membrane. Therefore, this 
observation once again argues against significant degranulation of the azurophilic granules 
in SSc neutrophils 303.  
I did observe an increase in the ratio of elastase activity: concentration in SSc serum. This 
may imply a decrease in the serum concentration or activity of neutrophil elastase inhibitors. 
SERPIN B1 was not decreased in the serum of patients with SSc, but this does not 
constitute the main capacity for elastase inhibition in the serum. In future experiments I 
would wish to explore the serum concentrations of α1-PI and α2-macroglobulin in SSc 
patients to see if these were decreased. I would measure these by ELISA. In addition 
however, it is important to note that serum elastase inhibitors can be oxidised in the 
presence of ROS and this decreases their affinity for elastase, reducing their inhibitory 
capacity 312 313. There is evidence for increased oxidative stress in SSc and therefore a 
normal concentration of elastase inhibitors does not necessarily equate to normal activity 11. 
Additional studies should therefore be performed to explore the elastase inhibitory capacity 
of SSc serum. 
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Although there was no increase overall in serum elastase activity in patients with SSc the 
apparent decrease in inhibitory capacity could have important consequences at a local level 
since elastase is likely to be released locally at the site of inflammation, but, α1-PI the 
predominant inhibitor, is produced by the liver 308. 
Neutrophil elastase has pleiotropic roles in the extracellular environment including profound 
effects on inflammation 306 307, such as it: 
1) Activates and degrades inflammatory cytokines 314 
2) Binds to the neutrophil integrin Mac-1=CD11b/CD18 thereby regulating neutrophil 
attachment and detachment 315 
3) Activates protein activated receptor 2 (PAR-2) leading to the release of IL-8 and 
MCP-1, though at higher concentrations in can inactivate the PAR-2 by a proteolytic 
mechanism 316 317.  
4) Activates TLR-4 leading to the release of IL-8, cathepsin B and MMP-2 318 319.  
5) Cleave the TNF p75 receptor and the IL-6R from cells leading to an increased pool of 
soluble receptor 320 321. This leads to inactivation of soluble TNFα but enhances IL-6 
trans signalling. 
6) Cleaves the phosphatidylserine receptor leading to defects in the phagocytic 
clearance of apoptotic cells 322.  
7) Enters endothelial cells and cleaves NF-κB leading to endothelial cell apoptosis 323. 
In co-cultures of control neutrophils with HDMECs and SSc serum, increased levels of 
endothelial cell activation and apoptosis were seen compared to control serum. The serine 
protease inhibitor AEBSF abrogated the effect on apoptosis but not on endothelial cell 
activation (Chapter 7). This implies that serine proteases contribute significantly to the ability 
of SSc serum to induce apoptosis in this context. Experiments using specific neutrophil 
elastase inhibitors could define whether neutrophil elastase is the serine protease 
responsible for this effect. 
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Whilst the role of neutrophil elastase in fibrosis is well established, the mechanism remains 
unclear. Certainly, elastase deficient mice are resistant to bleomycin induced fibrosis and 
treatment with elastase inhibitors also abolished fibrosis in this model 324-327.  
Neutrophil elastase can cleave TGFβ binding protein leading to release of latent TGFβ from 
extracellular matrix stores 328. It has also been shown to release PDGF and VEGF from 
stores by a similar mechanism 329. All of these cytokines are implicated in the pathogenesis 
of SSc; TGFβ and PDGF are profibrotic and VEGF is proangiogenic. Neutrophil elastase has 
other roles in promoting the activity of TGFβ. Intra-tracheal instillation of elastase in mice 
leads to a time-dependent increase in the TGFβ content of the bronchoalveolar lavage fluid 
330. In elastase deficient mice, the resistance to bleomycin is associated with an inability to 
activate TGFβ 324.  
It is interesting that serum elastase concentrations and activity are lower in RNP positive 
patients. This may imply that there is a different pathological process involved in RNP 
positive patients and that neutrophil elastase is unlikely to be a significant mediator in these 
patients. In fact, serum elastase concentrations were lower in RNP positive patients than 
controls (p=0.008). This may represent an accelerated loss of neutrophil elastase in RNP 
positive patients.  
Peripheral neutrophil cell count strongly correlated with Rodnan skin score, a measure of the 
extent of skin fibrosis in SSc. The reason for this is unclear, but it is possible that patients 
with the higher skin score tend to have higher levels of inflammation and therefore develop a 
relative neutrophilia. Conversely, if neutrophil elastase or another neutrophil derived 
mediator was instrumental in the development of fibrosis the higher neutrophil counts may 
lead to an increase in the levels of these mediators. Some patients had a neutropenia, and 
this may have protected them from neutrophil mediators that can promote fibrosis, including 
neutrophil elastase.  
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Patients whose neutrophil count did not correlate so well with the Rodnan skin score (low 
skin score despite high neutrophils) were frequently RNP positive but had no other 
distinguishing disease manifestations. In particular, they were not on steroids, and did not 
uniformly have a short disease duration. Of the 3 neutropenic patients (neutrophil count <2), 
all were on disease modifying therapies: 1 on oral prednisolone, 1 on hydroxychloroquine 
and 1 on methotrexate. 2 of these patients were RNP antibody positive. All 3 had a low skin 
score (≤5). 
Data on neutrophil count was only obtained at one single time point. It would be interesting 
to follow the neutrophil count longitudinally in SSc patients and see whether some patients 
had a consistently higher neutrophil count and whether this predisposed to the development 
of greater fibrosis. 
Analysis of the literature shows that neutrophil elastase could be an attractive mediator in 
SSc. It can promote chronic inflammation, cause endothelial cell apoptosis and it can 
promote TGFβ dependent fibrosis. Serum deficiency in elastase inhibitors, if confirmed, 
could lead to a localised excess of elastase activity despite normal serum concentrations. 
This could have potential therapeutic implications as neutrophil elastase inhibitors already 
exist in clinical practice and could be used in SSc patients if a systemic deficiency is 
confirmed. 
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Chapter 7. Neutrophil: endothelial cell co-cultures. 
7.1 Introduction. 
Previous studies have demonstrated an abnormal neutrophil phenotype in patients with SSc. 
There is a tendency for neutrophils from SSc patients to be hypoactive ex vivo in terms of 
ROS generation. It is postulated that this may indicate in vivo neutrophil activation prior to 
isolation and hence “exhaustion”. It is, however, difficult to directly test this hypothesis, partly 
because isolating neutrophils from blood removes the cells from the soluble mediators and 
cellular interactions which may have stimulated them in vivo. In addition, neutrophils in vivo 
are often exposed to hypoxia, acidosis and intermittent episodes of ischaemia, in addition to 
shear forces as they are under flow. These conditions are difficult to reproduce ex vivo. 
Further, the factors causing the postulated in vivo activation are unknown. 
Endothelial cells have been proposed to be the primary lesional target in this disease 5 331 332. 
Evidence for endothelial cell activation in SSc has often been observed, and there is some 
evidence to suggest that this may represent the earliest lesion that leads to secondary 
fibrosis and immune cell infiltration 6 7 15 19 24 333. It is postulated that, as a result of chronic 
inflammation and endothelial cell activation, there is fibroblast stimulation resulting in 
fibrosis, the phenotypic hallmark of this disease. 
It is essential therefore, when examining the phenotype and functionality of any cell type in 
SSc to make an attempt to simulate the in vivo conditions that may exist. One method that 
permits such modeling is live cell confocal microscopy which allows the simultaneous 
measurement of many cellular parameters in a co-culture system and can, in addition, be 
used to study cellular interactions. It also allows cells to remain intact and functional during 
assessment thereby providing dynamic measurements in real-time. 
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In this Chapter, I have used non-invasive live cell imaging to study the dynamic interactions 
between neutrophils and endothelial cells that may occur in SSc. The data presented 
highlight the usefulness of this experimental approach and uncover a novel role for IL-6 in 
promoting changes in cell phenotype that resemble those that occur in SSc. 
7.2 Methods. 
7.2.1 Human dermal microvascular endothelial cell (HDMEC) culture.  
HDMECs were used as the source of endothelial cells in culture as they are most 
representative of the lesional endothelial cells in SSc, being microvascular and dermal in 
origin. There is extensive evidence in the literature to support the argument that other 
endothelial cell cultures, especially HUVECs (human umbilical vein endothelial cells), are not 
phenotypically representative of all endothelial cells 334-336.  
HDMECs were cultured in 48 well plates seeded at 10,000 cells per well if cultured for 48h or 
20,000 cells per well if cultured for 24h. Cultures were used at passage 4-8, and once they 
had reached 90% confluence. The cell phenotype was guaranteed by Promocell up to 
passage 14. Cells were cultured in Promocell’s microvascular endothelial cell medium. 
7.2.2 Neutrophil isolation. 
Neutrophils were isolated from patients or healthy controls as described in Chapter 2 and 
were centrifuged at 1000xg for 3 min to pellet the cells. Neutrophils were resuspended in 
microvascular endothelial cell medium supplemented with 2mM glutamine at a concentration 
of 1x106 cells/ml or at 2x106 cells/ml when cultured with IL-6 immunodepleted serum. 
7.2.3 Neutrophil: endothelial cell co-cultures. 
The culture medium was aspirated at time 0 and 450µl of neutrophil suspension and 150µl of 
serum (or media in negative controls) were added to each well. 1.5µl of Annexin V FITC (to 
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detect apoptosis) was added to each well following initial experiments to optimise the 
concentration. In addition, monoclonal antibodies to ICAM-1 (conjugated to PE) or E-selectin 
(conjugated to APC) were added at time 0 to detect endothelial cell activation. Antibodies 
were diluted 1:10 and then 2.5µl of each was added to each well, again following 
optimisation experiments. 
In initial experiments, images were taken continuously over a 6h time period, however after 
this time excessive evaporation of media led to decreased cell viability. Therefore co-
cultures were incubated in a standard CO2 incubator for 24h and a single confocal image 
was taken at the end of the culture period. 
Confocal images were taken using a LSM-710 (Zeiss) confocal microscope using the Zen 
2009 software. Annexin V FITC and PE were excited using the 488nm laser whereas APC 
was excited using the 633nm laser. Images were taken using the optimum separation of 
emission spectra mode. Duplicate images were taken for each experimental variable. For 
each experiment a z-stack of 13 images was obtained over a distance of 9.91µm, focusing 
from the endothelial cells to the neutrophils using the 10x Ph2 objective.  
Images were analysed using the Image J software (NIH, USA). Total fluorescence values 
presented in the figures are those of the slice with the maximal fluorescence intensity 
corrected for the fluorescence intensity of cells cultured in media alone. Statistical analysis 
was performed using the paired T test. 
Initial experiments were performed comparing the effects of control and SSc neutrophils, and 
control and SSc serum on both neutrophil apoptosis and endothelial cell apoptosis and 
activation in co-cultures. Control experiments were conducted without neutrophils or without 
serum.  
Further experiments were conducted to explore the role of monocytes and lymphocytes 
under identical experimental conditions. Monocytes and lymphocytes were separated from 
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the PBMC layer (removed during neutrophil preparation using polymorph prep) using CD15 
positive selection Easysep beads and CD3 positive selection Dynabeads respectively, 
according to the manufacturers protocol. 
7.2.4 Labeling of neutrophils and endothelial cells for 24h time lapse imaging.  
Endothelial cells were seeded onto 3cm glass-bottomed culture dishes (iWAKI) and cultured 
until 90% confluence. Endothelial cells were incubated with calcein-AM (2.5µM) for 1h. 
Freshly isolated neutrophils were incubated with 100nM mitotracker red for 15min. 
Neutrophils were washed in PBS then resuspended in microvascular endothelial cell 
medium supplemented with 2mM glutamine, at 5 x 105 cells/ml. The endothelial cells were 
washed in PBS and medium was replaced with 1.5ml of the neutrophil suspension described 
above and 500µl of either control or SSc serum. 24h time-lapse movies were taken using a 
Pascal confocal microscope (Zeiss). FITC and Mitotracker Red were excited using the 
488nm and 543nm lasers respectively. Images were taken continuously from 6 separate 
fields over a period of 24h, and processed using the LSM510 software. 
7.2.5 Luminex cytokine assay. 
The Luminex multiplex assay allows simultaneous detection of up to 100 different analytes in 
a single sample e.g. plasma, serum, culture supernatant. Cytokine assay kits are available 
which can measure the concentration of up to 35 different cytokines. The assay is an 
immunoassay; antibodies for each cytokine are attached to different beads with unique 
fluorescent properties when excited by a 635nm laser. Cytokines bound to the bead-
mounted antibodies are detected using a streptavidin-PE labeled secondary antibody. The 
amount of PE fluorescence is then measured when excited by a 532nm laser. The assay 
has a high sensitivity (10pg/ml of cytokine). 
A 13-plex luminex cytokine profiling assay was used to explore the cytokine profile of co-
culture supernatants and control and SSc serum in order to investigate what might be 
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responsible for the increased endothelial cell activation in initial co-culture experiments. The 
cytokines measured were: TNF-α, GCSF, interferon-γ, GMCSF, IL-1β, IL-2, IL-4, IL-5, IL-6, 
IL-8, IL-10, IL-17, IL-1Ra. 
7.2.6 Exploration of potential mediators of endothelial cell activation in 
neutrophil: endothelial cell co-cultures. 
In further neutrophil: endothelial cell co-cultures, healthy control or SSc serum was 
substituted for heat-inactivated pooled human AB serum filtered through a 0.45µm filter and 
spiked with 200pg/ml of rIL-6 (Sigma), which was a similar concentration to the levels found 
in 2 of the patient sera samples tested above. 
In addition, healthy control and patient sera were complement-inactivated by heating to 56˚C 
for 30mins with intermittent vortexing. A polyclonal IL-6 antibody (Abcam) was added to the 
co-cultures in quantities sufficient to neutralise any IL-6 in the culture (1:400). A serine 
protease inhibitor, AEBSF (0.2mM), was added to the co-cultures, higher concentrations 
were toxic to neutrophils. Catalase (2000U/ml) was added to co-cultures in order to remove 
ROS. Healthy and control sera were immunodepleted of IL-6 using a direct immunodepletion 
kit (Pierce) using a polyclonal IL-6 antibody (Abcam) (see below). As sera required 2:1 
dilution prior to immunodepletion, 225µl of neutrophil suspension (2x106 per ml) was used, 
plus 75µl of media and 300µl of diluted, immunodepleted serum. 
7.2.7 IL-6 immunodepletion. 
A polyclonal mouse IL-6 antibody (1 µl) was conjugated to the direct immunodepletion beads 
(Pierce) according to the manufacturer’s protocol. This amount was chosen following 
optimization experiments using AB serum spiked with 200pg/ml rIL-6, which was 
subsequently subjected to immunodepletion. The depleted serum was retained. In addition 
as a control a portion of the sample was also submitted to a dummy procedure using resin 
which was not conjugated to IL-6 antibody. IL-6 concentrations in all samples were then 
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quantified by western blotting. The immunoprecipitation procedure resulted in a 60% 
reduction in IL-6 whereas the unconjugated resin led to a non-specific reduction of 15% (Fig. 
63). 
 
 
 
7.2.8 ELISA of sICAM-1 and sIL-6R in serum and culture supernatants. 
Serum samples from controls and SSc patients and 24h culture supernatants from co-
cultures incubated in the presence of 25% control or SSc serum were measured for their 
sICAM (Bender) and sIL6R (Invitrogen) content by ELISA according to manufacturer’s 
instructions. In addition, single cell cultures of neutrophils (107/ml) were incubated with 
control and SSc serum for 24h and sIL-6R concentrations were measured in the 
supernatants by ELISA. 
7.2.9 Statistics 
Apoptosis data from co-cultures was not normally distributed and so comparisons between 
samples were made using non-parametric tests (Wilcoxon signed rank test) E-selectin and 
ICAM expression data were however normally distributed and therefore comparisons 
between means were made using the paired T-test. 
Fig. 63. IL-6 immunoprecipitation results in a 60% reduction in IL-6 concentration. 
AB serum was spiked with 200pg/ml rIL-6. The sample was submitted to 
immunopreciptation against unconjugated resin (resin) and resin conjugated to a 
polyclonal IL-6 antibody (IP). 
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7.3 Results. 
7.3.1 Patient characteristics. 
Patient characteristics are summarized in table 13. 
Male: Female 1:16 
Median disease duration/mths (IQR) 37 (25.5,58) 
Median Raynaud’s duration/yrs (IQR) 6.5 (4, 10.5) 
Median Rodnan skin score (IQR) 6 (4,11) 
Clinical feature Number (%) 
Limited subtype 13/17 (76) 
Diffuse subtype 4/17 (24) 
Lung involvement 6/17 (35) 
Pulmonary artery hypertension 1/17(6) 
Renal involvement 0/17 (0) 
ANA positive 12/17 (71) 
Anticentromere positive 6/17 (35) 
Anti Scl70 positive 5/17 (29) 
Anti RNP positive 3/17 (18) 
DMARDs 6/17 (35) 
       Mycophenolate mofetil 5/17 (29) 
       Sildenafil 2/17 (12) 
       Methotrexate 1/17 (6) 
Table 13. Patient characteristics. 
7.3.2 Effects of SSc neutrophils on endothelial cell activation and apoptosis in 
co-cultures. 
Freshly isolated SSc neutrophils, when incubated with HDMECs in the absence of serum for 
24h did not induce any change in the levels of endothelial cell activation (ICAM-1 
expression) or apoptosis (Fig.64).  
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7.3.3 Effects of SSc serum on endothelial cell activation and apoptosis.  
SSc serum (in the absence of neutrophils) increased endothelial cell activation (ICAM-1 
expression) but not apoptosis after 24h. Serum from patients with newly-diagnosed, 
untreated rheumatoid arthritis did not increase either endothelial cell activation or apoptosis 
(Fig.65). The increase in ICAM-1 expression was lower in magnitude than the changes seen 
in neutrophil: endothelial cell co-cultures (Fig.66) and was not mirrored by an increase in E-
selectin expression (Fig.72A). 
Fig.64. SSc neutrophils did not increase endothelial cell apoptosis or ICAM-1 expression in 
co-cultures compared to control neutrophils. MFI=mean fluorescent intensity. 
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7.3.4 Effects of SSc serum on neutrophil: endothelial cell co-cultures. 
SSc serum increased apoptosis (p=0.02) and endothelial cell activation (p=0.007) as 
measured by ICAM-1 expression in neutrophil: endothelial cell co-cultures compared to 
control serum (Fig.66). Sera from patients with untreated, newly diagnosed, rheumatoid 
arthritis were used as an autoimmune, inflammatory control. 
Fig.65. SSc serum increased endothelial cell ICAM-1 expression but not apoptosis in single 
cell HDMEC cultures compared to control serum. Rheumatoid arthritis (RA) serum did not 
increase either endothelial cell ICAM-1 expression or apoptosis compared to control serum. 
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Serum from untreated early rheumatoid arthritis patients (RA) gave a similar increase in 
ICAM-1 expression in co-cultures but the magnitude of the changes was much smaller 
(Fig.66) and this did not reach statistical significance. RA serum did not increase ICAM-1 
expression in single cell endothelial cell cultures (Fig.65). RA serum had no significant effect 
on apoptosis (Fig.65 and 66). 
Confocal images demonstrated that ICAM-1 expression was increased on neutrophils as 
well as endothelial cells on exposure to SSc and RA sera (Fig.67). Furthermore, it has 
previously been shown that ICAM-1 expression in neutrophils can be increased by 
inflammatory cytokines 337. Therefore, further experiments were conducted using the more 
specific endothelial cell activation marker E-selectin. 
Fig.66. SSc serum increased apoptosis and ICAM-1 expression in neutrophil: endothelial cell 
co-cultures compared to control serum. RA serum also increased ICAM-1 expression, though 
to a lesser extent, but did not increase apoptosis. 
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SSc serum resulted in greater annexin-V binding (p=0.006) and E-selectin (p=0.00004) 
expression compared to control serum when added to neutrophil: endothelial cell co-cultures 
(Fig.68). When corrected for background staining in serum-free media, control serum did not 
increase E-selectin expression, whereas SSc serum resulted in a 2.5 fold increase in E-
selectin expression. Control serum resulted in a 2.5 fold increase in annexin-V staining, 
whereas SSc serum resulted in a 7-fold increase, compared to media alone.  
 
Fig.67. SSc serum-induced apoptosis and ICAM-1 expression in neutrophil: endothelial 
cell co-cultures. Human dermal microvascular endothelial cells (HDMECs) were cultured 
with healthy control neutrophils in the presence of 25% control (A) rheumatoid arthritis 
serum (B) or SSc serum (C). Apoptosis was measured by annexin V-FITC binding 
(green) and ICAM-1 was measured using a PE-conjugated monoclonal antibody to 
ICAM-1 (red). Fluorescence intensity was quantified and located by confocal microscopy. 
Patient sera increase ICAM-1 expression on neutrophils as well as endothelial cells. 
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There was wide variation in the effects the control sera and, in particular SSc sera (Fig.69), 
but pooled data from experiments using 17 separate samples of each type of serum, showed 
significantly enhanced apoptosis (p=0.006) and E-selectin expression (p=0.00004) by the 
SSc serum.  
 
Fig.68. SSc serum-induced apoptosis and E-selectin expression in neutrophil: endothelial 
cell co-cultures. Human dermal microvascular endothelial cells (HDMECs) were cultured 
with healthy control neutrophils in the presence of 25% control (A) or SSc serum (B). 
Apoptosis was measured by annexin V-FITC binding (green) and E-selectin was 
measured using an APC-conjugated monoclonal antibody to E-selectin (red). 
Fluorescence intensity was quantified and located by confocal microscopy. Arrow shows 
E-selectin stained endothelial cell. E-selectin staining also exists in microparticles. 
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Annexin-V binding was detected on both neutrophils and endothelial cells (Fig.68,70). E-
selectin is a specific endothelial cell marker and reflects endothelial cell activation. However, 
E-selectin expression in co-cultures was predominantly associated with cellular aggregates 
where it was difficult to distinguish between neutrophils or endothelial cells morphologically. 
High magnification z-stacks through the cellular aggregates were performed, but these could 
not unambiguously assign E-selectin staining to a particular cell type in these co-cultures. 
Therefore, cell-specific counter-staining was used. 24h time-lapse image series of co-
cultures, where endothelial cells were stained with calcein-AM (green) and neutrophils with 
Mitotracker red (red) showed that both endothelial cells and neutrophils were present in the 
cellular aggregates (Fig.71C). Such time lapse analyses also enabled us to show that 
endothelial cell apoptosis (as evidenced by membrane blebbing and cell detachment) 
(Fig.71B) was the initiating factor for the formation of the aggregates.  
p=0.00004 
p=0.006 
Fig.69. There was a large amount of variability in apoptosis and E-selectin expression 
between experimental repeats. Each line in A and B represents an individual experimental 
repeat (n=17). C shows the pooled data.  
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Fig.71. Time-lapse movies demonstrated that in the presence of SSc serum endothelial 
cells undergo apoptosis and form cellular aggregates with neutrophils in neutrophil: 
endothelial cell co-cultures. HDMECs were cultured with healthy control neutrophils for 
24h in the presence of 25% SSc serum. Endothelial cells were labeled with calcein-AM 
(green) and neutrophils were labeled with mitotracker red (red). A is an image taken at 
baseline. B is an image taken at 1h, endothelial cells are undergoing apoptosis as 
evidenced by cell blebbing and detachment. C demonstrates that both endothelial cells 
(green) and neutrophils form the cellular aggregates. 
 
Fig.70. Annexin V-FITC (green) binding was found on neutrophils (white 
arrows) and endothelial cells (black arrows) but was predominantly 
associated with cell aggregates. 
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SSc sera did not induce apoptosis or endothelial cell activation in the absence of neutrophils 
(Fig.72A). Somewhat surprisingly, although the effect of SSc serum on apoptosis was not 
seen in neutrophil single cell cultures there was a small but significant (p=0.02) apparent 
increase in E-selectin expression (Fig.72B). The increase was however much smaller than 
that seen in neutrophil: endothelial cell co-cultures. To explore this further, neutrophils from 
co-cultures were aspirated from the co-cultures after 24h following gentle agitation and 
analysed by flow cytometry. Neutrophils were gated according to typical forward and side 
scatter properties. No E-selectin expression was seen on these neutrophils. The proportion 
of Annexin V positive neutrophils was also unchanged between co-cultures with SSc and 
control serum (Fig.73). Much of the E-selectin seems to be associated with microparticles 
and indeed an increase in endothelial cell microparticles has been described in SSc and 
indicates endothelial cell activation338. 
 
 
 
 
Fig.72. Apoptosis and E-selectin expression in endothelial cell (A) and neutrophil (B) single 
cell cultures after 24h. There was no difference in apoptosis or E-selectin expression in 
endothelial cell cultures exposed to control or SSc serum (25%). There was no difference in 
neutrophil apoptosis on exposure to SSc or control serum however, there was a small but 
significant increase in E-selectin expression (p=0.02). 
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Further control experiments were performed to ascertain whether the effect of SSc serum 
was specific to endothelial cell co-cultures with neutrophils, or if other leukocytes would also 
give rise to a similar effect. Co-cultures with lymphocytes did not lead to increases in 
apoptosis or endothelial cell activation, but co-cultures with monocytes did (n=2)(Fig.74). 
 
 
 
 
Serum interleukin-6 (IL-6) concentrations were increased in patients with SSc and these 
correlated with the relative annexin V staining and ICAM-1 expression in neutrophil: 
Fig.73. Neutrophils co-cultured with endothelial 
cells for 24h with control or SSc serum (25%) were 
aspirated from the co-cultures following gentle 
agitation. % Annexin V positive neutrophils were 
measured by flow cytometry. 
Fig.74. Phagocytes increased apoptosis and endothelial cell activation in co-culture with 
endothelial cells in the presence of SSc serum, whereas lymphocytes did not. Neutrophils, 
lymphocytes and monocytes isolated from healthy controls were co-cultured with HDMECs 
in the presence of control or SSc serum (25%). Apoptosis was measured by annexin V 
binding (A) and endothelial cell activation was measured by an APC-conjugated monoclonal 
antibody to E-selectin (B) at 24h. Fluorescence was quantified and located by confocal 
microscopy. 
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endothelial cell co-cultures (Fig.75). The serum concentrations observed were in agreement 
with the levels found in plasma by Radstake et al who used a multiplex platform similar to 
the one used here in a large cohort of patients 339 but were higher than levels reported by 
ELISA on serum samples from a smaller cohort 81. 
  
 
 
 
Control serum spiked with rIL-6 200pg/ml increased annexin V staining and E-selectin 
expression in neutrophil: endothelial cell co-cultures (Fig.76). Neutrophils were essential in 
the co-culture for this effect (Fig.77). 
Fig.75. Serum IL-6 concentrations were elevated in SSc (median and interquartile range 
shown in A. p=0.1, N=3) and correlated with apoptosis (B) and endothelial cell activation 
(C) in neutrophils: endothelial cell co-cultures.  
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Fig.76. Recombinant IL-6 increased apoptosis and E-selectin expression in neutrophil 
endothelial cell co-cultures. HDMECs were co-cultured for 24h with neutrophils in the 
presence of AB serum (A) or AB serum spiked with 200pg/ml rIL-6. Apoptosis was 
measured using annexin V staining and E-selectin expression was measured using an 
APC-conjugated monoclonal antibody. Fluorescence was quantified and located by 
confocal microscopy. In addition to increasing annexin V staining and E-selectin 
expression, rIL-6 also increased the formation of cellular aggregates. 
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The addition of a polyclonal IL-6 neutralising antibody to neutrophil: endothelial cell co-
cultures decreased the effect of SSc serum on E-selectin expression and apoptosis 
(p=0.005, p=0.001 respectively). (Fig.78). 
 
p=0.01 
p=0.006 
Fig.77. Recombinant IL-6 significantly increased apoptosis and endothelial cell activation. 
Neutrophils were essential for this effect. HDMECs were cultured for 24h in the presence 
or absence of neutrophils with AB serum or AB serum spiked with 200pg/ml rIL-6. 
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Immunodepletion of IL-6 in SSc serum also decreased E-selectin expression in neutrophil: 
endothelial cell co-cultures (p=0.01). Apoptosis was also decreased but this did not reach 
statistical significance due to the high variability of the samples (Fig.79). 
p=0.005 
Fig.78. Neutralisation of IL-6 decreased the effect of SSc serum on endothelial cell 
activation. HDMECs were co-cultured with control neutrophils for 24h in the presence of 
control or SSc serum (25%). A polyclonal IL-6 antibody was added in neutralizing 
concentrations (1:400). Apoptosis was measured by annexin V staining, E-selectin 
expression was measured by an APC conjugated anti E-selectin antibody. Fluorescence 
was quantified by confocal microscopy. N=11. 
 
p=0.001 
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Soluble gp130, which specifically blocks IL-6 trans signalling, abrogated the effect of SSc 
serum on E-selectin expression (p=0.03). There was a decrease in apoptosis (p=0.06) in 
neutrophil: endothelial cell co-cultures but this did not reach significance (Fig.80). 
 
p=0.01 
Fig.79. Immunodepletion of IL-6 abrogated the effect of SSc serum on endothelial cell 
activation. HDMECs were co-cultured with control neutrophils for 24h in the presence of 
control or SSc serum (25%). SSc serum was either incubated with antiIL-6 conjugated 
beads (IP) or unconjugated beads. Apoptosis was measured by annexin V staining, E-
selectin expression was measured by an APC conjugated anti E-selectin antibody. 
Fluorescence was quantified by confocal microscopy. N=8. 
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Inactivation of complement in SSc serum by heating to 56˚C for 30mins did not significantly 
change the effect of SSc on apoptosis or endothelial cell activation in neutrophil: endothelial 
cell co-cultures (Fig.81). This implies that complement does not play a significant role in this 
effect. 
 
p=0.03 
p=0.06 
Fig.80. Soluble gp130 (500ng/ml) decreased the effect of SSc serum on apoptosis and 
endothelial cell activation in neutrophil: endothelial cell co-cultures. HDMECs were co-
cultured with control neutrophils for 24h in the presence of control or SSc sera (25%). 
Soluble gp130 (500ng/ml) was added to block IL-6 trans-signalling. Apoptosis was 
measured by annexin V staining, E-selectin expression was measured by an APC 
conjugated anti E-selectin antibody. Fluorescence was quantified by confocal microscopy. 
N=5. 
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The addition of the serine protease inhibitor (AEBSF) decreased the pro-apoptotic effect of 
SSc serum (p=0.04) and endothelial cell activation (p=0.06) in neutrophil: endothelial cell co-
cultures the effect on E-selectin expression did not reach statistical significance (Fig.82). 
 
 
p=0.65 
p=0.58 
Fig.81. Complement inactivation did not change the effect of SSc serum on apoptosis or 
endothelial cell activation in neutrophils: endothelial co-cultures. HDMECs were co-
cultured with control neutrophils for 24h in the presence of control or SSc serum (25%). 
Complement inactivation (CI) was performed by heating serum to 56˚C for 30mins. 
Apoptosis was measured by annexin V staining, E-selectin expression was measured by 
an APC conjugated anti E-selectin antibody. Fluorescence was quantified by confocal 
microscopy. N=7. 
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Removal of hydrogen peroxide from co-cultures by the addition of an excess of catalase, did 
not significantly change the effect of SSc serum on apoptosis and endothelial cell activation 
in neutrophil: endothelial cell co-cultures (Fig.83). However, in 3 individual patients the 
addition of catalase did significantly abrogate the effect of SSc serum (Fig.84). This was 
explored further in Chapter 3. 
p=0.04 
p=0.06 
Fig.82.The serine protease inhibitor AEBSF decreased apoptosis and endothelial activation in 
neutrophil: endothelial cell co-cultures but this did not reach statistical significance. HDMECs 
were co-cultured with control neutrophils for 24h in the presence of control or SSc serum (25%). 
The serine protease inhibitor AEBSF (PI) was added (0.2mM). Apoptosis was measured by 
annexin V staining, E-selectin expression was measured by an APC conjugated anti E-selectin 
antibody. Fluorescence was quantified by confocal microscopy. N=8. 
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p=0.11 
p=0.37 
Fig.83. Catalase did not significantly alter the effect of SSc serum on apoptosis 
and endothelial cell activation in neutrophil: endothelial cell co-cultures. HDMECs 
were co-cultured with control neutrophils for 24h in the presence of control or SSc 
serum (25%). Catalase was added (2000U/ml). Apoptosis was measured by 
annexin V staining, E-selectin expression was measured by an APC conjugated 
anti E-selectin antibody. Fluorescence was quantified by confocal microscopy. 
N=7. 
 
Fig.84. In 3 patients, the addition of catalase significantly decreased E-selectin expression in 
response to SSc serum in neutrophil: endothelial cell co-cultures. In addition, catalase 
decreased apoptosis in 2 of these cases. 
 
Page 194 of 236 
 
Analyses were performed to explore whether this unusual response to catalase was 
associated with any clinical features including: disease duration, Raynaud’s duration, use of 
DMARDs, organ involvement, auto-antibody profile, skin score, organ involvement or 
disease subtype (limited vs. diffuse). No clinical correlates were found. 
7.3.5 Soluble IL-6R concentrations in serum and culture supernatants.  
Soluble IL-6R concentrations were measured by ELISA, performed on serum, co-culture 
supernatants and neutrophils cultured with SSc serum. No difference was found between 
patient and control serum levels of sIL-6R, and no difference was found in the levels of sIL-
6R when neutrophils were incubated with SSc serum. There was an increase in sIL6R levels 
in co-culture supernatants in the presence of SSc serum compared to control, but this did 
not reach statistical significance (Fig.85). 
 
 
 
Fig.85. Soluble IL-6R levels were not significantly different between control or SSc serum, 
or between cultures containing control or SSc serum. There was a tendency for higher 
levels of sIL-6R in co-cultures containing SSc serum but this was not statistically 
significant. sIL-6R concentrations were measured by ELISA in control and SSc serum 
(N=9), in supernatants from 24h neutrophil cultures containing 106 neutrophils/ml and 25% 
control or SSc serum (N=6), or in supernatants from 24h cultures of neutrophils and 
endothelial cells in the presence of 25% control or SSc serum (N=5). 
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7.3.6 Soluble ICAM-1 concentrations in serum and culture supernatants.  
Soluble ICAM-1 (sICAM-1) levels were also measured in serum and in the supernatants 
from 24h neutrophil: endothelial cell co-cultures in the presence of 25% control or SSc 
serum, and in supernatants from endothelial cell co-cultures in the presence of 25% control 
or SSc serum. We confirmed an increase in serum concentrations of sICAM-1 in SSc 
compared to controls. However, when corrected for added serum concentrations, there was 
no difference in sICAM-1 concentrations in culture supernatants (Fig.86). It is likely that there 
are several factors dictating the concentrations of sICAM-1 in the cultures, not just cleavage 
from the cell surface but also degradation of cleaved sICAM-1. In addition, given the 
relatively high levels in serum, small changes in the release of sICAM-1 from cells in cultures 
containing sera are likely to be swamped, and therefore undetectable.  
 
 
 
 
Fig.86. Soluble ICAM-1 concentrations were elevated in SSc serum but not in culture 
supernatants containing SSc serum compared to control serum. sICAM-1 levels were 
measured by ELISA in serum, supernatants from 24h endothelial cell cultures containing 
25% control or SSc serum and in supernatants from 24h neutrophil: endothelial cell co-
cultures containing 25% control or SSc serum. In supernatants, levels were corrected for 
the amount already present in the added serum, to try to detect increases in sICAM-1 in 
the cultures. No significant differences were found. N=5. 
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7.4 Discussion. 
The results of this study show that SSc serum causes activation of endothelial cells as 
evidenced by an increase in E-selectin and ICAM-1 expression. SSc serum also causes an 
increase in neutrophil ICAM-1 expression, which has previously been reported in response 
to inflammatory sera 337. E-selectin however represents a much more specific marker of 
endothelial activation. E-selectin is not usually expressed in unstimulated endothelial cells 
and has to be generated de novo which takes several hours, unlike ICAM-1 which is 
constitutively expressed by endothelial cells on the cell membrane, and also exists in 
intracellular stores that can be rapidly mobilised following endothelial cell activation.  
Neutrophils aspirated from the co-cultures do not express any E-selectin, confirming the 
specificity of this marker, although there is the possibility that some neutrophils may be 
adherent to the endothelial cell layer, and E-selectin expression in those cells cannot be 
excluded. 
In neutrophil: endothelial cell co-cultures there is, in addition, an increase in apoptosis of 
both neutrophils and endothelial cells in response to SSc serum compared to control serum, 
as assessed by confocal microscopy. However, when the neutrophils were removed and 
annexin V binding measured by flow cytometry, there was no increase in the percentage of 
apoptotic cells in response to SSc serum. An explanation for this may be that during the 24h 
culture, apoptotic neutrophils may have undergone secondary necrosis decreasing the 
number of recovered neutrophils, and leading to an underestimation of the total levels of 
apoptosis. However, when neutrophils were cultured in the absence of endothelial cells, 
there was no increase in neutrophil apoptosis with SSc serum compared to control serum. 
Therefore, it seems most likely that the observed increase in apoptosis is predominantly in 
the endothelial cell population. 
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During time-lapse videos of neutrophil: endothelial cell co-cultures endothelial cell apoptosis 
was observed, and these apoptotic cells then appear to attract neutrophils, forming the 
cellular aggregates observed in the presence of SSc serum. However, overall levels of 
apoptosis in the co-cultures incubated on the confocal microscope were higher than 
expected when compared to cultures that were performed in a standard incubator (37˚C, 5% 
CO2, humidified). This is likely to be due to technical difficulties in maintaining uniform CO2 
concentrations and ample humidification on the confocal microscope.  
IL-6 is considered as an anti-apoptotic cytokine but, its effects are dependent on the cell 
type. Previous studies have shown a decrease in endothelial cell apoptosis in response to 
IL-6 in cultured human umbilical vein endothelial cells (HUVECs) 340 341. However, no studies 
are reported using HDMECs and endothelial cell heterogeneity may explain the effects 
reported here . Other explanations for the apoptosis seen in these experiments may include 
an indirect effect of IL-6 or an interaction with other cytokines. Indeed IL-6 pretreatment has 
been reported to cause increased hepatocyte apoptosis in response to TNFα 342. Deficiency 
of the apoptosis protective protein, Tie-2, rendered endothelial cells sensitive to IL-6 induced 
apoptosis 343. The balance of effects may be concentration dependent, as described for 
TNFα, and the concentrations of IL-6 in the lesional tissue are unknown. Finally, the effect 
may be dependent on direct contact between neutrophils and endothelial cells. To further 
explore this effect, future experiments should be performed using cell culture inserts with 
semi-permeable membranes. Neutrophils would be cultured in these chambers, suspended 
above cultured HDMECs The semi-permeable membranes would allow free diffusion of 
soluble mediators but prevent direct cell-cell contact. 
Endothelial cell apoptosis and activation are thought to be central to the pathogenesis of 
SSc. In animal models of SSc, endothelial cell activation is seen early in the disease, 
preceding the fibrotic changes that are the hallmark of this disease 6 7. Soluble markers of 
endothelial activation, sICAM-1 and sE-selectin, as well as other markers of endothelial cell 
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activation, vWF and ET-1 are increased in the serum of patients with SSc and correlate with 
clinical manifestations and clinical markers of severity 15 19 333. Treatments that ameliorate the 
clinical features of SSc e.g. Iloprost, decrease markers of endothelial cell activation 344. 
The mechanism for endothelial cell activation, however, is not clear. Pro-inflammatory 
cytokines interleukin-1 (IL-1), tumour necrosis factor α (TNFα) and interleukin-6 (IL-6) are 
capable of activating endothelial cells in vitro. 13-plex luminex studies of serum from SSc 
patients revealed a tendency for an increase in these inflammatory cytokines, and indeed 
there are many, though conflicting, reports in the literature of increases in serum levels of 
pro-inflammatory cytokines 78 80-82 142. Within my data, IL-6 serum concentrations correlate 
with the degree of endothelial cell activation and apoptosis seen within co-cultures. 
Endothelial cells, however, do not express the IL-6 receptor (gp80, IL6R) and are thought to 
respond to IL-6 through a process known as trans signalling 93. Soluble IL-6 receptors (sIL-
6R) exist in the serum and bind to IL-6 forming an IL-6-sIL-6R complex. This complex can 
bind to the gp130 receptor, which is expressed ubiquitously on cells including endothelial 
cells, which activates the STAT3 signalling pathway 98 99. Endothelial cell activation via trans 
signalling results in an increase in the expression of adhesion molecules (ICAM-1, E-
selectin), the release of chemokines (IL-8 and MCP) and the release of IL-6 93 96 (Fig.87). 
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The IL-6R is expressed on hepatocytes, monocytes, B-cells and neutrophils in humans. It is 
also found on a subset of T-cells, but there is evidence that T-cells respond to IL-6 
predominantly through trans signalling 98. sIL-6R is produced by two separate mechanisms, 
firstly by proteolytic cleavage from the surface of neutrophils and secondly by secretion of an 
alternatively spliced version 345-348.  
Fig.87. Interleukin-6 trans signalling. 
IL-6 receptors are expressed on leukocytes including neutrophils but they are not 
expressed on tissue resident cells e.g. Endothelial cells. Endothelial cells can respond to 
IL-6 through the gp130 receptor only when the IL-6 is bound to a soluble IL-6 receptor 
(sIL-6R). sIL-6Rs are formed by secretion of an alternatively spliced version of the 
receptor or proteolytic cleavage from the surface of neutrophils. There is also a pool of 
sgp130 (sgp130) which can bind IL-6/sIL6R complexes and prevent them binding to 
cellular gp130. Therefore, the local concentrations of IL-6, sIL-6R and sgp130 regulate 
IL-6 signalling.  
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The regulation of the proteolytic cleavage has been partially elucidated and is stimulated by 
C-reactive protein (CRP). Cleavage from the surface of neutrophils, but not monocytes, is 
also stimulated by chemoattractants (IL-8, C5a, LTB4 and PAF) 349. Proteolytic cleavage can 
occur via a TACE-like enzyme though this does not account for all of the proteolytic 
cleavage.  
Levels of IL-8 were elevated in the SSc serum, as measured by luminex, in keeping with 
previous reports in the literature, and this may stimulate the release of sIL-6R from 
neutrophils within the co-cultures 224 350. In addition there are reports in the literature that 
LTB4 levels are elevated in the broncheoalveolar lavage fluid of patients with SSc lung 
disease 226, and while this was not measured within this study it may also contribute to the 
generation of sIL-6R.  
SSc serum alone, in the absence of neutrophils, increased endothelial cell ICAM-1 
expression after 24h, but the magnitude of the change was lower than that observed in the 
presence of neutrophils. SSc serum alone did not increase endothelial cell apoptosis or E-
selectin expression. The fact that neutrophils are required in the co-culture for this effect may 
be explained by the fact that they are required as a sIL-6R donor. 
IL-6 is a pleiotropic cytokine, and several observations support a role for this cytokine in 
SSc. Fibroblasts from patients with SSc are phenotypically unique. When isolated and 
cultured in vitro they continue to produce an excess of collagen 27 91. IL-6 has been shown to 
either increase or decrease fibroblast proliferation, increase fibroblast collagen, 
glycosaminoglycan and TIMP-1 synthesis and increase MCP-1 and IL-6 production 84 85 89 91 
351 352. IL-6 regulates the expression of VEGF, an important mediator of angiogenesis and 
fibrosis which is elevated in patients with SSc 353.  
IL-6 transcription is under the control of a hypoxic response element via HIF-1-α. 
Measurements taken from the lesional skin of patients shows that there is a persistent 
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decrease in oxygen tension 60. Levels of oxygen equivalent to 3% have been found in the 
lesional skin, which reflect levels sufficient to induce HIF-1α signalling 60. However, RT-PCR 
results show that there is no increase in IL-6 mRNA in neutrophils in response to hypoxia 
(data not shown). Indeed, the low levels of IL-6 mRNA detected in these experiments are 
likely to represent monocyte or eosinophil contamination and no enhancement due to 
hypoxia. Previous reviews of the literature support the fact that neutrophils do not transcribe 
or secrete IL-6 229. 
Fibroblasts isolated and cultured from the lesional skin of patients with SSc constitutively 
produce higher levels of IL-6 than non-lesional or healthy donor fibroblasts 32. This 
demonstrates the importance of considering local concentrations of cytokines in disease. 
Serum concentrations may not necessarily reflect local levels of a relevant cytokine at the 
lesional site. Local interactions between fibroblasts, endothelial cells and immune cells in the 
presence of locally elevated levels of cytokines may be more important in in vitro models. 
Stimulated and unstimulated fibroblasts from lesional skin have also been shown to produce 
increased levels of IL-8 which may be implicated in local release of sIL6R from neutrophils 
34. 
It is important to note that hemodynamic flow may affect IL-6 induced signalling in 
endothelial cells 354. Hemodynamic flow is dysregulated in patients with SSc and this may 
play an important role in modeling the effects of IL-6 on endothelial cells in this disease. 
Flow was not incorporated in the model used in this study, representing a limitation of this 
system. I would wish to consider this in further experiments. 
IL-6 also has a profound effect on B-cells giving rise to plasma cell differentiation and 
antibody production. This may explain the polyclonal B cell expansion and 
hypergammaglobulinaemia which is frequently seen in SSc 99. 
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IL-6 has been implicated in the generation and propagation of chronic inflammation. Initially 
in acute inflammation, pro-inflammatory cytokines lead to neutrophil accumulation and the 
release of IL-6. Neutrophils then shed their IL-6Rs in response to chemokines e.g. IL-8. This 
promotes differential regulation of chemokine production by endothelial cells, promoting 
MCP production and decreasing IL-8 production therefore favouring monocyte accumulation. 
IL-6 trans signalling also increases the expression of endothelial leukocyte adhesion 
molecules (VCAM-1, ICAM-1 and E-selectin) therefore further promoting leukocyte 
accumulation 96 97. In addition, IL-6 may have a role in promoting neutrophil apoptosis and 
therefore the resolution of acute (non-specific) inflammation 95 100. Others however have 
reported an anti-apoptotic effect of interleukin-6 on neutrophils 102 while Biffl et al have 
shown that the effect depends on the neutrophil concentration 101. We have been unable to 
reproduce any IL-6 specific effect on neutrophil apoptosis in our laboratory at concentrations 
of IL-6 ranging from 0.1-100ng/ml (personal communication Helen Wright).  
Conversely, IL-6 reportedly rescues T-cells from apoptosis, which promotes a chronic 
inflammatory cell infiltrate 355-358. IL-6 trans signalling also promotes the release of IL-6 from 
fibroblasts and endothelial cells in a positive autocrine feedback system. Therefore, it can be 
envisaged that IL-6 may have a role in propagating chronic inflammation, such as that seen 
in SSc. This is in keeping with immunocytochemical experiments which demonstrate that IL-
8 and IL-6 are over-expressed in the lesional skin of patients with SSc, though in different 
patterns. The over-expression of IL-8 is associated with early disease (<1yr) whereas IL-6 
over-expression is associated with later disease 79. 
IL-6 has also been implicated in autoimmunity. Evidence from patients with Crohn’s disease 
indicates that autoreactive T-cells are resistant to apoptosis due to protection by IL-6 trans 
signalling via the STAT3 signalling pathway 359. IL-6 inhibits a Na2+/K+ ATPase which 
regulates endosmosis and antigen presentation by dendritic cells to T-cells, which may 
promote presentation of autoantigens 360 361. Finally, according to Matzinger’s “ danger 
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theory”, naïve T-cells die if they receive a signal from proper antigen presentation but this is 
not followed up by ligation of CD40 362. There is evidence that IL-6/sIL-6R complex can 
inappropriately substitute for this second signal and therefore lead to the persistence of 
autoreactive T-cells 363. Incidentally, autoimmune phenomena increase with age, in concert 
with an age-related increase in sIL-6R shedding 364. SSc is a disease associated with 
autoimmune phenomena. Many different auto-antibodies are found in SSc (see Table 14.) 
and the auto-antibody profile in many cases correlates with clinical manifestations. There is 
however, no convincing evidence for a direct relationship with pathogenesis, though some 
investigators have reported that anti-endothelial cell antibodies, found in a proportion of 
patients are associated with endothelial cell activation 9 365. 
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In this study, monocytes triggered similar levels of endothelial cell activation in co-cultures to 
neutrophils. Monocytes are also capable of donating sIL-6R, though evidence implies that 
they do this most frequently by an increase in the secreted, alternatively spliced form 366. 
Certainly, in monocytes, cleavage of the IL-6R from the cell surface is not mediated by 
chemoattractants, as it is for neutrophils. A monocytic infiltrate is more commonly seen in the 
Table 14. Systemic sclerosis associated auto-antibodies. Panel A outlines the systemic 
sclerosis associated antibodies, their frequency in systemic sclerosis patients and their 
disease associations. Panel B outlines potentially pathogenic antibodies which have 
been described in a proportion of patients with systemic sclerosis. Reviewed in 4. 
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lesional skin of SSc patients reflecting the chronic inflammatory phase of the disease. 
Therefore, monocyte derived sIL-6R may mediate a continuation of IL-6 trans signalling and 
hence fibroblast and endothelial cell activation in this disease. However, during this study I 
have only explored the role of trans signalling in neutrophil: endothelial cell co-cultures. In 
future, I would like to perform confirmatory experiments to show that IL-6 trans signalling is 
also responsible for endothelial cell activation in monocyte-endothelial cell co-cultures. This 
would further confirm that blockade of IL-6 trans signalling would be an appropriate 
therapeutic target in SSc. Previous research has shown that PBMCs from SSc patients, 
when cultured in vitro, produce higher levels of IL-6 and sIL-6R in the culture supernatants 
than control PBMCs, though levels of sgp130 were equivalent 169. As monocytes form a 
large part of the immune cell infiltrate in the tissue, they may play a significant role in 
disease, but at the endothelial cell surface, the high number of neutrophils in the circulation, 
together with the presence of increased endothelial cell adhesion molecules and the release 
by endothelial cells of neutrophil chemoattractants, would argue for a significant role for 
neutrophil derived IL-6R. 
IL-6 concentrations measured by luminex were not elevated in the supernatants from 24h 
neutrophil: endothelial cell co-cultures. This is in keeping with the previously reported 
inability of neutrophils to express IL-6 229. sIL-6R levels measured by ELISA were elevated in 
co-culture supernatants containing SSc serum compared to those containing control serum, 
although the difference was not significant. There was no difference in serum sIL-6R 
concentrations between SSc patients and healthy controls. In addition, there was no 
increase in sIL-6R concentration in the supernatants of neutrophils cultured with SSc serum 
for 24h in the absence of endothelial cells compared to control serum. These results 
demonstrate that local levels of sIL-6R are the important factor in controlling IL-6 signalling, 
and that overall serum levels are not likely to reflect what might be pathogenically significant 
changes in cytokine signalling at the cellular level. Secondly, the fact that neutrophils do not 
appear to shed sIL-6R in culture with SSc serum in the absence of endothelial cells implies 
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that the endothelial cell: neutrophil interactions may be even more complex. This may 
suggest that an unidentified factor in the SSc serum induces endothelial cell production of a 
further factor which in turn stimulates the proteolytic cleavage of sIL-6R from the neutrophil 
membrane. Interleukin-8 (IL-8) would be a good candidate for the intermediary produced by 
the endothelial cell. Endothelial cells can be stimulated to produce IL-8 in response to the 
proinflammatory cytokines IL-1 and TNF. Interestingly these were increased in the serum of 
patients compared to controls, though low sample size meant that this difference was not 
statistically-significant. Future work would include an assessment of the effect of blocking 
interleukin-8 in my co-culture system. In addition, measurement of SSc neutrophil IL6R 
expression by flow cytometry compared to controls may help to show whether there has 
been cleavage of the surface receptor. However the situation may be complicated as the 
regulation of cell surface expression of IL6R is not fully elucidated and may involve dynamic 
replacement by mobilisation of intracellular stores, in keeping with other neutrophil cell 
surface receptors. 
Tocilizumab, an IL-6 receptor monoclonal antibody is licensed for the treatment of 
rheumatoid arthritis (RA) and is extremely effective 367-369. I propose that IL-6 blockade is a 
potentially novel therapeutic strategy in SSc, targeting multiple aspects of the disease 
including endothelial dysfunction and fibrosis. There is evidence that IL-6 is important in 
early disease but is also likely to be important in continuing and progressive disease activity. 
It could represent an important intervention in a large number of patients suffering with this 
disabling and difficult to treat disease. 
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Chapter 8: Conclusion 
8.1 Summary of results. 
In Chapter 3 the functional phenotype of SSc neutrophils was explored. Neutrophils were 
found to be hypofunctional in terms of unstimulated ROS generation and chemotaxis along 
an fMLP gradient. Data also implied (though did not quantitatively prove) an increase in 
neutrophil adhesion both to inert materials and to each other. The hypofunctionality in terms 
of unstimulated ROS production was overcome using neutrophil stimulants e.g. fMLP and 
PMA implying that the neutrophils were not inherently dysfunctional but rather, activated in 
vivo. SSc neutrophils, in fact, produced significantly more ROS in response to fMLP than 
control neutrophils when unprimed, implying some in vivo priming of SSc neutrophils. 
Proteomic studies, both whole cell and plasma membrane, showed evidence of dynamic 
changes in the actin cytoskeleton and actin-associated machinery. The changes observed in 
SSc neutrophils mimicked those seen in response to chemoattractant doses of fMLP and are 
also likely, again, to reflect in vivo neutrophil activation. L-plastin, an actin-associated protein 
that is activated by IL-8 and activates, in turn, neutrophil integrin function, was increased in 
the plasma membrane fraction of SSc neutrophils. In addition, proteomic studies highlighted 
differential expression of S100A8 and S100A9 in SSc neutrophils with increased intracellular 
concentrations and decreased plasma membrane concentrations of these proteins.  
Neutrophil elastase was not increased in the serum of patients with SSc nor was there 
greater serum neutrophil elastase activity overall. However, in SSc serum there was more 
elastase activity detected for each unit of elastase protein detected. This may imply a deficit 
in neutrophil elastase inhibition, which may lead to important local effects of neutrophil 
elastase, which has powerful roles in the modulation and propagation of inflammation and 
the promotion of fibrosis.  
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There was an interesting observation that peripheral blood neutrophil count correlated 
strongly with the extent of skin thickening.  
Finally, modelling the effects of neutrophil endothelial cell interactions revealed that SSc 
serum increased the amount of E-selectin expression and apoptosis compared to control 
serum, as well as stimulating the formation of cellular aggregates. Neutrophils were essential 
for this effect which appears to be mediated by interleukin-6. Serine proteases also play an 
important role in the induction of apoptosis in this in vitro model and reactive oxygen species 
may play a role in some individual patients. 
8.2 Interpretation. 
Neutrophils may be hypofunctional ex vivo for two reasons: either the neutrophils are 
hypofunctional per se, or they have decreased function in vitro following previous in vivo 
activation. It seems unlikely that SSc neutrophils are hypofunctional per se, since they 
produced normal responses to in vitro activating agents. In fact, given that they are 
hypofunctional at baseline in vitro, the magnitude of the response to activating agents was 
greater in SSc than in control neutrophils. 
Proteomic studies have added important additional information in support of this proposal of 
in vivo activation. The proteomic profile of freshly-isolated neutrophils is likely to reflect the in 
vivo activation state of the neutrophil. Indeed, the proteomic profile of neutrophils mimicked 
that found in response to activating agents TNF and LPS, implying that neutrophils are in 
fact activated in vivo. Further evidence comes from the proteomic and confocal evidence 
that there are changes in the actin cytoskeleton in SSc neutrophils. The actin cytoskeleton is 
involved in many active cellular processes including, adhesion, degranulation, chemotaxis, 
signal transduction and neutrophil priming. All of these events reflect neutrophil activation.  
There is evidence that SSc neutrophils may be primed for ROS generation. Substances that 
cause activation often lead, at lower concentrations, to neutrophil priming.  
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The fact that peripheral blood neutrophil counts correlate with Rodnan skin score provides 
some circumstantial evidence to imply that neutrophils or neutrophil mediators may 
eventually lead to fibrosis. This may or may not be a direct effect and may be a surrogate 
marker for the increased inflammation in these patients. However, it would be important to 
explore whether this relationship exists for other cells of the immune system in the peripheral 
blood and to examine the neutrophil counts longitudinally to see whether this relationship still 
exists. 
8.3 Significance. 
Although neutrophils are traditionally thought of as immune cells with a limited repertoire of 
functions, there is increasing evidence that they have diverse and important roles in not only 
initiating, but perpetuating inflammation and modulating the inflammatory response. A good 
example of this is through the shedding of its interleukin-6 receptor, to induce trans signalling 
on those cells that do not normally express this receptor. This can amplify IL-6 mediated 
events, leading to the promotion of chronic inflammation, endothelial cell activation and 
fibrosis. 
As an abundant source of the S100 proteins S100A8 and S100A9, neutrophils can trigger 
profound effects on inflammatory events by; mediating responses to reactive oxygen 
species; promoting endothelial cell activation and apoptosis; amplifying the immune 
response and recruiting cells of the adaptive immune system by the activation of TLR4 
receptors. Neutrophil elastase also has well established roles in the promotion of 
inflammation and fibrosis, and in endothelial cell apoptosis.  
Neutrophil activation can lead to the release of S100 proteins and elastase, in addition to 
reactive oxygen species. Therefore, neutrophil activation could have profound effects at the 
endothelial surface that could give rise to pathogenically-relevant consequences. Neutrophil 
activation seems very likely given the fact that neutrophil chemotactins (IL-8) are elevated in 
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SSc serum and in the tissue of SSc patients, that endothelial cells express increased 
quantities of cell surface leukocyte adhesion molecules and that binding to these molecules 
activates neutrophils. In addition, increased concentrations of neutrophil activating cytokines 
e.g. TNFα, IL-1 and IL-8 are also reported in SSc serum and are produced by SSc tissue.  
Neutrophils do not constitute a large part of the skin infiltrate in SSc, and the reason for this 
is not known.  It may reflect the absence of a chemotactic gradient into the fibrotic tissue or it 
may reflect a defect in neutrophil diapedesis, due to either neutrophil or endothelial cell 
factors. However, the lack of neutrophilic infiltrate does not rule out interaction between 
neutrophils and endothelial cells in the lumen of blood vessels.  
Co-culture models, in fact, imply that neutrophils are likely to interact with endothelial cells 
and each other in the presence of factors in SSc serum, and that this interaction results in 
increased endothelial cell activation and apoptosis. It is not clear from this model whether 
neutrophil activation forms part of this interaction leading to the release of mediators that 
then cause endothelial cell activation and apoptosis, but this seems likely. Mediators may 
include those outlined above. 
Neutrophils appear to be more likely to form cell aggregates in response to SSc serum and 
when isolated from SSc patients. This may be of great pathological relevance as these may 
form microemboli, which could contribute to the ischaemic phenomena which occur in SSc 
patients. 
The conclusions drawn from these studies are weakened due to the heterogeneity of the 
patients studied. Small numbers precluded disease subtype analysis and therefore important 
information was lost regarding the precise relevance of neutrophils in these different disease 
manifestations. More importantly, patients were not recruited exclusively early in the 
disease, when neutrophils are most likely to relevant to the pathogenesis. Small numbers of 
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such early patients prevented stratified recruitment according to disease duration and also 
precluded meaningful subgroup analyses of such patients. 
8.4 Addressing the hypothesis. 
The hypothesis “Neutrophils are activated in SSc and contribute to endothelial cell activation 
and injury” has been addressed in this thesis. 
Proteomic evidence supports neutrophil activation in SSc and functional studies support 
neutrophil priming and also imply in vivo neutrophil activation. Confocal studies show 
dynamic changes in the actin cytoskeleton and observations suggest increased neutrophil 
adhesiveness. Together, these strongly point towards neutrophil activation in SSc. 
Neutrophil: endothelial cell co-cultures suggest that SSc serum can induce endothelial cell 
activation and injury (apoptosis) and that neutrophils are required for this effect. Evidence 
supports a role for IL-6 trans signalling in this effect and neutrophils may be required to 
donate the interleukin-6 receptor. Although there is no direct evidence that neutrophil 
activation is required for the effect of SSc serum, serine proteases appear to have a role in 
endothelial cell apoptosis in these experiments and neutrophil activation may lead to the 
release of serine proteases e.g. neutrophil elastase. In addition, in some but not all patients, 
the effect of sera is abolished by catalase which scavenges ROS. Again, activated 
neutrophils are the likely, but not only potential, source of ROS in this system. 
These studies, taken together, show that neutrophil activation does indeed occur in SSc and 
uniquely, in vitro models demonstrate that this is likely to lead to endothelial cell activation 
and injury. This may lead to a paradigm change in the design of therapeutic targets in SSc. 
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Appendix A: 
Standard  SDS-PAGE: 
a) Reducing (sample) buffer 
 1M Tris pH 6.8 
 10% glycerol (v/v) 
 3% SDS (w/v) 
 100mM DTT 
 0.001% Bromophenol blue (w/v) 
 
b) Wash buffer 
 10mM Tris pH 8.0 
 150mM NaCl  
 0.075% Tween 20 
 
c) Running buffer 
 25mM Tris 
 250mM Glycine 
 0.1% SDS 
 
d) Transfer buffer 
 25mM Tris pH 8.0 
 0.2M Glycine 
 20% Methanol 
Tris-Tricene SDS-PAGE. 
a) Inner chamber buffer 
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 200mM Tris 
 200mM Tricene 
 0.2% SDS 
 pH 8.5 
 
b) Outer chamber buffer 
 400mM Tris pH 8.8 
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